



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07H 21/00, C12N 1/15, 1/21, 5/10, 15/10, 15/12, 15/63	A1	(11) International Publication Number: WO 99/19339 (43) International Publication Date: 22 April 1999 (22.04.99)																		
(21) International Application Number: PCT/US98/21142 (22) International Filing Date: 8 October 1998 (08.10.98) (30) Priority Data: <table border="0" style="width: 100%;"> <tr> <td style="width: 40%;">60/061,463</td> <td style="width: 40%;">9 October 1997 (09.10.97)</td> <td style="width: 20%;">US</td> </tr> <tr> <td>60/061,529</td> <td>9 October 1997 (09.10.97)</td> <td>US</td> </tr> <tr> <td>60/071,498</td> <td>9 October 1997 (09.10.97)</td> <td>US</td> </tr> <tr> <td>60/061,527</td> <td>9 October 1997 (09.10.97)</td> <td>US</td> </tr> <tr> <td>60/061,536</td> <td>9 October 1997 (09.10.97)</td> <td>US</td> </tr> <tr> <td>60/061,532</td> <td>9 October 1997 (09.10.97)</td> <td>US</td> </tr> </table> (71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BREWER, Laurie, A. [US/US]; Apartment 115, 410 Van Dyke Street, St. Paul, MN 55119-4321 (US). OLSEN, Henrik, S. [DK/US]; 182 Kendrick Place No. 24, Gaithersburg, MD 20878 (US). DUAN, Roxanne [US/US]; 5515 Northfield Place, Bethesda, MD 20817 (US). EBNER, Reinhard [DE/US]; 9906 Shelburne Terrace No. 316, Gaithersburg, MD 20878 (US). ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Road, Laytonville, MD 20882 (US). RUBEN, Steven, M. [US/US];		60/061,463	9 October 1997 (09.10.97)	US	60/061,529	9 October 1997 (09.10.97)	US	60/071,498	9 October 1997 (09.10.97)	US	60/061,527	9 October 1997 (09.10.97)	US	60/061,536	9 October 1997 (09.10.97)	US	60/061,532	9 October 1997 (09.10.97)	US	18528 Heritage Hills Drive, Olney, MD 20832 (US). FLORENCE, Kimberly, A. [US/US]; 12805 Atlantic Avenue, Rockville, MD 20851 (US). YOUNG, Paul, E. [US/US]; 122 Beckwith Street, Gaithersburg, MD 20878 (US). GREENE, John, M. [US/US]; 872 Diamond Drive, Gaithersburg, MD 20878 (US). YU, Guo-Liang [CN/US]; 1714-C Marina Court, San Mateo, CA 94403 (US). FERRIE, Ann, M. [US/US]; 120 Fox Run Drive, Tewksbury, MA 01876 (US). FLORENCE, Charles [US/US]; 12805 Atlantic Avenue, Rockville, MD 20851 (US). (74) Agents: BROOKES, A., Anders et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
60/061,463	9 October 1997 (09.10.97)	US																		
60/061,529	9 October 1997 (09.10.97)	US																		
60/071,498	9 October 1997 (09.10.97)	US																		
60/061,527	9 October 1997 (09.10.97)	US																		
60/061,536	9 October 1997 (09.10.97)	US																		
60/061,532	9 October 1997 (09.10.97)	US																		
(54) Title: 53 HUMAN SECRETED PROTEINS (57) Abstract The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.																				

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

53 Human Secreted Proteins

Field of the Invention

This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and polypeptides, and their production.

Background of the Invention

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins include the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoietin. Thus, in light of the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent medical disorders by using secreted proteins or the genes that encode them.

Summary of the Invention

The present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting disorders related to the polypeptides, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying binding partners of the polypeptides.

Detailed Description

Definitions

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide.

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig

analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 10801 University Boulevard,
5 Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.

A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained
10 in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an overnight incubation at 42°C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the
15 filters in 0.1x SSC at about 65°C.

Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages
20 of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37°C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH₂PO₄; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 µg/ml salmon sperm blocking DNA; followed by washes at 50°C with 1XSSPE, 0.1% SDS. In addition, to achieve even
25 lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include
30 Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA+ sequences (such
35 as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a

complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).

5 The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and
10 double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability
15 or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

 The polypeptide of the present invention can be composed of amino acids joined
20 to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs,
25 as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be
30 branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a
35 nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine,

formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS -
 5 STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990);
 10 Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.

"A polypeptide having biological activity" refers to polypeptides exhibiting
 15 activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present
 20 invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)

25 **Polynucleotides and Polypeptides of the Invention**

FEATURES OF PROTEIN ENCODED BY GENE NO: 1

30 The translation product of this gene shares sequence homology with rabbit renal cortical Na/Pa-i-contransporter which is thought to be important in cellular metabolism and kidney function.

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

35 HELGGLLADFLLSRKILRLITIRKLFTAIGVLFPVSILVSLPWVRSSHSM TMTFLV
 LSSAISSFCESGALVNFLDIAPRYTGFLKGLLQVFAHIAGAISPTAAGFFISQDSE
 FG WRNVFLLSAAVNISGLVFYLIFGRAD VQDWAKEQTFTHL (SEQ ID

NO:119), and/or LMKNPAAVGEMAPAMCAKTCNSPLRKPVYRGAISKKLT RAPDSQKLLMAEDSTKKVMVMLWDLTQGRDTRITDGKRTPMAVKSFLMV MSLR IFLERRKSASRPPSSC (SEQ ID NO:120). Polynucleotides encoding these polypeptides are also encompassed by the invention.

5 This gene is expressed primarily in human adult small intestine.

 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, renal and gastrointestinal disorders, or other disorders where ion
10 homeostasis is aberrant. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the renal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. renal, neural,
15 gastrointestinal, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, bile, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 65 as residues: Thr-27 to Arg-45.

 The tissue distribution in intestinal tissue combined with the homology to a conserved Na/Pa-i-contransporter suggests that polynucleotides and polypeptides corresponding to this gene are useful for the study, diagnosis and treatment of renal and
25 gastrointestinal disorders and/or diseases. The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of
30 other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anaemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility);
35 chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as

antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behaviour. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:11 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 666 of SEQ ID NO:11, b is an integer of 15 to 680, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:11, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 2

The translation product of this gene shares sequence homology with a chromaffin granule ATPase, in addition to the putative E1-E2 ATPase from *Mus musculus*, which are thought to be important in phagocytosis, blood clotting, and cellular metabolism (See Genbank Accession No.gil2895095 (AF011337)). The polynucleotide sequence of this clone may have a frame shift. Therefore the preferred signal peptide may reside in a frame other than the associated polynucleotides of the above referenced gene.

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

EYSTPDTVHLRKTILFSVKVPVLSEKMYCICPKSSVMFRARHCSCESVSSSY
NCMSWLMKYTWHALTISMEXYKEMGSKPAELYHVKNELTAAVTGDKEL
PSDLGT (SEQ ID NO:121), NQGSAEQQWAPLQAXKLERQ (SEQ ID NO:122),
and/or IRHETLRNTDAXXGIVIYAGHETKALLNNSGPRYKRXXSWRGR (SEQ ID NO:123). Polynucleotides encoding these polypeptides are also encompassed by the invention.

The gene encoding the disclosed cDNA is believed to reside on chromosome 15. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 15.

This gene is expressed primarily in human prostate.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive or cellular metabolism disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, seminal fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in prostate tissue combined with the homology to a conserved ATPase suggests that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of reproductive, metabolic, or haemopoietic disorders, such as congenital afflictions or proliferative conditions, including cancers. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:12 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 727 of SEQ ID NO:12, b is an integer of 15 to 741, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:12, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 3

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: HELGPVCLHAIMLAELIFLFRSLHGILASAGTIGAVAAWL

(SEQ ID NO:124). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in human testes.

Therefore, polynucleotides and polypeptides of the invention are useful as
5 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive disorders, particularly of the testes. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of
10 disorders of the above tissues or cells, particularly of the male reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. reproductive, testes, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, seminal fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a
15 disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 67 as residues: Glu-32 to Asn-54, His-98 to Arg-106, Ser-126 to Ser-134.

The tissue distribution in testes suggests that polynucleotides and polypeptides
20 corresponding to this gene are useful for the diagnosis and treatment of various reproductive or endocrine disorders, such as male infertility and hormone imbalances. The secreted protein may also be used as a contraceptive. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available
25 and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:13 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome.
30 Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 605 of SEQ ID NO:13, b is an integer of 15 to 619, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:13, and where b is greater than or equal to a + 14.

35

FEATURES OF PROTEIN ENCODED BY GENE NO: 4

The translation product of this clone has been shown to have homology to the Y isoform of the conserved human TPR motif which is thought to be important in maintaining cellular metabolism in addition to a possible connection in increasing an individual's susceptibility to male infertility (See Genbank Accession No.gil2580574 (AF000994)).

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

DFGTXSDPKLFEMIKYCLLKILKQYQTLREALVAAGKEVIWHGRTNDEPAH
YCSICEVEVFNLLFVTNESNTQKTYIVHCHDCARKTSKSLENFVVLEQYKMED
LIQVYDQFTLASPPMDQSAFTSSLLRPIKALGSGRAEQTSGDQLQKGATH
SRASSLLRAAEMTRRPASREELPDPGLFCHSIKLLFVLL (SEQ ID NO:125).

Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in activated human neutrophils and synovium.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly inflammatory conditions, and/or autoimmune disorders, such as arthritis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the inflammatory and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g.immune, skeletal, and cancerous and wounded tissues) or bodily fluids (e.g.lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in neutrophils and synovium suggests that polynucleotides and polypeptides corresponding to this gene are useful for the study, diagnosis, and treatment of inflammatory and immune disorders. Moreover, the protein may be useful for the detection and/or treatment of disorders and conditions affecting the skeletal system, in particular osteoporosis, bone cancer, as well as, disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as

dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:14 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 597 of SEQ ID NO:14, b is an integer of 15 to 611, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:14, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 5

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: LPGNFRPPRVILTFQWRFYLSFRKL (SEQ ID NO:126), and/or YLLLP CGLLSFWMCGALVVSPFVQNGQGQRLREARSLCLLKGT WIFLMLSLP HFLVQELKFSNFFSTVVIFSTSGFLQPTLIFLKLSWKSTHL (SEQ ID NO:127). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in anergic T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly inflammatory or immunodeficiency conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample

taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO.
5 69 as residues: Thr-32 to Leu-43.

The tissue distribution in T-cells suggests that polynucleotides and polypeptides corresponding to this gene are useful for the study and treatment of immune defects. More specifically, the gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness
10 in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease,
15 sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease,
20 scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available
25 and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:15 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome.
30 Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 571 of SEQ ID NO:15, b is an integer of 15 to 585, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 6

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

- 5 YMMVHCKYSVYNLLNKWIGFSIFPHWTWIDLEIGGLNLQVEIKGPNNCRVAG
EG RYKCSKGGSR (SEQ ID NO:128). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in anergic T-cells.

- Therefore, polynucleotides and polypeptides of the invention are useful as
10 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and hemopoietic disorders, particularly inflammatory or immunodeficiency conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification
15 of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample
20 taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

- The tissue distribution in T-cells suggests that polynucleotides and polypeptides corresponding to this gene are useful for the study and treatment of inflammation, and
25 other immune and hematopoietic disorders. Specifically, the gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also
30 used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-
35 host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene

product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

- 5 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:16 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome.
- 10 Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1026 of SEQ ID NO:16, b is an integer of 15 to 1040, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14.

15

FEATURES OF PROTEIN ENCODED BY GENE NO: 7

- In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:
- 20 MSAALWTYMRFLACLNHSSGSMYLSVNSTPVLLLLLVPN SARARA EFLQPG
GXTSSRAAXXAVELQLLFPLXXG (SEQ ID NO:129), FRQARNLMYVHNAAD
IHSSLPQHITVISPRELCHTFSLK PATLDLLCSLSVGNLFRIS ERQCKH (SEQ ID
NO:130), and/or RVNVSSIMDIHEVPGLSKSQLWFNVPVCQLHTCVAVAARA EF
25 GTSSCRIPAARGXH (SEQ ID NO:131). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in prostate cancer.

- Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a
- 30 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive disorders, particular prostate cancer or infertility. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cancer, especially
- 35 of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g.reproductive, prostate, and cancerous and wounded tissues) or bodily fluids (e.g.lymph, seminal

fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 71 as residues: Gln-51 to Thr-61, Ser-65 to Thr-71, Pro-85 to Gln-91.

The tissue distribution in prostate suggests that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of disorders of the reproductive system, particular proliferative conditions such as cancer.
10 Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:17 and may have been publicly available prior to conception of the present
15 invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 611 of SEQ ID NO:17, b is an integer of 15 to
20 625, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 8

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: IRHEGNSCTNKTAAHVLASYTECSC (SEQ ID NO:132). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in prostate.

30 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the reproductive system, particularly cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing
35 immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely

detected in certain tissues or cell types (e.g.reproductive, prostate, and cancerous and wounded tissues) or bodily fluids (e.g.lymph, seminal fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in prostate suggests that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of the reproductive system, such as proliferative conditions, including, but not limited to, prostate cancer.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:18 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 805 of SEQ ID NO:18, b is an integer of 15 to 819, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 9

This gene is expressed primarily in anergic T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and blood disorders, particularly inflammatory or immunodeficiency conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g.immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g.lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene

expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in T-cells suggests that polynucleotides and polypeptides corresponding to this gene are useful for the study and treatment of immune and inflammatory disorders. Moreover, the gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:19 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 768 of SEQ ID NO:19, b is an integer of 15 to 782, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 10

This gene is expressed primarily in anergic T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly inflammatory conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in T-cells suggests that polynucleotides and polypeptides corresponding to this gene are useful for the study and treatment of immune and blood disorders. Moreover, This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:20 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the

scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 641 of SEQ ID NO:20, b is an integer of 15 to 655, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 11

10

When tested against K562 cell lines, supernatants removed from cells containing this gene activated the ISRE (interferon-sensitive responsive element) pathway. Thus, it is likely that this gene activates leukemia cells through the Jak-STAT signal transduction pathway. ISRE is a promoter element found upstream in many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

20

This gene is expressed primarily in smooth muscle.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, vascular disorders, particularly microvascular disease, atherosclerosis, aneurysm, and stroke. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the vascular and smooth muscle tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. vascular tissue, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

35

The tissue distribution in smooth muscle, combined with the detected ISRE biological activity, suggests that polynucleotides and polypeptides corresponding to this gene are useful for the study, diagnosis, and treatment of vascular disorders. Protein,

as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:21 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 784 of SEQ ID NO:21, b is an integer of 15 to 798, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:21, and where b is greater than or equal to a + 14.

15 FEATURES OF PROTEIN ENCODED BY GENE NO: 12

The translation product of this gene shares sequence homology with the human IL-8 receptor (PF4AR), which is thought to be important in inflammatory disorders.

This gene is expressed primarily in synovial sarcoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, inflammatory disorders such as rheumatoid arthritis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, skeletal, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 76 as residues: Thr-17 to Leu-22.

The tissue distribution in synovial sarcoma, combined with the homology to an IL-8 receptor (PF4AR), suggests that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of inflammatory disorders such as rheumatoid arthritis. Similarly, this gene product may also be useful for the detection

and treatment of osteoporosis, bone cancer, as well as, disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:22 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 632 of SEQ ID NO:22, b is an integer of 15 to 646, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:22, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 13

When tested against PC12 cell lines, supernatants removed from cells containing this gene activated the EGR1 (early growth response gene 1) promoter element. Thus, it is likely that this gene activates sensory neuron cells through the EGR1 signal transduction pathway. EGR1 is a separate signal transduction pathway from Jak-STAT, genes containing the EGR1 promoter are induced in various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation.

This gene is expressed primarily in human testes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive disorders, particularly afflictions of the testes, such as male infertility. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s)

or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. reproductive, testes, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, seminal fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 77 as residues: Glu-33 to Arg-45.

The tissue distribution in testes combined with the detected EGR1 biological activity suggests that polynucleotides and polypeptides corresponding to this gene are useful for various reproductive disorders such as male infertility or associated endocrine disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:23 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 738 of SEQ ID NO:23, b is an integer of 15 to 752, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:23, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 14

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

YKVVLVWREDQSSHKIHLSTLIQNKALTLFNSMKAERGEE AXGKNVSS
(SEQ ID NO:133), and/or DGELSKCCMCSDYTIDCYFPISLPLLGRPYYLRHNIEI
RPYINHTMASKGSSKRMGCTSFTLTQKLEIILSEKGMWKAIEGQK LGXLHHS
(SEQ ID NO:134). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in fetal bone and testicular tumors.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental, skeletal, or reproductive disorders, particularly proliferative conditions such as testicular cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the male reproductive systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. reproductive, skeletal, testes, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in testes suggests that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of testicular cancer. Moreover, this gene product may be useful in the detection and treatment of disorders and conditions afflicting the skeletal system, in particular osteoporosis, bone cancer, as well as, disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Expression within fetal tissue and other cellular sources marked by proliferating cells suggests that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:24 and may have been publicly available prior to conception of the present

invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 801 of SEQ ID NO:24, b is an integer of 15 to 815, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:24, and where b is greater than or equal to a + 14.

10 FEATURES OF PROTEIN ENCODED BY GENE NO: 15

This gene is expressed primarily in stomach.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, gastrointestinal and digestive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the gastrointestinal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g.gastrointestinal, stomach, and cancerous and wounded tissues) or bodily fluids (e.g.lymph, bile, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 79 as residues: Ser-14 to Gln-23, Pro-32 to Lys-39.

The tissue distribution in stomach tissue suggests that polynucleotides and polypeptides corresponding to this gene are useful for the study and treatment of gastrointestinal, digestive, and general metabolic disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:25 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 864 of SEQ ID NO:25, b is an integer of 15 to 878, where both a and b correspond to the positions of nucleotide residues shown in
5 SEQ ID NO:25, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 16

10 In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: MLCINVQTHVYECA (SEQ ID NOP:135). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in anergic T-cells and CD34 depleted cord blood.

15 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hemopoietic, immune, or reproductive conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing
20 immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g.hemopoietic, immune, or reproductive, and cancerous and wounded tissues) or bodily fluids (e.g.lymph, amniotic fluid, serum,
25 plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in T-cells suggests that polynucleotides and polypeptides
30 corresponding to this gene are useful for the study and treatment of immune, inflammatory and other hematopoietic disorders. In addition, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of
35 cells of hematopoietic lineages. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis,

therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies
 5 directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:26 and may have been publicly available prior to conception of the present
 10 invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 836 of SEQ ID NO:26, b is an integer of 15 to
 15 850, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:26, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 17

20 In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:
 LCCPGWSAVVRSWLTATLASWVQAILMDSASQVAGITSVHHQAQLSFVFLVEM
 GLCHV GQAGLKLLASSDLPASASQSAGITGMSHHSWPERTSFIFKI (SEQ ID
 25 NO:136). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in human adult small intestine.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a
 30 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, gastrointestinal disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the gastrointestinal system, expression of this gene at
 35 significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g.gastrointestinal, metabolic, and cancerous and wounded tissues) or bodily fluids (e.g.lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another

tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in small intestine suggests that polynucleotides and polypeptides corresponding to this gene are useful for the study, diagnosis, and treatment of gastrointestinal disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:27 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 774 of SEQ ID NO:27, b is an integer of 15 to 788, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:27, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 18

The translation product of this gene was shown to have homology to the F33H2.2 protein from *Caenorhabditis elegans* (See Genbank Accession No.gnllPIDle1297838). Considering the homology to a *C.elegans* protein, an important and vital function may be attributed to this clone based upon its conservation. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

FGRGNTILFLRHNKDLVAQTAQPDQPNYGFPLDLLRCESLLGLDPATCSRVLN
KNYTL LVSMAPLTNEIRPVSSCTPQHIGPAIPEVSSVWFKLYIYHVTGQGPPSLL
LSKGTRLRLKLPDIFQSYDRLXITSWGHDPGVVPTSNVLTMLNDALTHSAVLIQ
GHGLHGIGETVHVPPFDETELQGEFTRVNMGVHVKALQILRNRVXLQHLCG
YVTMLNASSQLADRKLSDASDERGEPDLASGSDVNGSTESFEMVIEEATIDSAT
KQTSGATTEADWVPLV (SEQ ID NO:137). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in healing groin wound, and to a lesser extent, in synovium.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental, wound healing, and synovial disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the synovium and epithelium, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. developmental, skeletal, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in wounded tissue suggests that polynucleotides and polypeptides corresponding to this gene are useful for the study, diagnosis, and treatment of disorders involving the synovium and epithelium. Specifically, polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders including congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, urticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. In addition, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, athlete's foot, and ringworm). Moreover, the protein product of this clone may also be useful for the treatment or diagnosis of various connective tissue disorders such as arthritis, trauma, tendonitis, chondromalacia and inflammation, autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the

protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:28 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 834 of SEQ ID NO:28, b is an integer of 15 to 848, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:28, and where b is greater than or equal to a + 14.

15 FEATURES OF PROTEIN ENCODED BY GENE NO: 19

This gene is expressed primarily in ovarian cancer.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the reproductive system, particularly proliferative disorders of the ovary, such as cancer and cysts. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g.reproductive, ovarian tissue, and cancerous and wounded tissues) or bodily fluids (e.g.lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in ovarian tissue suggests that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of disorders of the reproductive system and cancers. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:29 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 741 of SEQ ID NO:29, b is an integer of 15 to 755, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:29, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 20

This gene is expressed primarily in prostate cancer.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive disorders, particularly proliferative conditions of the prostate, such as cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive disorders and cancer, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. reproductive, prostate, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 84 as residues: Lys-16 to Ser-21, Gly-36 to Asp-41.

The tissue distribution in prostate suggests that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of disorders of the reproductive organs and cancers, such as male infertility. Protein may also be useful as a contraceptive. The protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:30 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 799 of SEQ ID NO:30, b is an integer of 15 to 813, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:30, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 21

This gene is expressed primarily in B-cells and rhabdomyosarcoma. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, hematopoietic, or muscular disorders, particularly proliferative conditions such as cancer or fibroids. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the haemopoietic and muscular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, muscular, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in immune and muscle tissues or cells suggests that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of a variety of disorders, such as for the detection, and/or prevention of muscular dystrophy, cardiomyopathy, fibroids, myomas, and rhabdomyosarcomas. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ

ID NO:31 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more
5 polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 499 of SEQ ID NO:31, b is an integer of 15 to 513, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:31, and where b is greater than or equal to a + 14.

10

FEATURES OF PROTEIN ENCODED BY GENE NO: 22

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: GTRSINLLFFRCILEGGKSVEEQLCNSYKFS (SEQ ID
15 NO:138). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in anergic T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a
20 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and blood conditions, particularly inflammatory or immunodeficiency disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells,
25 particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene
30 expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in T-cells suggests that polynucleotides and polypeptides corresponding to this gene are useful for the study and treatment of inflammation and immune disorders. More specifically, the gene product may be involved in the
35 regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene

product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:32 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 562 of SEQ ID NO:32, b is an integer of 15 to 576, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:32, and where b is greater than or equal to a + 14.

25

FEATURES OF PROTEIN ENCODED BY GENE NO: 23

The translation product of this gene was shown to have homology to the gil2501808 brain digoxin carrier protein of *Rattus norvegicus* which is thought to serve the role as a sodium-independent organic anion transporter. This gene may also play a role in hormone transport. When tested against U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates promyelocytic cells through the Jak-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the

GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

5 LTVPRRCPAATETNVDGQKVYRDCSCIPQNLSSGFGHATAGXMHFNLSEKAPP
SGFHIRCEFSLSXSSIPALTATLRCVRDPQRSFALGIQWIVVRILGGIPGPIAFG
W VIDKACLLWQXQCGQXGSCLVYQXRP (SEQ ID NO:139). Polynucleotides
encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in retina.

10 Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, visual disorders. Similarly, polypeptides and antibodies directed to these
polypeptides are useful in providing immunological probes for differential identification
15 of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells,
particularly of the eye, expression of this gene at significantly higher or lower levels
may be routinely detected in certain tissues or cell types (e.g.ophthalmic tissue, retinal
tissue, cancerous and wounded tissues) or bodily fluids (e.g.lymph, vitreous humor,
aqueous humor, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue
20 or cell sample taken from an individual having such a disorder, relative to the standard
gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an
individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO.
87 as residues: Gln-27 to Arg-36.

25 The tissue distribution in retinal tissue combined with the detected GAS
biological activity suggests that polynucleotides and polypeptides corresponding to this
gene are useful for the diagnosis and treatment of visual disorders of the eye. Protein,
as well as, antibodies directed against the protein may show utility as a tumor marker
and/or immunotherapy targets for the above listed tissues.

30 Many polynucleotide sequences, such as EST sequences, are publicly available
and accessible through sequence databases. Some of these sequences are related to SEQ
ID NO:33 and may have been publicly available prior to conception of the present
invention. Preferably, such related polynucleotides are specifically excluded from the
scope of the present invention. To list every related sequence would be cumbersome.

35 Accordingly, preferably excluded from the present invention are one or more
polynucleotides comprising a nucleotide sequence described by the general formula of
a-b, where a is any integer between 1 to 1005 of SEQ ID NO:33, b is an integer of 15

to 1019, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:33, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 24

This gene is expressed primarily in synovial fluid of a patient with chronic synovitis.

Therefore, polynucleotides and polypeptides of the invention are useful as
10 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or skeletal disorders, particularly inflammatory disorders such as arthritis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s)
15 or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, skeletal, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken
20 from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in synovial fluid suggests that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of
25 inflammatory disorders such as arthritis. Moreover, the expression of this gene product in synovium would suggest a role in the detection and treatment of disorders and conditions affecting the skeletal system, in particular osteoporosis, bone cancer, as well as, disorders afflicting connective tissues (e.g. trauma, tendonitis, chondromalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders
30 such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or
35 immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ

ID NO:34 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more
5 polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 419 of SEQ ID NO:34, b is an integer of 15 to 433, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:34, and where b is greater than or equal to a + 14.

10

FEATURES OF PROTEIN ENCODED BY GENE NO: 25

The polynucleotide sequence of this clone may have a frame shift. Therefore the preferred signal peptide may reside in a frame other its associated polynucleotides. In
15 specific embodiments, polypeptides of the invention comprise the following amino acid sequence: LVMQCLGQVLSPLRTSVCLPIERGRWPGMVPHTTSALGG (SEQ ID NO:140), and/or QNTIHSLLPQGRMTKSLVLEEQKRKAGRSEMKLELLMRVSL WYSGQALVLLGLITN LSCSVLGKSFHLSGPLSVSL (SEQ ID NO:141).

Polynucleotides encoding these polypeptides are also encompassed by the invention.

20 This gene is expressed primarily in human synovium.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and inflammatory disorders, such as arthritis. Similarly,
25 polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and inflammatory systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g.skeletal, synovium, and
30 cancerous and wounded tissues) or bodily fluids (e.g.lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

35 The tissue distribution in synovium suggests that polynucleotides and polypeptides corresponding to this gene are useful for the study, diagnosis, and treatment of immune and inflammatory disorders. In addition, the gene product may

play a role in the detection and treatment of disorders and conditions affecting the skeletal system, in particular osteoporosis, bone cancer, as well as, disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:35 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 628 of SEQ ID NO:35, b is an integer of 15 to 642, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:35, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 26

This gene is expressed primarily in synovial fluid of a patient with chronic synovitis.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or skeletal disorders, particularly inflammatory disorders such as arthritis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, skeletal, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual

having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 90 as residues: Pro-29 to Ser-35.

The tissue distribution in synovium suggests that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of inflammatory disorders such as arthritis. In addition, the gene product may play a role in the detection and treatment of disorders and conditions affecting the skeletal system, in particular osteoporosis, bone cancer, as well as, disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:36 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 653 of SEQ ID NO:36, b is an integer of 15 to 667, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:36, and where b is greater than or equal to a + 14.

30

FEATURES OF PROTEIN ENCODED BY GENE NO: 27

When tested against K562 cell lines, supernatants removed from cells containing this gene activated the ISRE (interferon-sensitive responsive element) promoter element. Thus, it is likely that this gene activates leukemia cells through the Jak-STAT signal transduction pathway. ISRE is a promoter element found upstream in many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a

35

large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

5 This gene is expressed primarily in anergic T-cells.

 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and blood disorders, particularly inflammatory or
10 immunodeficiency disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune,
15 hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 91 as residues: Gly-31 to Phe-36.

 The tissue distribution in T-cells, combined with the detected ISRE biological activity suggests that polynucleotides and polypeptides corresponding to this gene are useful for the study and treatment of immune and blood diseases. More specifically, the
25 gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including
30 arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune
35 infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of

stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

- 5 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:37 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome.
- 10 Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 640 of SEQ ID NO:37, b is an integer of 15 to 654, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:37, and where b is greater than or equal to a + 14.
- 15

FEATURES OF PROTEIN ENCODED BY GENE NO: 28

- When tested against K562 cell lines, supernatants removed from cells
- 20 containing this gene activated the ISRE (interferon-sensitive responsive element) promoter element. Thus, it is likely that this gene activates leukemia cells through the Jak-STAT signal transduction pathway. ISRE is a promoter element found upstream in many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of
- 25 cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in human fibrosarcoma.

- Therefore, polynucleotides and polypeptides of the invention are useful as
- 30 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, muscle disorders, particularly proliferative conditions such as cancer or fibroids. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s)
- 35 or cell type(s). For a number of disorders of the above tissues or cells, particularly of the metabolic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g.muscle, and cancerous and

wounded tissues) or bodily fluids (e.g.lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 92 as residues: Asn-12 to Thr-18.

The tissue distribution in fibrosarcoma, combined with the detected ISRE biological activity, suggests that polynucleotides and polypeptides corresponding to this gene are useful for the study, diagnosis, and/or treatment of various cancers. Protein,
10 as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:38 and may have been publicly available prior to conception of the present
15 invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 717 of SEQ ID NO:38, b is an integer of 15 to
20 731, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:38, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 29

25

This gene is expressed primarily in salivary gland.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are
30 not limited to, epithelial, immune, and digestive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the epithelial, digestive, and immune systems, expression of this gene at significantly higher or lower levels may be routinely
35 detected in certain tissues or cell types (e.g.epithelial, immune, digestive tissues, and cancerous and wounded tissues) or bodily fluids (e.g.lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual

having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5 The tissue distribution in salivary tissue suggests that polynucleotides and polypeptides corresponding to this gene are useful for the study, diagnosis, and treatment of various disorders of the immune, digestive and epithelial systems. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

10 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:39 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more
15 polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 364 of SEQ ID NO:39, b is an integer of 15 to 378, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:39, and where b is greater than or equal to a + 14.

20

FEATURES OF PROTEIN ENCODED BY GENE NO: 30

This gene is expressed primarily in spongy brain tissue obtained from Alzheimer's patients.

25 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, Alzheimer's disease; neurodegenerative disorders including, but not restricted to Alzheimer's, such as schizophrenia, ALS, etc. Similarly, polypeptides and
30 antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain and nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, cancerous and wounded tissues) or bodily fluids
35 (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard

gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 94 as residues: Leu-69 to Leu-74.

5 The tissue distribution suggests that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of neurodegenerative disorders, particularly Alzheimer's disease. Specific expression of this gene product in the brain tissue of Alzheimer's patients suggests that it may play a deleterious role in the progression of the disease. Alternately, it may represent an attempted response by the body to combat the progression of Alzheimer's. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

10 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:40 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 628 of SEQ ID NO:40, b is an integer of 15 to 642, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:40, and where b is greater than or equal to a + 14.

25 **FEATURES OF PROTEIN ENCODED BY GENE NO: 31**

This gene is expressed primarily in epididymus, and to a lesser extent, in colon tissue.

30 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, infertility; sperm developmental/survival disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types or cell types (e.g. reproductive, cancerous and

wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 95 as residues: Lys-35 to Glu-41, Ala-62 to Asn-67.

The tissue distribution in epididymus suggests that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of male infertility. Specific expression of this gene product within the epididymus
10 suggests that it plays key roles in the development and/or survival of sperm. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ
15 ID NO:41 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of
20 a-b, where a is any integer between 1 to 428 of SEQ ID NO:41, b is an integer of 15 to 442, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:41, and where b is greater than or equal to a + 14.

25 **FEATURES OF PROTEIN ENCODED BY GENE NO: 32**

The gene encoding the disclosed cDNA is thought to reside on chromosome 4. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 4.

30 This gene is expressed primarily in resting T-cells, and to a lesser extent, in healing groin wound library.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are
35 not limited to, immunological disorders and wound healing. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of

disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types or cell types (e.g. immune, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or
5 another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 96 as residues: Lys-29 to Val-34, Cys-94 to Asp-99, Ser-102 to Val-107, Gln-133 to
10 Lys-139.

The tissue distribution in T-cells suggests that polynucleotides and polypeptides corresponding to this gene are useful for modulating the immune response during wound repair. The translation product of this gene may function as a stimulator for the growth of bone, cartilage, tendons, ligaments and/or nerves, which would be useful for
15 the treatment of wounds. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ
20 ID NO:42 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of
25 a-b, where a is any integer between 1 to 1720 of SEQ ID NO:42, b is an integer of 15 to 1734, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:42, and where b is greater than or equal to a + 14.

30 **FEATURES OF PROTEIN ENCODED BY GENE NO: 33**

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

MPRPSPLSSPGSPVTSQLCSPMPSLNPALPWGLLLALPGLSLHTPFQTLTAASP

35 HQPSGDSAAHLSAHSFLLDSH (SEQ ID NO: 142). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune-related diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types or cell types (e.g. immune, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 97 as residues: Pro-46 to Pro-53, His-55 to Cys-63.

The tissue distribution in neutrophils suggests that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treating immune related diseases. Expression of this gene product in neutrophils suggests a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:43 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the

scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 503 of SEQ ID NO:43, b is an integer of 15 to 517, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:43, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 34

This gene is expressed primarily in 12 week-old human embryos.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental abnormalities; cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the embryo, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types or cell types (e.g. embryonic, cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 98 as residues: Ser-37 to Tyr-43.

The tissue distribution in embryonic tissue suggests that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, detection, and/or treatment of developmental disorders. The relatively specific expression of this gene product during embryogenesis suggests that it may be a key player in the proliferation, maintenance, and/or differentiation of various cell types during development. It may also act as a morphogen to control cell and tissue type specification. Expression within embryonic tissue and other cellular sources marked by proliferating cells suggests that this protein may play a role in the regulation of cellular division. Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:44 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 472 of SEQ ID NO:44, b is an integer of 15 to 486, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 35

This gene is expressed primarily in CD34 depleted buffy coat (cord blood). Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, blood and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types or cell types (e.g. immune, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 99 as residues: Pro-26 to Arg-40, Pro-43 to Lys-49.

The tissue distribution in CD34 depleted buffy coat cells suggests that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of haemopoietic and immune disorders. Expression of this gene product in CD34 depleted buffy coat (cord blood) suggests a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a

usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:45 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 812 of SEQ ID NO:45, b is an integer of 15 to 826, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 36

25

This gene is expressed primarily in adipose tissue, and to a lesser extent, in placental tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, metabolic or reproductive disorders, particularly obesity. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the metabolic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types or cell types (e.g. adipose, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal

fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5 The tissue distribution in adipose tissue suggests that polynucleotides and polypeptides corresponding to this gene are useful for treatment of obesity by targeting adipose cells. Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues.

10 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:46 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more
15 polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 680 of SEQ ID NO:46, b is an integer of 15 to 694, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14.

20

FEATURES OF PROTEIN ENCODED BY GENE NO: 37

This gene is expressed primarily in adult pulmonary tissue.

25 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, pulmonary disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above
30 tissues or cells, particularly of the pulmonary system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types or cell types (e.g. lung, cancerous and wounded tissues) or bodily fluids (e.g. lymph, pulmonary surfactant or sputum, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a
35 disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in pulmonary tissue suggests that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of certain pulmonary disorders, such as lung cancer, ARDS, and emphysema. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:47 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 842 of SEQ ID NO:47, b is an integer of 15 to 856, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 38

This gene is expressed primarily in amygdala of the brain, and to a lesser extent, in infant brain tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental and neurodegenerative diseases of the brain and nervous system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system (CNS), expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types or cell types (e.g. brain, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 102 as residues: Pro-30 to Gln-35, Pro-44 to Leu-50.

The tissue distribution in neural tissues suggests that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of behavioral or nervous system disorders, such as depression, schizophrenia, Alzheimer's disease, dementia, paranoia, autism, and addictive behavior. The amygdala processes sensory information and relays this to other areas of the brain including the endocrine and autonomic domains of the hypothalamus and the brain stem. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:48 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1629 of SEQ ID NO:48, b is an integer of 15 to 1643, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 39

This gene is expressed primarily in synovial hypoxia.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, connective tissue disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the connective tissue system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., skeletal, connective, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 103 as residues: Asn-30 to Gly-37.

The tissue distribution in skeletal tissue suggests that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of diseases of connective tissue, particularly synovia, including but not limited to inflammation, rheumatoid arthritis, osteoarthritis, and cartilage tears and physical injury, as well as osteoporosis, tendonitis, chondromalacia and inflammation. Furthermore, the translation product of this gene may be useful in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:49 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 695 of SEQ ID NO:49, b is an integer of 15 to 709, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 40

This gene is expressed primarily in synovial cells stimulated with IL-1 and TNF.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, inflammation of connective tissue. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of

the above tissues or cells, particularly of connective tissue, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types or cell types (e.g. connective, skeletal, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another
5 tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 104 as residues: Gln-31 to Pro-39.

10 The tissue distribution in synovial cells suggests that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of inflammation of connective tissues, particularly the synovium, in diseases such as rheumatoid arthritis, sepsis, infection of the joint, and tissue damage from physical injury. Furthermore, the expression of this gene product may be useful in the diagnosis
15 or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the
20 protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:50 and may have been publicly available prior to conception of the present
25 invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 527 of SEQ ID NO:50, b is an integer of 15 to
30 541, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:50, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 41

35 When tested against U937 myeloid cell lines as well as Jurkat T-cell cell lines, supernatants removed from cells containing this gene activated the GAS assay.

Therefore, it is likely that this gene activates immune cells through the Jak-STAT signal transduction pathway. Gamma activating sequence (GAS) is a promoter element found upstream of many genes involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in melanocytes, and to a lesser extent, in the synovium and CD34 cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, from the discoloration of the skin to arthritis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal/ muscle system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types or cell types (e.g. bone, cartilage, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 105 as residues: Arg-35 to Ala-41.

The tissue distribution in synovium suggests that polynucleotides and polypeptides corresponding to this gene are useful for the treatment or diagnosis of diseases affecting the skeletal system, in particular osteoporosis, as well as disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ

ID NO:51 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more
5 polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 706 of SEQ ID NO:51, b is an integer of 15 to 720, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:51, and where b is greater than or equal to a + 14.

10

FEATURES OF PROTEIN ENCODED BY GENE NO: 42

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

15 MDTYTFLIKICKIFCSFLKCHIQVCGHLLFLIFTSIKWARKQHHCSRCKAIGLSS
(SEQ ID NO: 143). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in synovial tissue and neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as
20 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above
25 tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types or cell types (e.g. immune, skeletal, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to
30 the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in synovium and neutrophils suggests that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of immune diseases, particularly inflammatory conditions such as
35 arthritis. Expression of this gene product in neutrophils suggests a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be

involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:52 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 965 of SEQ ID NO:52, b is an integer of 15 to 979, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:52, and where b is greater than or equal to a + 14.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 43

This gene is expressed primarily in CD34 depleted buffy coat (cord blood).

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, blood, developmental, and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types or cell types (e.g. immune, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or

another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO.
5 107 as residues: Ser-41 to Lys-49.

The tissue distribution in CD34 depleted buffy coat suggests that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of haemopoietic and immune disorders. Furthermore, expression of this gene product in CD34 depleted buffy coat (cord blood) suggests a
10 role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by
15 boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product
20 may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available
25 and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:53 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more
30 polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 366 of SEQ ID NO:53, b is an integer of 15 to 380, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:53, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 44

The translation product of this gene shares sequence homology with the
5 conserved NADH-isocitrate dehydrogenase which is thought to be important in the
proliferation of lymphocytes. When tested against Jurkat T-cell cell lines, supernatants
removed from cells containing this gene activated the GAS assay. Therefore, it is likely
that this gene activates immune cells through the Jak-STAT signal transduction
pathway. Gamma activating sequence (GAS) is a promoter element found upstream of
10 many genes involved in the Jak-STAT pathway. The Jak-STAT pathway is a large,
signal transduction pathway involved in the differentiation and proliferation of cells.
Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS
element, can be used to indicate proteins involved in the proliferation and differentiation
of cells. It is likely that a frame shift or shifts occur in the translation of the sequence,
15 which can be easily corrected by those individuals skilled in the art of molecular
biology.

This gene is expressed primarily in T-cells and B-cells and to a lesser extent in
breast cancer.

Therefore, polynucleotides and polypeptides of the invention are useful as
20 reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, breast cancer, leukemia, HIV, and tonsillitis. Similarly, polypeptides and
antibodies directed to these polypeptides are useful in providing immunological probes
for differential identification of the tissue(s) or cell type(s). For a number of disorders
25 of the above tissues or cells, particularly of the immune/lymphoid system, expression
of this gene at significantly higher or lower levels may be routinely detected in certain
tissues or cell types (e.g., immune, reproductive, breast, cancerous and wounded
tissues) or bodily fluids (e.g. lymph, breast milk, serum, plasma, urine, synovial fluid
and spinal fluid) or another tissue or cell sample taken from an individual having such a
30 disorder, relative to the standard gene expression level, i.e., the expression level in
healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO.
108 as residues: Cys-31 to Trp-36.

The tissue distribution in immune cells, combined with the detected gas
35 biological activity, and its homology to the NADH-isocitrate dehydrogenase suggests
that polynucleotides and polypeptides corresponding to this gene are useful for the
treatment or diagnosis of diseases related to the proliferation of lymphoid cells.

Furthermore, it could be especially useful in helping the body produce mature lymphocytes to enhance the immune system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

5 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:54 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome.

10 Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2009 of SEQ ID NO:54, b is an integer of 15 to 2023, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:54, and where b is greater than or equal to a + 14.

15

FEATURES OF PROTEIN ENCODED BY GENE NO: 45

This gene is expressed primarily in PHA treated T-cells.

20 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, T-cell disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification

25 of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types or cell types (e.g. immune, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an

30 individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in T-cells suggests that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune

35 disorders involving T-cells. Furthermore, the gene product may play a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be

involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:55 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 871 of SEQ ID NO:55, b is an integer of 15 to 885, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:55, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 46

This gene is expressed primarily in fetal heart.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, mitrovalve prolapse, congenital heart diseases or arhythmic heartbeats. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types or cell types (e.g. cardiac, developmental, cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic

fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5 The tissue distribution in fetal heart suggests that polynucleotides and polypeptides corresponding to this gene are useful for the treatment or diagnosis of heart diseases especially in the developing fetus. The sequence itself could be used in genetic therapy, in utero, to correct defects in the developing fetus. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or
10 immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:56 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the
15 scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1092 of SEQ ID NO:56, b is an integer of 15 to 1106, where both a and b correspond to the positions of nucleotide residues shown
20 in SEQ ID NO:56, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 47

25 This gene is expressed primarily in spleen tissue of chronic lymphocytic leukemia patient.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are
30 not limited to, leukemia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types or cell types (e.g.
35 immune, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.,

the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 111 as residues: Pro-42 to Lys-49.

5 The tissue distribution in spleen suggests that polynucleotides and polypeptides corresponding to this gene are useful for the treatment or diagnosis of patients with leukemia. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available
10 and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:57 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more
15 polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 750 of SEQ ID NO:57, b is an integer of 15 to 764, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:57, and where b is greater than or equal to a + 14.

20

FEATURES OF PROTEIN ENCODED BY GENE NO: 48

This gene is expressed primarily in liver cancer tissue, and to a lesser extent in bone marrow, neutrophils, and CD34 cells.

25 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, liver cancer, scerosis of the liver. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for
30 differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the lymphatic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types or cell types (e.g. liver, immune, hematopoietic, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal
35 fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in liver tissue suggests that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of liver cancer, possibly before the onset of symptoms. Similarly, this gene would be useful for the detection and treatment of liver disorders and cancers (e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:58 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 724 of SEQ ID NO:58, b is an integer of 15 to 738, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:58, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 49

This gene is expressed primarily in synovial hypoxia.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, connective tissue and joint disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of connective tissue, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types or cell types (e.g. connective, skeletal, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in synovial hypoxia suggests that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of diseases of connective tissue, particularly synovia, including but not limited to inflammation, rheumatoid arthritis, osteoarthritis, and cartilage tears and physical injury. Furthermore, polynucleotides and polypeptides corresponding to this gene are useful in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:59 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 427 of SEQ ID NO:59, b is an integer of 15 to 441, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:59, and where b is greater than or equal to a + 14.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 50

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

MIMGYKSQKTFGLFDLXXVKGKTSVLEFDVWVQIPVASLLALWLNRLLSVK
30 WALKXCVIHSVAVNX (SEQ ID NO: 144). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in B-cell lymphoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, B-cell lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential

identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types or cell types (e.g. immune, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 114 as residues: Arg-32 to Gly-40.

The tissue distribution in B-cell lymphoma suggests that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune or hematopoietic disorders, particularly those involving proliferative cells or tissues such as in cancers. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:60 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 770 of SEQ ID NO:60, b is an integer of 15 to 784, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:60, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 51

30

This gene is expressed primarily in synovial hypoxia.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, connective tissue disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of

the above tissues or cells, particularly of connective tissue, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types or cell types (e.g. connective, skeletal, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another
5 tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in synovial hypoxia suggests that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of
10 diseases of connective tissue, particularly synovia, including but not limited to inflammation, rheumatoid arthritis, osteoarthritis, and cartilage tears and physical injury. Furthermore, polynucleotides and polypeptides corresponding to this gene are useful in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism,
15 spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:61 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome.
25 Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 525 of SEQ ID NO:61, b is an integer of 15 to 539, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:61, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 52

This gene is expressed primarily in synovial cells stimulated with IL-1 and TNF
35 and also in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include, but are not limited to, inflammation of connective tissue and joints. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of connective tissue, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types or cell types (e.g. connective, skeletal, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 116 as residues: Val-4 to Glu-9, Lys-42 to Lys-47.

The tissue distribution in synovial cells suggests that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of inflammation of connective tissues, particularly the synovium, in diseases such as rheumatoid arthritis, sepsis, infection of the joint, and tissue damage from physical injury. Furthermore, polynucleotides and polypeptides corresponding to this gene are useful in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:62 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 590 of SEQ ID NO:62, b is an integer of 15 to 604, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:62, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 53

In specific embodiments, polypeptides of the invention comprise the following
5 amino acid sequence:
MKSFPSTYFKSSSFQNTKYQTGVISVLISYEIEYAAFYHLSCKITLPSSVSRNCFI
SEXLVASQCLDT (SEQ ID NO: 145). Polynucleotides encoding these polypeptides
are also encompassed by the invention.

This gene is expressed primarily in frontal cortex sampled from an epileptic
10 patient.

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, epilepsy. Similarly, polypeptides and antibodies directed to these
15 polypeptides are useful in providing immunological probes for differential identification
of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells,
particularly of the nervous system, expression of this gene at significantly higher or
lower levels may be routinely detected in certain tissues or cell types (e.g. brain,
cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine,
20 synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual
having such a disorder, relative to the standard gene expression level, i.e., the
expression level in healthy tissue or bodily fluid from an individual not having the
disorder.

The tissue distribution in frontal cortex suggests that polynucleotides and
25 polypeptides corresponding to this gene are useful for the treatment and diagnosis of
epilepsy and related brain disorders. Additionally, the tissue distribution suggests that
polynucleotides and polypeptides corresponding to this gene are useful for the
diagnosis and/or treatment of disorders of the brain and nervous system. Elevated
expression of this gene product within the frontal cortex of the brain suggests that it
30 may be involved in neuronal survival; synapse formation; conductance; neural
differentiation, etc. Such involvement may impact many processes, such as learning
and cognition. It may also be useful in the treatment of such neurodegenerative
disorders as schizophrenia; ALS; or Alzheimer's. Protein, as well as, antibodies
directed against the protein may show utility as a tumor marker and/or immunotherapy
35 targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available
and accessible through sequence databases. Some of these sequences are related to SEQ

ID NO:63 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more

5 polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 738 of SEQ ID NO:63, b is an integer of 15 to 752, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:63, and where b is greater than or equal to a + 14.

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
1	HSIDU19	209244 09/12/97	Uni-ZAP XR	11	680	1	680	352	352	65	1	21	22	73
2	HPRSB76	209244 09/12/97	pBluescript	12	741	1	741	127	127	66	1	22	23	59
3	HTEIL66	209244 09/12/97	Uni-ZAP XR	13	619	1	619	123	123	67	1	24	25	134
4	HSNAY92	209244 09/12/97	Uni-ZAP XR	14	611	1	611	127	127	68	1	29	30	35
5	HSABG21	209244 09/12/97	pBluescript SK-	15	585	1	585	96	96	69	1	24	25	125
6	HSAXB32	209244 09/12/97	Uni-ZAP XR	16	1040	1	1040	97	97	70	1	36	37	51
7	HPEAD48	209244 09/12/97	Uni-ZAP XR	17	625	1	625	203	203	71	1	18	19	97

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
8	HPVAB94	209244 09/12/97	Uni-ZAP XR	18	819	1	819	80	80	72	1	25	26	44
9	HSAXB81	209244 09/12/97	Uni-ZAP XR	19	782	1	782	143	143	73	1	20	21	47
10	HSAYC21	209244 09/12/97	Uni-ZAP XR	20	655	1	655	155	155	74	1			26
11	HSLCU73	209244 09/12/97	Uni-ZAP XR	21	798	1	798	7	7	75	1	22	23	41
12	HSSFZ70	209244 09/12/97	Uni-ZAP XR	22	646	1	646	212	212	76	1	22	23	22
13	HTEIP36	209244 09/12/97	Uni-ZAP XR	23	752	1	752	22	22	77	1	19	20	58
14	HYBAY77	209244 09/12/97	Uni-ZAP XR	24	815	60	815	157	157	78	1	44	45	47
15	HROAE78	209244 09/12/97	Uni-ZAP XR	25	878	1	878	132	132	79	1	16	17	52

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
16	HSVP17	209244 09/12/97	Uni-ZAP XR	26	850	1	850	69	69	80	1	18	19	44
17	HSIEA14	209244 09/12/97	Uni-ZAP XR	27	788	1	788	141	141	81	1	22	23	60
18	HSNAQ47	209244 09/12/97	Uni-ZAP XR	28	848	1	848	85	85	82	1	21	22	24
19	HODDN65	209244 09/12/97	Uni-ZAP XR	29	755	1	755	251	251	83	1	14	15	20
20	HPEAD79	209244 09/12/97	Uni-ZAP XR	30	813	1	813	51	51	84	1	15	16	41
21	HRDED19	209244 09/12/97	Uni-ZAP XR	31	513	1	513	75	75	85	1	20	21	47
22	HSAYS89	209244 09/12/97	Uni-ZAP XR	32	576	1	576	94	94	86	1	15	16	43
23	HTODK73	209244 09/12/97	Uni-ZAP XR	33	1019	4	1019	43	43	87	1	23	24	59

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
24	HSVAM10	209244 09/12/97	Uni-ZAP XR	34	433	1	433	46	46	88	1	27	28	51
25	HSNBN57	209244 09/12/97	Uni-ZAP XR	35	642	1	642	198	198	89	1	20	21	31
26	HSVBD22	209244 09/12/97	Uni-ZAP XR	36	667	1	667	61	61	90	1	24	25	35
27	HSAWA27	209244 09/12/97	Uni-ZAP XR	37	654	1	654	319	319	91	1	29	30	49
28	HSFAH43	209244 09/12/97	Uni-ZAP XR	38	731	1	731	191	191	92	1	22	23	24
29	HSPAA60	209244 09/12/97	pSport1	39	378	1	378	198	198	93	1	45	46	46
30	HFAEF57	209277 09/18/97	Uni-ZAP XR	40	642	1	642	232	232	94	1	42	43	86
31	HEGAH43	209277 09/18/97	Uni-ZAP XR	41	442	1	442	29	29	95	1	20	21	111

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
32	HAGDG59	209277 09/18/97	Uni-ZAP XR	42	1734	44	1717	124	124	96	1	18	19	300
33	HNGBX63	209277 09/18/97	Uni-ZAP XR	43	517	1	517	120	120	97	1	15	16	104
34	HE2AG50	209277 09/18/97	Uni-ZAP XR	44	486	1	486	19	19	98	1	32	33	43
35	HCUIN80	209277 09/18/97	ZAP Express	45	826	1	826	106	106	99	1	16	17	49
36	HADCL29	209277 09/18/97	pSport1	46	694	1	694	248	248	100	1	16	17	47
37	HAPPS89	209277 09/18/97	Uni-ZAP XR	47	856	1	856	54	54	101	1	29	30	99
38	HFGAH44	209277 09/18/97	Uni-ZAP XR	48	1643	1	1643	34	34	102	1	20	21	58
39	HFIHZ96	209277 09/18/97	pSport1	49	709	1	709	39	39	103	1	24	25	64

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
40	HFIUR10	209277 09/18/97	pSport1	50	541	1	541	50	50	104	1	22	23	44
41	HLDNA86	209277 09/18/97	pCMVSPORT 3.0	51	720	1	717	45	45	105	1	31	32	92
42	HNGAN75	209277 09/18/97	Uni-ZAP XR	52	979	1	979	41	41	106	1	25	26	25
43	HCUIO20	209277 09/18/97	ZAP Express	53	380	1	380	43	43	107	1	19	20	67
44	HLTEF12	209277 09/18/97	Uni-ZAP XR	54	2023	624	1498	686	686	108	1	21	22	44
45	HCFBJ91	209277 09/18/97	pSport1	55	885	1	885	61	61	109	1	20	21	52
46	HHFHP90	209277 09/18/97	Uni-ZAP XR	56	1106	1	1106	42	42	110	1	14	15	43
47	HLYCQ48	209277 09/18/97	pSport1	57	764	1	764	58	58	111	1	40	41	64

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
48	HHLAB07	209277 09/18/97	pBluescript SK-	58	738	1	738	108	108	112	1	34	35	69
49	HFOXEX30	209277 09/18/97	pSport1	59	441	1	441	38	38	113	1	18	19	53
50	HBJEL68	209277 09/18/97	Uni-ZAP XR	60	784	1	784	109	109	114	1	33	34	41
50	HBJEL68	209277 09/18/97	Uni-ZAP XR	64	769	1	769	111	111	118	1			26
51	HFOXA73	209277 09/18/97	pSport1	61	539	1	539	15	15	115	1			17
52	HFIUR35	209277 09/18/97	pSport1	62	604	1	604	42	42	116	1	31	32	70
53	HFPDE86	209277 09/18/97	Uni-ZAP XR	63	752	1	752	300	300	117	1			16

Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

SEQ ID NO:X and the translated SEQ ID NO:Y are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used to generate antibodies which bind specifically to the secreted proteins encoded by the cDNA clones identified in Table 1.

Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid
5 sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide
10 sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1. The nucleotide sequence of each deposited clone can readily be determined by
15 sequencing the deposited clone in accordance with known methods. The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its
20 sequence.

The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include preparing probes or primers from the disclosed sequence and
25 identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are species homologs. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for the desired
30 homologue.

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well
35 understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below).

It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

5 The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified by the one-step method described in Smith and Johnson, *Gene* 67:31-40 (1988). Polypeptides of the invention also can be purified from natural or recombinant sources
10 using antibodies of the invention raised against the secreted protein in methods which are well known in the art.

Signal Sequences

Methods for predicting whether a protein has a signal sequence, as well as the
15 cleavage point for that sequence, are available. For instance, the method of McGeoch, *Virus Res.* 3:271-286 (1985), uses the information from a short N-terminal charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, *Nucleic Acids Res.* 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1
20 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of these methods is in the range of 75-80%. (von Heinje, *supra*.) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

In the present case, the deduced amino acid sequence of the secreted polypeptide
25 was analyzed by a computer program called SignalP (Henrik Nielsen et al., *Protein Engineering* 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results
30 shown in Table 1.

As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty. Accordingly, the present invention provides secreted polypeptides having a sequence shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., +
35 or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely

uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Polynucleotide and Polypeptide Variants

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

By a polynucleotide having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown in Table 1, the ORF (open reading frame), or any fragment specified as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization

Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query

amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions,
5 interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequences shown in Table 1 or to the amino acid sequence encoded by deposited DNA clone can be
10 determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and
15 subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window
20 Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity.
25 For subject sequences truncated at the N- and C-termini, relative to the the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of
30 the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are
35 considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired
5 residues represent 10% of the sequence (number of residues at the N- and C- termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence.
10 This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query
15 sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or
20 activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in
25 the human mRNA to those preferred by a bacterial host such as *E. coli*).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level.
30 Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be
35 deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., *J. Biol. Chem.* 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after

deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., J. Biotechnology 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used. (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

Polynucleotide and Polypeptide Fragments

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence contained in the deposited clone or shown in SEQ ID NO:X. The short nucleotide fragments are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in the deposited clone or the nucleotide sequence shown in SEQ ID NO:X. These nucleotide fragments are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments having a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X or the cDNA contained in the deposited clone. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein.

In the present invention, a "polypeptide fragment" refers to a short amino acid sequence contained in SEQ ID NO:Y or encoded by the cDNA contained in the deposited clone. Protein fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-

60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred.

5 Similarly, polynucleotide fragments encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-
10 forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotide
15 fragments encoding these domains are also contemplated.

Other preferred fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.
20

Epitopes & Antibodies

In the present invention, "epitopes" refer to polypeptide fragments having antigenic or immunogenic activity in an animal, especially in a human. A preferred embodiment of the present invention relates to a polypeptide fragment comprising an
25 epitope, as well as the polynucleotide encoding this fragment. A region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope." In contrast, an "immunogenic epitope" is defined as a part of a protein that elicits an antibody response. (See, for instance, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998- 4002 (1983).)

30 Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, R. A., Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985) further described in U.S. Patent No. 4,631,211.)

In the present invention, antigenic epitopes preferably contain a sequence of at least seven, more preferably at least nine, and most preferably between about 15 to
35 about 30 amino acids. Antigenic epitopes are useful to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe, J. G. et al., Science 219:660-666 (1983).)

Similarly, immunogenic epitopes can be used to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow, M. et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle, F. J. et al., J. Gen. Virol. 66:2347-2354 (1985).) A preferred immunogenic epitope includes the secreted protein. The immunogenic epitopes may be presented together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse) or, if it is long enough (at least about 25 amino acids), without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting.)

As used herein, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and F(ab')₂ fragments) which are capable of specifically binding to protein. Fab and F(ab')₂ fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody. (Wahl et al., J. Nucl. Med. 24:316-325 (1983).) Thus, these fragments are preferred, as well as the products of a FAB or other immunoglobulin expression library. Moreover, antibodies of the present invention include chimeric, single chain, and humanized antibodies.

Fusion Proteins

Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the

polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker et al., *Nature* 331:84-86 (1988).) Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., *J. Biochem.* 270:3958-3964 (1995).)

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., *J. Molecular Recognition* 8:52-58 (1995); K. Johanson et al., *J. Biol. Chem.* 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., *Proc. Natl. Acad. Sci. USA* 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., *Cell* 37:767 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

Vectors, Host Cells, and Protein Production

The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in E. coli and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as E. coli, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods
5 In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography,
10 phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention, and preferably the secreted form, can also
15 be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production
20 procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein
25 after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

30 **Uses of the Polynucleotides**

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

The polynucleotides of the present invention are useful for chromosome
35 identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat

polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be
5 selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the
10 polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, and preselection by hybridization to construct chromosome
15 specific-cDNA libraries.

Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al.,
20 "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes). Preferred polynucleotides
25 correspond to the noncoding regions of the cDNAs because the coding sequences are more likely conserved within gene families, thus increasing the chance of cross hybridization during chromosomal mapping.

Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage
30 analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library) .) Assuming 1 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease
35 could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined.

First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Both methods rely on binding of the polynucleotide to DNA or RNA. For these techniques, preferred polynucleotides are usually 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat disease.

Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identifying

personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

5 The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a unique set
10 of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological samples such as
15 tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erich, H., PCR Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more
20 restriction enzymes, yielding an identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of
25 unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

30 In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using
35 DNA immunization techniques, and as an antigen to elicit an immune response.

Uses of the Polypeptides

Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

5 A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell . Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay
10 (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine (125I, 121I), carbon (14C), sulfur (35S), tritium (3H), indium (112In), and technetium (99mTc), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

15 In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for
20 NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example, 131I,
25 112In, 99mTc), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human
30 subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of 99mTc. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The
35 Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).)

Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder.

Moreover, polypeptides of the present invention can be used to treat disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B), to inhibit the activity of a polypeptide (e.g., an oncogene), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

Biological Activities

The polynucleotides and polypeptides of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides and polypeptides could be used to treat the associated disease.

Immune Activity

A polypeptide or polynucleotide of the present invention may be useful in treating deficiencies or disorders of the immune system, by activating or inhibiting the

proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune deficiencies or disorders may be genetic, somatic, such as cancer or some autoimmune disorders, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, a polynucleotide or polypeptide of the present invention can be used as a marker or detector of a particular immune system disease or disorder.

A polynucleotide or polypeptide of the present invention may be useful in treating or detecting deficiencies or disorders of hematopoietic cells. A polypeptide or polynucleotide of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat those disorders associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to: blood protein disorders (e.g. agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, DiGeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

Moreover, a polypeptide or polynucleotide of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, a polynucleotide or polypeptide of the present invention could be used to treat blood coagulation disorders (e.g., afibrinogenemia, factor deficiencies), blood platelet disorders (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, a polynucleotide or polypeptide of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment of heart attacks (infarction), strokes, or scarring.

A polynucleotide or polypeptide of the present invention may also be useful in treating or detecting autoimmune disorders. Many autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of a polypeptide or polynucleotide of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

Examples of autoimmune disorders that can be treated or detected by the present invention include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated by a polypeptide or polynucleotide of the present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

A polynucleotide or polypeptide of the present invention may also be used to treat and/or prevent organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of a polypeptide or polynucleotide of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, a polypeptide or polynucleotide of the present invention may also be used to modulate inflammation. For example, the polypeptide or polynucleotide may inhibit the proliferation and differentiation of cells involved in an inflammatory response. These molecules can be used to treat inflammatory conditions, both chronic and acute conditions, including inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)

Hyperproliferative Disorders

A polypeptide or polynucleotide can be used to treat or detect hyperproliferative disorders, including neoplasms. A polypeptide or polynucleotide of the present invention may inhibit the proliferation of the disorder through direct or indirect

interactions. Alternatively, a polypeptide or polynucleotide of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

Examples of hyperproliferative disorders that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but are not limited to neoplasms located in the: abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative disorders can also be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstrom's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

Infectious Disease

A polypeptide or polynucleotide of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, the polypeptide or polynucleotide of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of viruses, include, but are not limited to the following DNA and RNA viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes

Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza), Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following Gram-Negative and Gram-positive bacterial families and fungi: Actinomycetales (e.g., Corynebacterium, Mycobacterium, Nocardia), Aspergillosis, Bacillaceae (e.g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia, Brucellosis, Candidiasis, Campylobacter, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, Enterobacteriaceae (Klebsiella, Salmonella, Serratia, Yersinia), Erysipelothrix, Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmatales, Neisseriaceae (e.g., Acinetobacter, Gonorrhea, Meningococcal), Pasteurellaceae Infections (e.g., Actinobacillus, Haemophilus, Pasteurella), Pseudomonas, Rickettsiaceae, Chlamydiaceae, Syphilis, and Staphylococcal. These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea, meningitis, Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Moreover, parasitic agents causing disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following families: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas. These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), Malaria, pregnancy complications, and toxoplasmosis. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Preferably, treatment using a polypeptide or polynucleotide of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

Regeneration

A polynucleotide or polypeptide of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vascular (including vascular endothelium), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide of the present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. A polynucleotide or polypeptide of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue

regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a polynucleotide or polypeptide of the present invention to proliferate and differentiate
5 nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral
10 neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the polynucleotide or polypeptide of the present invention.

15 **Chemotaxis**

A polynucleotide or polypeptide of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of
20 hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

A polynucleotide or polypeptide of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system
25 disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

It is also contemplated that a polynucleotide or polypeptide of the present
30 invention may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, a polynucleotide or polypeptide of the present invention could be used as an inhibitor of chemotaxis.

Binding Activity

35 A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit

(antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues.

Therefore, the invention includes a method of identifying compounds which bind to a polypeptide of the invention comprising the steps of: (a) incubating a candidate binding compound with a polypeptide of the invention; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with a polypeptide of the invention, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

Other Activities

A polypeptide or polynucleotide of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

A polypeptide or polynucleotide of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, a polypeptide or polynucleotide of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

A polypeptide or polynucleotide of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, circadian rhythms, depression (including depressive disorders), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

A polypeptide or polynucleotide of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

Other Preferred Embodiments

Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of

positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous
5 nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Similarly preferred is a nucleic acid molecule wherein said sequence of
10 contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide
15 sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide
sequence which is at least 95% identical to a sequence of at least about 500 contiguous
20 nucleotides in the nucleotide sequence of SEQ ID NO:X.

A further preferred embodiment is a nucleic acid molecule comprising a
nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ
ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the
First Amino Acid of the Signal Peptide and ending with the nucleotide at about the
25 position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in
Table 1.

A further preferred embodiment is an isolated nucleic acid molecule comprising
a nucleotide sequence which is at least 95% identical to the complete nucleotide
sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under
30 stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which
35 comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the material deposited with the American Type

Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide
5 comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

10 Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

15 Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid
20 sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is defined in Table 1; and an amino acid sequence of a secreted portion of a protein encoded by a human
25 cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an
30 individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of
35 illustration and are not intended as limiting.

Examples

Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

5 Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector. Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For
10 example, where a particular clone is identified in Table 1 as being isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

	<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited Plasmid</u>
	Lambda Zap	pBluescript (pBS)
	Uni-Zap XR	pBluescript (pBS)
15	Zap Express	pBK
	lafmid BA	plafmid BA
	pSport1	pSport1
	pCMVSPORT 2.0	pCMVSPORT 2.0
	pCMVSPORT 3.0	pCMVSPORT 3.0
20	pCR [®] 2.1	pCR [®] 2.1

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Altling-Mees, M. A. and Short, J. M., Nucleic Acids Res. 25 17:9494 (1989)) and pBK (Altling-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS. 30 The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the f1 origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the f1 ori generates sense strand DNA and in the other, antisense.

35 Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain

DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., *Focus* 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into *E. coli* strain XL-1 Blue. Vector pCR[®]2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into *E. coli* strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., *Nuc. Acids Res.* 16:9677-9686 (1988) and Mead, D. et al., *Bio/Technology* 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with ³²P-γ-ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring, NY (1982).) The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

Alternatively, two primers of 17-20 nucleotides derived from both ends of the SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 μ l of reaction mixture with 0.5 μ g of the above cDNA template. A convenient reaction mixture is 1.5-5 mM $MgCl_2$, 0.01% (w/v) gelatin, 20 μ M each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94°C for 1 min; annealing at 55°C for 1 min; elongation at 72°C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., *Nucleic Acids Res.* 21(7):1683-1684 (1993).)

Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is

used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

5

Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

10

Example 3: Tissue Distribution of Polypeptide

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P³² using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

15

20

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70°C overnight, and the films developed according to standard procedures.

25

Example 4: Chromosomal Mapping of the Polynucleotides

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95°C; 1 minute, 56°C; 1 minute, 70°C. This cycle is repeated 32 times followed by one 5 minute cycle at 70°C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on

30

35

either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

5 **Example 5: Bacterial Expression of a Polypeptide**

A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as
10 BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp^r), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site
15 (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses
20 the lacI repressor and also confers kanamycin resistance (Kan^r). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml).
25 The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

30 Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4°C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from
35 QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high

affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

5 Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

10 The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4° C or frozen at -80° C.

15 In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains: 1) a 20 neomycinphosphotransferase gene as a selection marker, 2) an E. coli origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (lacIq). The origin of replication (oriC) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

25 DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or 30 Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

35 **Example 6: Purification of a Polypeptide from an Inclusion Body**

The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10°C.

Upon completion of the production phase of the *E. coli* fermentation, the cell
5 culture is cooled to 4-10°C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a
10 high shear mixer.

The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M
15 NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4°C overnight to allow further GuHCl extraction.

20 Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4°C without mixing for 12 hours prior to further purification steps.

25 To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 µm membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted
30 with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem

columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column
5 volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant A_{280} monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the above
10 refolding and purification steps. No major contaminant bands should be observed from Comassie blue stained 16% SDS-PAGE gel when 5 μ g of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

15 **Example 7: Cloning and Expression of a Polypeptide in a Baculovirus Expression System**

In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus
20 (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak *Drosophila* promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The
25 inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as
30 long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., *Virology* 170:31-39 (1989).

Specifically, the cDNA sequence contained in the deposited clone, including the
35 AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring

signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures,"

5 Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

10 The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue
15 (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

20 Five µg of a plasmid containing the polynucleotide is co-transfected with 1.0 µg of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One µg of BaculoGold™ virus DNA and 5 µg of the plasmid are mixed in a sterile well of a
25 microtiter plate containing 50 µl of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 µl Lipofectin plus 90 µl Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then
30 incubated for 5 hours at 27° C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27° C for four days.

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life
35 Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture

and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 µl of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4° C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 µCi of ³⁵S-methionine and 5 µCi ³⁵S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

Example 8: Expression of a Polypeptide in Mammalian Cells

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLV, HIV and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSport 2.0, and pCMVSport 3.0. Mammalian host cells that could be used include, human HeLa, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

5 The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and
10 Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a
15 chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No.209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the
20 CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse
25 DHFR gene under control of the SV40 early promoter.

Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol
30 outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

The amplified fragment is isolated from a 1% agarose gel using a commercially
35 available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five μg of the expression plasmid pC6 is cotransfected with 0.5 μg of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 μM , 2 μM , 5 μM , 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 μM . Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

Example 9: Protein Fusions

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the half-life time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

5 For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that
10 the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a
15 heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

GGGATCCGGAGCCCAAATCTTCTGACAAACTCACACATGCCCACCGTGCC
CAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCAAACC
20 CAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTACATGCGTGGTGGT
GGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACG
GCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAAC
AGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTG
AATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAACCCCC
25 ATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGT
GTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCT
GACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGTGGAGTGGGA
GAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCTCCCGTGCTGG
ACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCA
30 GGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGC
ACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGTGC
GACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

Example 10: Production of an Antibody from a Polypeptide

35 The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) For example, cells expressing a polypeptide of the present invention is administered to an animal to induce the production of sera

containing polyclonal antibodies. In a preferred method, a preparation of the secreted protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

5 In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology. (Köhler et al., *Nature* 256:495 (1975); Köhler et al., *Eur. J. Immunol.* 6:511 (1976); Köhler et al., *Eur. J. Immunol.* 6:292 (1976); Hammerling et al., in: *Monoclonal Antibodies and T-Cell Hybridomas*, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures
10 involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at
15 about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line
20 (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (*Gastroenterology* 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

25 Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a
30 mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of further protein-specific
35 antibodies.

It will be appreciated that Fab and F(ab')₂ and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

Example 11: Production Of Secreted Protein For High-Throughput Screening Assays

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described in Examples 13-20.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at 2×10^5 cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in

Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37°C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of CaCl₂ (anhyd); 0.00130 mg/L CuSO₄·5H₂O; 0.050 mg/L of Fe(NO₃)₃·9H₂O; 0.417 mg/L of FeSO₄·7H₂O; 311.80 mg/L of KCl; 28.64 mg/L of MgCl₂; 48.84 mg/L of MgSO₄; 6995.50 mg/L of NaCl; 2400.0 mg/L of NaHCO₃; 62.50 mg/L of NaH₂PO₄·H₂O; 71.02 mg/L of Na₂HPO₄; .4320 mg/L of ZnSO₄·7H₂O; .002 mg/L of Arachidonic Acid ; 1.022 mg/L of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitic Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml of L-Asparagine-H₂O; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL-H₂O; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-H₂O; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2H₂O; 99.65 mg/ml of L-Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and 0.680 mg/L of Vitamin B₁₂; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine;

0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person B adds 1.5ml appropriate media to each well. Incubate at 37°C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 13-20.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

Example 12: Construction of GAS Reporter Construct

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, *Ann. Rev. Biochem.* 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN- α , IFN- γ , and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

	<u>Ligand</u>	<u>tyk2</u>	<u>JAKs</u>		<u>STATS</u>		<u>GAS(elements) or ISRE</u>
			<u>Jak1</u>	<u>Jak2</u>	<u>Jak3</u>		
	<u>IFN family</u>						
5	IFN-a/B	+	+	-	-	1,2,3	ISRE
	IFN-g		+	+	-	1	GAS (IRF1>Lys6>IFP)
	IL-10	+	?	?	-	1,3	
	<u>gp130 family</u>						
10	IL-6 (Pleiotrohic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
	IL-11(Pleiotrohic)	?	+	?	?	1,3	
	OnM(Pleiotrohic)	?	+	+	?	1,3	
	LIF(Pleiotrohic)	?	+	+	?	1,3	
	CNTF(Pleiotrohic)	-/+	+	+	?	1,3	
15	G-CSF(Pleiotrohic)	?	+	?	?	1,3	
	IL-12(Pleiotrohic)	+	-	+	+	1,3	
	<u>g-C family</u>						
	IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
20	IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP >>Ly6)(IgH)
	IL-7 (lymphocytes)	-	+	-	+	5	GAS
	IL-9 (lymphocytes)	-	+	-	+	5	GAS
	IL-13 (lymphocyte)	-	+	?	?	6	GAS
	IL-15	?	+	?	+	5	GAS
25	<u>gp140 family</u>						
	IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
	IL-5 (myeloid)	-	-	+	-	5	GAS
	GM-CSF (myeloid)	-	-	+	-	5	GAS
30	<u>Growth hormone family</u>						
	GH	?	-	+	-	5	
	PRL	?	+/-	+	-	1,3,5	
	EPO	?	-	+	-	5	GAS(B-
35	CAS>IRF1=IFP>>Ly6)						
	<u>Receptor Tyrosine Kinases</u>						
	EGF	?	+	+	-	1,3	GAS (IRF1)
	PDGF	?	+	+	-	1,3	
40	CSF-1	?	+	+	-	1,3	GAS (not IRF1)

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

5':GCGCCTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCCG
10 AAATGATTTCCCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

5':CTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCCGAAATG
20 ATTTCCCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCC
CTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGC
CCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCTCGGC
CTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTT
TGCAAAAAGCTT:3' (SEQ ID NO:5)

25 With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase,
30 alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a
35 neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

Example 13: High-Throughput Screening Assay for T-cell Activity.

The following protocol is used to assess T-cell activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies)

with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells (10^7 per transfection), and resuspend in OPTI-MEM to a final
5 concentration of 10^7 cells/ml. Then add 1ml of 1×10^7 cells in OPTI-MEM to T25 flask and incubate at 37°C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Gentacin, and 1% Pen-Strep. These cells are treated with supernatants containing a polypeptide as produced by the protocol described in Example 11.

10 On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

15 Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100, 000 cells per well).

After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12
20 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples
25 from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophane covers) and stored at -20°C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4°C and serve as a source of material for repeating the assay on a specific well if desired.

30 As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

35 **Example 14: High-Throughput Screening Assay Identifying Myeloid Activity**

The following protocol is used to assess myeloid activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate myeloid cells. Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest 2×10^7 U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$, 1 mM MgCl_2 , and 675 uM CaCl_2 . Incubate at 37°C for 45 min.

Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37°C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

These cells are tested by harvesting 1×10^8 cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of 5×10^5 cells/ml. Plate 200 ul cells per well in the 96-well plate (or 1×10^5 cells/well).

Add 50 ul of the supernatant prepared by the protocol described in Example 11. Incubate at 37°C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.

When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon

activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat phenochromocytoma cells) are known to proliferate and/or
5 differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor). The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

10 The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)

5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

15 Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

20 To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker)
25 containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

30 Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

35 To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS

(Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count
5 the cell number and add more low serum medium to reach final cell density as 5×10^5 cells/ml.

Add 200 μ l of the cell suspension to each well of 96-well plate (equivalent to 1×10^5 cells/well). Add 50 μ l supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR
10 can be used, such as 50 ng/ μ l of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

Example 16: High-Throughput Screening Assay for T-cell Activity

15 NF- κ B (Nuclear Factor κ B) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF- κ B regulates the expression of genes involved in immune cell activation, control of apoptosis (NF-
20 κ B appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, NF- κ B is retained in the cytoplasm with I- κ B (Inhibitor κ B). However, upon stimulation, I- κ B is phosphorylated and degraded, causing NF- κ B to shuttle to the nucleus, thereby activating transcription of target
25 genes. Target genes activated by NF- κ B include IL-2, IL-6, GM-CSF, ICAM-1 and class 1 MHC.

Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF- κ B promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF- κ B would be useful in treating
30 diseases. For example, inhibitors of NF- κ B could be used to treat those diseases related to the acute or chronic activation of NF- κ B, such as rheumatoid arthritis.

To construct a vector containing the NF- κ B promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF- κ B binding site (GGGGACTTTCCC) (SEQ ID NO:8), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:

5 5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGAC
TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:

5':GCGGCAAGCTTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

10 PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene) Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

15 5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCC
ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCCA
TCCCGCCCCTAACTCCGCCCAGTTCGCCCCATTCTCCGCCCCATGGCTGACT
AATTTTTTTTTATTTATGCAGAGGCCGAGGCCGCTCGGCCTCTGAGCTATTC
20 CAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTT:
3' (SEQ ID NO:10)

Next, replace the SV40 minimal promoter element present in the pSEAP2-promoter plasmid (Clontech) with this NF- κ B/SV40 fragment using XhoI and HindIII.

25 However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

In order to generate stable mammalian cell lines, the NF- κ B/SV40/SEAP cassette is removed from the above NF- κ B/SEAP vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly, the
30 NF- κ B/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with SalI and NotI.

Once NF- κ B/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described

in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

Example 17: Assay for SEAP Activity

5 As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

10 Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 μ l of 2.5x dilution buffer into Optiplates containing 35 μ l of a supernatant. Seal the plates with a plastic sealer and incubate at 65°C for 30 min. Separate the Optiplates to avoid uneven heating.

Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 μ l Assay Buffer and incubate at room
15 temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 μ l Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

20 Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

Reaction Buffer Formulation:

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6
23	125	6.25
24	130	6.5
25	135	6.75
26	140	7
27	145	7.25

28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-3, used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO₂ incubator for 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-3 is made in 10% pluronic acid DMSO. To load the cells with fluo-3, 50 ul of 12 ug/ml fluo-3 is added to each well. The plate is

incubated at 37°C in a CO₂ incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to 2-5x10⁶ cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-3 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37°C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1x10⁶ cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-3. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular Ca⁺⁺ concentration.

Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating

tyrosine kinase signal transduction pathways are of interest. Therefore, the following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e.g., primary keratinocytes) at a density of approximately
5 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or
10 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4°C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are
15 used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20
20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na₃VO₄, 2 mM Na₄P₂O₇ and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for
25 5 minutes at 4°C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and
30 centrifuged for 15 minutes at 4°C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a
35 biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and

PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg₂₊ (5mM
5 ATP/50mM MgCl₂), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl₂, 5 mM MnCl₂, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30°C for 2 min. Initiate the reaction by adding 10ul of the control enzyme or the filtered supernatant.

10 The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mM EDTA and place the reactions on ice.

Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37°C for 20 min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide.
15 Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37°C for one hour. Wash the well as above.

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and
20 incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

25 **Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity**

As a potential alternative and/or complement to the assay of protein tyrosine kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be
30 used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by
35 substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4°C until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

Example 21: Method of Determining Alterations in a Gene

Corresponding to a Polynucleotide

RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95°C for 30 seconds; 60-120 seconds at 52-58°C; and 60-120 seconds at 70°C, using buffer solutions described in Sidransky, D., et al., Science 252:706 (1991).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR

products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

PCR products is cloned into T-tailed vectors as described in Holton, T.A. and Graham, M.W., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenin deoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson, Cg. et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson, Cv. et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10.

The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to
5 validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove
10 unbounded conjugate.

Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on
15 the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

Example 23: Formulating a Polypeptide

The secreted polypeptide composition will be formulated and dosed in a fashion
20 consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the secreted polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of secreted polypeptide administered parenterally per dose will be in the range of about 1 µg/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If
30 given continuously, the secreted polypeptide is typically administered at a dose rate of about 1 µg/kg/hour to about 50 µg/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending
35 on the desired effect.

Pharmaceutical compositions containing the secreted protein of the invention are administered orally, rectally, parenterally, intracisternally, intravaginally,

intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes
5 of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

The secreted polypeptide is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules.

10 Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., Biopolymers 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (R. Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and R. Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D- (-)-3-hydroxybutyric
15 acid (EP 133,988). Sustained-release compositions also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. USA 82:3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008;
20 U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

For parenteral administration, in one embodiment, the secreted polypeptide is
25 formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are
30 known to be deleterious to polypeptides.

Generally, the formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood
35 of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The secreted polypeptide is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any polypeptide to be used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous polypeptide solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized polypeptide using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the polypeptides of the present invention may be employed in conjunction with other therapeutic compounds.

Example 24: Method of Treating Decreased Levels of the Polypeptide

It will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

Example 25: Method of Treating Increased Levels of the Polypeptide

Antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

Example 26: Method of Treatment Using Gene Therapy

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37°C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

5 The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the
10 presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

15 The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

20 Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media
25 from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

30 The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

35 It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

 The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other

disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties.

Applicant's or agent's file reference number	PZ018PCT	International application No.
--	----------	-------------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>71</u> , line <u>7</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet ☐	
Name of depositary institution American Type Culture Collection ("ATCC")	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 12 SEPTEMBER 1997	Accession Number 209244
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet ☐	
DNA Plasmid PS-060 In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4)EPC).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only
☒ This sheet was received with the international application
Authorized officer PAUL F. URRUTIA INTERNATIONAL DIVISION 4681

For International Bureau use only
☐ This sheet was received by the International Bureau on:
Authorized officer

Applicant's or agent's file reference number	PZ018PCT	International application N.
--	----------	------------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>74</u> , line <u>20</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet ☐	
Name of depositary institution American Type Culture Collection ("ATCC")	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 18 SEPTEMBER 1997	Accession Number 209277
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet ☐	
DNA Plasmid PS-06f	
In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4)EPC).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
☒ This sheet was received with the international application	☐ This sheet was received by the International Bureau on:
Authorized officer PAUL F. URRUTIA INTERNATIONAL DIVISION 305-3681	Authorized officer

What Is Claimed Is:

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X, having biological activity;

(f) a polynucleotide which is a variant of SEQ ID NO:X;

(g) a polynucleotide which is an allelic variant of SEQ ID NO:X;

(h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;

(i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.

3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.
5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.
8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.
9. A recombinant host cell produced by the method of claim 8.
10. The recombinant host cell of claim 9 comprising vector sequences.
11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:
 - (a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
 - (b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;
 - (c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
 - (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
 - (e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
 - (f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

- (g) a variant of SEQ ID NO:Y;
- (h) an allelic variant of SEQ ID NO:Y; or
- (i) a species homologue of the SEQ ID NO:Y.

12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

14. A recombinant host cell that expresses the isolated polypeptide of claim 11.

15. A method of making an isolated polypeptide comprising:
(a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and
(b) recovering said polypeptide.

16. The polypeptide produced by claim 15.

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

- (a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and
- (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

- (a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and
- (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

- (a) contacting the polypeptide of claim 11 with a binding partner; and
- (b) determining whether the binding partner effects an activity of the polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

22. A method of identifying an activity in a biological assay, wherein the method comprises:

- (a) expressing SEQ ID NO:X in a cell;
- (b) isolating the supernatant;
- (c) detecting an activity in a biological assay; and
- (d) identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 20.

<110> Human Genome Sciences, Inc. et al.

<120> 53 Human Secreted Proteins

<130> PZ018.PCT

<140> PCT/US98/21142

<141> 1998-10-08

<150> 60/061,527

<151> 1997-10-09

<150> 60/061,536

<151> 1997-10-09

<150> 60/061,532

<151> 1997-10-09

<150> 60/061,463

<151> 1997-10-09

<150> 60/061,529

<151> 1997-10-09

<150> 60/071,498

<151> 1997-10-09

<160> 145

<170> PatentIn Ver. 2.0

<210> 1

<211> 733

<212> DNA

<213> Homo sapiens

<400> 1

gggatccgga	gcccaaattct	tctgacaaaa	ctcacacatg	cccaccgtgc	ccagcacctg	60
aattcgaggg	tgcaccgtca	gtcttctctt	tcccccaaa	acccaaggac	accctcatga	120
tctcccgga	tcctgaggtc	acatgcgtgg	tggtagacgt	aagccacgaa	gaccctgagg	180
tcaagttcaa	ctggtacgtg	gacggcgtgg	aggtgcataa	tgccaagaca	aagccgcggg	240
aggagcagta	caacagcacg	taccgtgtgg	tcagcgtcct	caccgtcctg	caccaggact	300
ggctgaatgg	caaggagtac	aagtgcgaagg	tctccaacaa	agccctccca	accccatcg	360
agaaaaccat	ctccaaagcc	aaagggcagc	cccgagaacc	acaggtgtac	accctgcccc	420
catcccggga	tgagctgacc	aagaaccagg	tcagcctgac	ctgcctgggc	aaaggcttct	480
atccaagcga	catcgccgtg	gagtgggaga	gcaatgggca	gccggagAAC	aactacaaga	540
ccacgcctcc	cgtgctggac	tccgacggct	ccttcttctt	ctacagcaag	ctcaccgtgg	600
acaagagcag	gtggcagcag	gggaacgtct	tctcatgctc	cgtgatgcat	gaggctctgc	660
acaaccacta	cacgcagaag	agcctctccc	tgtctccggg	taaatagagt	cgacggccgc	720
gactctagag	gat					733

<210> 2

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<221> Site

<222> (3)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 2

Trp	Ser	Xaa	Trp	Ser
1				5

<210> 3

<211> 86

<212> DNA

<213> Homo sapiens

<400> 3

gcgcctcgag	atttccccga	aatctagatt	tccccgaaat	gatttccccg	aatgatttc	60
cccgaaatat	ctgccatctc	aattag				86

<210> 4

<211> 27

<212> DNA

<213> Homo sapiens

<400> 4

gcggcaagct	ttttgcaaag	cctaggc	27
------------	------------	---------	----

<210> 5

<211> 271

<212> DNA

<213> Homo sapiens

<400> 5

ctcgagattt	ccccgaaatc	tagatttccc	cgaaatgatt	tccccgaaat	gatttccccg	60
aatatctgc	catctcaatt	agtcagcaac	catagtcccg	cccctaactc	cgcccatccc	120
gcccctaact	ccgccagtt	ccgccattc	tccgcccac	ggctgactaa	ttttttttat	180
ttatgcagag	gccgaggccg	cctcggcctc	tgagctattc	cagaagtagt	gaggaggctt	240
ttttggaggc	ctaggctttt	gcaaaaagct	t			271

<210> 6

<211> 32

<212> DNA

<213> Homo sapiens

<400> 6

gcgctcgagg	gatgacagcg	atagaacccc	gg	32
------------	------------	------------	----	----

<210> 7

<211> 31

<212> DNA

<213> Homo sapiens

<400> 7

3

gcgaagcttc gcgactcccc ggatccgcct c

31

<210> 8

<211> 12

<212> DNA

<213> Homo sapiens

<400> 8

ggggactttc cc

12

<210> 9

<211> 73

<212> DNA

<213> Homo sapiens

<400> 9

gcggcctcga ggggactttc ccggggactt tccggggact ttccgggact ttccatcctg
ccatctcaat tag

60

73

<210> 10

<211> 256

<212> DNA

<213> Homo sapiens

<400> 10

ctcgagggga ctttccccggg gactttccgg ggactttccg ggactttcca tctgccatct 60
caattagtcg gcaaccatag tcccgcccct aactccgccc atcccgcccc taactccgcc 120
cagttccgcc cattctccgc cccatggctg actaattttt tttatttatg cagaggccga 180
ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg 240
cttttgcaaa aagctt 256

<210> 11

<211> 680

<212> DNA

<213> Homo sapiens

<400> 11

ggcacgagct tggaggtcta ctggcagact tccttctctc cagaaaaatc ctcagactca 60
tcaccatcag gaaactcttc actgccattg gggttctctt cccatccgtg atcctcgtgt 120
ccctgccctg ggtcagatcc agccacagca tgaccatgac cttcttggtg ctgtcttctg 180
ccatcagcag cttctgtgaa tcaggagccc ttgttaactt cttggatatt gtcctcgggt 240
acactggctt tctcaaagga ctattgcaag tctttgcaca catagctgga gccatctctc 300
ctactgctgc tggatttttc atcagtcagg attcagagtt tggttggaga aatgtcttct 360
tgctttcagc tgctgttaac atatcgggcc tggttttcta cctcatcttt ggccgagcag 420
atgtgcagga ctgggctaaa gagcagacat tcacccacct ctgagcaaac cgagagatgt 480
gctagatcct ggtgcttagt tcatcattgt tttccctcac agacatttct ttttcatgcc 540
tgcttgactg ataagccatt agctagacct tgactatgta acgctaaaga ttttaccatg 600
cctggaaatt ttacagggga agaaaacacg ctagttattt aactgcaaaa aaaaaaaaaa 660
aaaaaaaaaa aaaactcgta 680

<210> 12

<211> 741

<212> DNA

<213> Homo sapiens

SUBSTITUTE SHEET (RULE 26)

<220>
 <221> SITE
 <222> (35)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (39)
 <223> n equals a,t,g, or c

<400> 12
 aattcggcac gagaccctta ggaacacgga cgcancgtnc ggcatgtgtca tctacgcagg 60
 acatgaaacc aaggctctgc tgaacaacag tgggccccgc tacaagcgca saagctggag 120
 aggcagatga actgcgacgt gctctggtgt gtcctgctcc ttgtttgcak gtctctgttt 180
 tcagcagtcg gacatggact gtggatatgg cggatatcaag agaagaagtc attattttat 240
 gtccccaagt ctgatggaag ctctttatcc ccagtcacag ctgcagttaa ctcattttta 300
 acatgatata gttckgcagg ttttgatccc atttccttat acgkttccat tgaaattgtt 360
 aaagcatgcc aagtgtactt cattaaccag gacatgcagt tgtatgacga agaaacagac 420
 tcgcagctgc agtgccgagc tctgaacatc acggaagact taggacagat acagtacatt 480
 ttctcagata aaactggcac tttgacagag aataagatgg ttttccgaag atgcactgtg 540
 tctggtgtag aatattctca tgatgcaaat gaggtctat taagagatgc gcagtgttcc 600
 acgcggtgg cgggtcccat aagtatctcc ttctccggcc tcttgacagg cccctgctgc 660
 tttgactcag caccatgcct gtgcttgaag ttctgattaa acggttggtc tgataagtaa 720
 aaaaaaaaaa aaaaactcgt a 741

<210> 13
 <211> 619
 <212> DNA
 <213> Homo sapiens

<400> 13
 ggcacgagct ggggcctgtg tgccctccag ccataatgct ggcagaactg atattttctct 60
 ttaggagtct ccattgggata cttgcctccg caggcaccat aggagcagtg gcagcttggc 120
 tgatgagcta taagccagcc ttgtttgggt tcctattcct tctgctgttg cttagcaact 180
 ggttgggtcaa gtatgaacac aagctcacc tcccagagcc ccagcaggag gaagagaaac 240
 caaagacttc tgaaaacgac tccaagaaca gcaaggccgt gaacacaaaa gaagtcaata 300
 gaacgcatgc ctgctttgcc ctccaggagc agatcctcca acggctgttg ttcagtgaag 360
 tgaagatgaa ggtcctagaa aatcagatgt tcatcatatg gaataaaatg aatcaccacg 420
 ggcggtcaag cagacatcgg aattttccca tgaaaaaaca cagaatgagg aggcataagt 480
 caatttgccc caccctgtct gactgtactt cgagttcccc cagctaataa ggycgaggcg 540
 ggctggcctc tgccgatgtt accttttacc tcagtaaaac ccagtcacag cctaaaaaaa 600
 aaaaaaaaaa aaactcgta 619

<210> 14
 <211> 611
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (17)
 <223> n equals a,t,g, or c

<400> 14
 aggatttcgg cagcagntca gatccaaagc tttttgaaat gattaagtat tgtcttttga 60
 aaattctgaa gcaatatcag acattgagag aagctcttgt tgcagcagga aaagagggtta 120

5

tatggcatgg	gcggacaaat	gatgaaccag	ctcattactg	tagcatttgt	gaggtggagg	180
tttttaatat	gctttttgtc	actaatgaaa	gcaataactca	aaaaacctac	atagtacatt	240
gccatgattg	tgacgaaaaa	acaagcaaaa	gtttggaaaa	ttttgtggtg	ctcgaacagt	300
acaaaatgga	ggacctaatc	caagtttatg	atcaatttac	actagcctcc	ccatggccac	360
ccatggacca	gtcggcattc	acttctctcc	ttctgcggcc	cataaaaagg	ctgggttcag	420
gcagagctga	gcagacatca	ggtgaccagc	tgacagaaagg	agctaccac	tccagggcct	480
catctctgct	gagagctgca	gagatgacca	gaagacctgc	atccagagag	gagcttctctg	540
atccagggct	attctgtcac	tcaataaagg	ttctctttgt	cttggttaaaa	aaaaaaaaaa	600
aaaaactcgt	a					611

<210> 15

<211> 585

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (5)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (15)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (19)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (29)

<223> n equals a,t,g, or c

<400> 15

gttgnatccc	cccnggggnc	ttgccaggna	atttccggcc	accgaggggtg	attttaactt	60
tccaatggcg	tttttacctt	tcttttagaa	aactaatgcy	atggatatta	atacttggtta	120
ttgccttggtg	gtttattgag	cttttggatg	tgtggagcac	ttgtagtcag	cccatttggtg	180
caaaatggac	aaggacagag	gctgaggga	gcaagaagtc	tttgtcttct	gaagggcacc	240
acatggatct	tcctgatggt	gtcattacct	cacttcctgg	ttcaggagct	gaaattctca	300
aacaactttt	tttcaacagt	agtgattttc	tctacatcag	ggttcctaca	gcctacattg	360
atatttctga	aactgagttg	gaaatcgact	catttgtaga	tgcttgtaga	tggaagtgtc	420
agatatccgc	agtgggcatt	ttcgtttact	ccgaggctgg	ttgcagtcct	tagtccagga	480
cacaaaatta	catttgcaaa	acatccatct	gcatgaacct	aataggggta	aactggccca	540
atatttttga	atgaataagg	acaaaaaaaa	aaaaaaaaaa	ctcga		585

<210> 16

<211> 1040

<212> DNA

<213> Homo sapiens

<400> 16

ggcacgaggt	gaatccccag	cctgaggtcg	tgcttaagtg	ccacctgctc	aagagagaag	60
gcttcctgcc	cgcgcccatg	atgtaagtcc	ccccagatgc	tttccaccat	cctgtccttt	120
gtctgtaatt	gcgcttgctg	cttgaacaga	atcctaattg	tgctgattac	atgtttaatt	180
ttgggtctccc	ctgtaagaca	ggcatgcttt	ttggaggcag	ggactgaatg	tcattcacat	240

SUBSTITUTE SHEET (RULE 26)

6

ctgtgctcct	agggtctaata	acatgatggg	gcattgtaag	tattcagtat	ataacttggt	300
gaataaatgg	atcggtttaa	gcattttccc	ccattggacc	tggattgacc	tggaaattgg	360
tggactgaac	ctgcaagtag	agattaaagg	acctaacaac	tgtagagtgg	ctggtgaagg	420
tagatataag	tgcagtaagg	gagggagtcg	ttgatgtkgt	tttggttcgt	agtgcagaat	480
aaagctactt	atggaaatat	acgactccta	ctcttagttt	ctgctttgat	gtggtwackg	540
ctgttgttta	gcgtaagcat	ataaacaat	cactggctta	gtgggttaat	ttttcttctc	600
ttttgttaaa	cagctgagtt	tttgctgttt	tcaaagttag	ccaaaaattc	cattttcatg	660
tttaaatgat	ttagaaaaat	catttttctt	taaaaaataa	cagtacataa	aaagaaaaca	720
ttctcggctg	ggcgcggtgg	ctcacgcctg	taaccagca	ctttgggagg	ctgagacagg	780
cagttcacct	gaggtcagga	gtttgagacc	agcctgacca	acatggagaa	actccgtctc	840
tactaaaaac	acaaaaattt	tagccgggcg	ttgtgccacg	ttcctgtaat	cccagctact	900
cgggaggctg	aggcaggaga	atcgcttgaa	cccgggaggc	agaggttgca	gtgagccgag	960
atcggtcat	tgcactccag	cctgggcaac	aagagcgaaa	ctccatctca	aaaaataaaa	1020
aaaaaaaaaa	aaaactcgta					1040

<210> 17

<211> 625

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (6)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (11)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (43)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (46)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (68)

<223> n equals a,t,g, or c

<400> 17

ttaccntcac	ntaaggggaa	caaaagctgg	agctccaccg	cgntgncggc	cgctctagaa	60
ctagtggntc	ccccgggctg	caggaattcg	gcacgagctc	gtgccgaatt	cggcacgagc	120
agcaacagca	acacaggtgt	ggagttgaca	gacaggtaca	ttgaaccaga	gctgtgattt	180
agacaagcca	ggaacctcat	gtatgtccat	aatgctgctg	acattcactc	ttcacttccc	240
cagcacatta	ctgtcatatc	tcccagagaa	ttatgtcata	ccttctctct	tctcaaacct	300
gcaacactgg	atctgctgtg	ttcactctca	gttggttaacc	tgtttcgtat	ttcagagaga	360
caatgtaagc	actgagaaga	gaactcttgc	acactccaac	acctcatctg	ccacctctca	420
ccatctgtct	ccttgtagta	ctggagatgg	tctgacctcc	tcctggggag	gccaaactca	480
tccacttctg	cactagattc	cgtcctcttt	tatcttccct	acatcatgtg	ttttccttct	540
atactcatca	ttccttttag	caataaatat	ctttaaaaaa	aaaactcgag	ggggggcccg	600
gtaccaaat	cgccctatag	tggag				625

SUBSTITUTE SHEET (RULE 26)

<210> 18
 <211> 819
 <212> DNA
 <213> Homo sapiens

<400> 18
 aattcggcac gagggaaact catgcacaaa caaaacagca catgctgtac tcacagccag 60
 ttacacagaa tgctcatgca tgcacatgtt gcttattaat tttcttcctg ctgtttgtat 120
 cattcttttg aagaatctcc agcaagcttt gtgctttgcc caattgttta taatgtctat 180
 aaatcagggg cttggaccaaa atgaaatgtc ttagtagtgt ttgcaaaata tttggatatt 240
 ctgattgcgt tttattttcc cagctttaga aaacatatag atagcctctg ttgggaactt 300
 atattctcgt tactccttgt ctcttttctt ttttcaggaa ttggtcactc tttcagccaa 360
 ctctagagggt caaacaatgt ttacatgtag tgctcagttt gttttaactt cckgctgtag 420
 acattgacag ttttlycttc cyaagagtct tatgaatagg caacaaacca aaacccaaac 480
 aggcaagtcc catctattac tacgtactta caaatccagg tgaaagtgtc tgggtgaacag 540
 tctatgtttt agcaactgtt ttttaacgtt tgggtgtgac attttttaac aacagccatt 600
 gttcaattgt taaactatgt ttggatttga ggtctgaatg agctgaattc aaaatatggg 660
 actttttatt agaaaccctg gtaaagtggg cactggggaa aaagcccaag atttcatgtg 720
 tttgatttat tgactatgtg cgtcaacagc ctgcttttaa ttctcagagt aaaataaaaa 780
 tactcagaat ctaaaaaaaa aaaaaaaaaa aaaactcga 819

<210> 19
 <211> 782
 <212> DNA
 <213> Homo sapiens

<400> 19
 ggcacgaggt ttattccctg tcacccacct tatccactg tcttattctt agagttgtct 60
 ttcagaaacc caaatacaga tcatgtcaca gatactgaga agttccttat tgccttgata 120
 aggtgataca taaaacctta gaatggcttt cagggttctt tactattccg tctggtttat 180
 ctttttacac gtgtcatttg ccactccaaa agttacagga ctaattgcct caacatacca 240
 ttttctttat gtcttcatgt ttctgctcat gatcctttct gcctaattgt tttccacatc 300
 ttccatttcc gctttgagga actccttttt ctttcttcaa gatacaatgc ttgcagtctt 360
 aatcttccat gacagtgtc tcatagttta gtttaacctc tgcaatagga tatacctcat 420
 gattactaca atttatatgt gtttcctttt accaaactct taggaaaaag gagagcctgg 480
 gccgggtggg gtggctcag cctgtagtcc cagcacttgg ggaggccgag gccggaggatc 540
 acaagggtcag gagattgaga ccagcctggc caacatagtg aaaccccgtc tctcctaaaa 600
 acacaaaaat cagctgggtg tgggtggcgc cgcagctgta atcccagcta ctcaggaggc 660
 tgaagycagg agaatcgctt gaaccccgga ggccgggatt gcagtgagcc aggatggcgc 720
 cactgcactc cagcttggtg acagcgagat ccgtcttaaa aaaaaaaaaa aaaaactcgt 780
 ag 782

<210> 20
 <211> 655
 <212> DNA
 <213> Homo sapiens

<400> 20
 gtctgttgtt tactaaaatg aaaattcagt tgaaaatgcc actaattcag aaattagtaa 60
 atcctattta ttatgtattt taccaattaa tagaatacaa aggtatcata tacaactacc 120
 atggaggtgg caggaagaag attgactttt tcaaatggc ttcatactgg aacagattaa 180
 aaaccaagtc ttcttttctt tctcctgtt aaaactcact tgtgtctcac attaagctcc 240
 taaatgtgcc ctctgtttcc ctaggccaga gccagtgtct aacaagtaat gcatttggag 300
 ggtcatggcc caacagtcta cattcagcca ggatttagga acttcattcc aatgatcttt 360
 gaaggacttg tacaactcta gccagccttt gaaggaggta ttttgggaac tgggaagaga 420
 tctttctagt cctcccatgg agacagcaag gttatggtga agtttggaat cagataaaac 480

8

taatggaggc	attacatctc	taatctaaaa	tgaggattat	agtctaggtg	tggtggcaca	540
cacctgtaat	cccatcactt	tgaggaggcca	aggccagagg	attgcttgtc	caaggagttg	600
gggaccagcc	tgggcaacat	acagatgcaa	aaaaaaaaaa	aaaaaaaaaac	tcgta	655

<210> 21
 <211> 798
 <212> DNA
 <213> Homo sapiens

<400> 21

ggaaaaatgc	agctaattca	gtcataaact	ttaacaatta	cacaagtgct	tttcctggat	60
accatcatgt	ctacatatgt	agcagatacg	gattatgtgg	ttcttcctgt	ttcatcccat	120
aaaawattct	aaagacattc	aaaagttgag	atttaataaa	ataattttta	gtactttatc	180
aagggcattc	taagtgaatt	cgtgctcttt	tttttaaacc	ataagtacat	agcagtaaag	240
aagacaataa	ccacattttt	gtgtctctgc	ctttatctgt	ggtaagctga	cagcagtttt	300
acccaccatt	gcttctgcac	catcagtgc	aatgtcaaaa	tagtgaaaag	gccaggtgca	360
ktggctcaca	cctgtgggtc	tagcaatttg	ggatgctgag	gcgggtggtt	tacctggtca	420
ggagtttgag	gccagcctgg	ccaacatgg	gaaaccccat	ctctgctgaa	aatacaaaga	480
ttagccgggt	gtgggtggcg	cctgtagtcc	cagctactcg	ggaggtagac	gcaggagaat	540
cgctggaatc	cgggaggcgg	aggttcag	gagccgagac	cgcgccaaca	tggtgaaacc	600
gtgtctctac	taaaaataaa	aaaattagcg	agacctgggt	gtgggcgcct	gtaatcccag	660
ctactcggga	agttgaggca	ggagaattgc	ttaaaccag	gagaccgagg	ttgcagtgag	720
ctgaaaccac	gtcattgcaa	tccagcctgg	gcaacagagc	gagactctgt	ctcaaaaaaa	780
aaaaaaaaaa	aactcgaa					798

<210> 22
 <211> 646
 <212> DNA
 <213> Homo sapiens

<400> 22

aggctcttgt	ttcaaattgg	ttagatggaa	ggagaaaagt	ggtcaccatt	ttaattctca	60
gaagaggaag	ttaatcgggt	ttctgcatct	gactttcacc	tccctccttc	ctttcctttg	120
tcagttagga	taggtgacac	ttcttttctt	ttacggctat	tatcagagat	tttgtgttta	180
atagttgctg	ggtcacattt	tacaagtgc	aatgactttg	atgacctcca	tttacttttt	240
cttagctatc	ttcatgtcta	caaggagtga	aaggctataa	agcattcagg	caggctcctg	300
ttttgatcag	cctctccagg	tgatcattat	acccaagtca	aaaagtcaat	gcactcccca	360
aatgagaaac	atatatatat	atatatagga	aatctccctt	ttacaagatc	gtagtgcata	420
tcctgggttt	tttcccatcc	ttgtgagtca	gttagtttgt	aattgactct	ctaaccagcc	480
ttccaccttc	tgtaaacctt	tattacctat	agtcaaaggg	acctcaggaa	tgcgagagac	540
cccccccsaa	actccctgcg	gcttttaagt	ctcatcttac	agcattcccc	ctcaaaccta	600
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	ctcgta		646

<210> 23
 <211> 752
 <212> DNA
 <213> Homo sapiens

<400> 23

gatcaaatcc	tgaagtggta	catgtcacta	ctgttcatag	tctctttgct	ggaacttggt	60
cctatggccc	tactggcaga	gaggaaggct	atgaaaccca	gtctaggcct	gcgcctagaa	120
gaagaagaag	aagaaacacc	ttttgaagaa	cagagagcag	tctctgtcat	accaggrgta	180
cctgtcatat	actttagtaa	caaaaataag	taacattttta	attattgaaa	caatgtaaca	240
actttaaaca	cagtttcata	actaggagt	aatcacccat	aatctcatat	ccggaacaaa	300
atatctgtta	gtatgatgca	cctttacata	gctgtaatct	taaagggcat	gtacttcctt	360
ctttgctttc	cttttttttt	ttcttcatcc	tttccctctc	tccctctctc	cctctctccc	420

SUBSTITUTE SHEET (RULE 26)

9

tttctccctt	ccttctttct	tttcttcctt	tctttctgat	tttctaactt	ccttctttta	480
acattccttg	atcgtctgtg	ggtctggaca	gcaacatgga	gatcaattag	gcgcagcatt	540
ttaaatttgc	cctcaagaag	ttccactagt	gtaagagtag	gcaagtaacc	aattattaca	600
atagtgggac	aagcgctgtg	atagaaataa	atacagagta	ctgtggcagt	ccttaccag	660
aaaaagatat	ctagggtaga	tggtagctga	actgagaatt	aaagaataaa	tagaagatag	720
catggcaaaa	aaaaaaaaaa	aaaaactcgt	ag			752

<210> 24

<211> 815

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (1)

<223> n equals a,t,g, or c

<400> 24

ngcttcaccg	tgcactttca	tgttagagag	atcttaaact	tcaagaacca	acctctgcta	60
gcttgagaca	ttttttcctr	cagcttcctc	acctctctca	gccttcatgg	aattgaagag	120
agttagggcc	ttgttctgga	ttagggtttg	gcttaaatga	attttgtggc	tgctctgatc	180
ttctctccag	accaatacaa	ctttatatta	aggataaggc	tgttttgggt	tcttatcatt	240
tgtgtgttga	gtggaatatt	acttttattt	ccttcgagaa	ccttttcttt	gcatccataa	300
cttgggctaa	ctatggtgca	agagccttag	cttttggcct	atctctgctt	tccacatgcc	360
tttctcacta	agtataataa	tttctagctt	ttgagttaaa	gtgaaagacg	tgcaaccat	420
ccttttactt	gaacccttag	aggccattgt	atgggttaata	tatggcctaa	tttcaatatt	480
gtgtctcaga	taatagggac	gcccagtag	aggagagag	atgggaaaat	agcagtcaat	540
ggtgtagtca	gaacacatac	agcatttact	aagttcacca	tcttatatgg	gtgcggttag	600
tggtgctcca	aaacaattac	aatacaaaaca	tcaaagatta	ctgagcacag	atcaccaagt	660
agaaacaatt	ataatgaaaa	aataggggaat	attgcaagaa	ttaccaaata	gtgacacaga	720
gacatgctgt	aaaaatgata	ccaataaaact	tgccttaatgc	acagttgcca	caagctttca	780
atgtgttaac	aaaaaaaaaa	aaaaaaaaaac	tcgta			815

<210> 25

<211> 878

<212> DNA

<213> Homo sapiens

<400> 25

gcaacagatg	aattttgggt	gacacaaaaca	ttcagaccat	agcagtcact	atctaacaac	60
agggtggatg	gacgtttgtc	taaaccgaat	tgtacttcgg	taacaggatc	atataaggac	120
aaattttaacc	aatgtctttt	ttagttttta	gtttcttttg	ttttggtttt	agcaactcta	180
gattttctag	agactatcaa	cattaccttt	ctttgctctc	cagcccccat	gccagaaaaa	240
gaaataagat	tattagggag	tcaagcatct	cggtctttct	tacctcttag	ggtagtaaat	300
tgctttttgt	atgcgagtgg	ttttgcgtat	gtgaagataa	ttttgagata	ggagtagaat	360
gccctgaaga	taatgcttat	gttttaaaga	taataagcca	acacagtga	cgaataaagc	420
tgcactggac	ctgaggagt	aggttaaata	gggaagtaag	acaccacctg	gagacagtat	480
tgctcaagac	tgaaagtgga	tgagggttgc	aaagctgttt	gcacagtgtc	tctgaagcat	540
catggcagcc	tggggaattt	cccatgctga	gcttgccctg	agtatgtgtg	tgtatgcatg	600
catgtgtatg	tgcattcgtt	tgtgtgtgaa	ggaaggggag	cagagctgct	ggcttagtca	660
gctacctttg	aatgcttctc	cctcaacaga	ggctgagaac	cagaccctt	gcctttgtcc	720
ctgaattata	ttagctcagg	ggttcttatg	ccatccaaag	ataaggacat	aagaagaata	780
gggaaagtgc	tgggattgca	ggtgtgagcc	actgtgtctg	gtccattatt	ttagagggta	840
ctcctactca	ttaaaaaaaa	aaaaaaaaaaa	actcgtag			878

<210> 26

SUBSTITUTE SHEET (RULE 26)

<211> 850

<212> DNA

<213> Homo sapiens

<400> 26

gggcaaacat	tgtctacaag	taataaatgc	tttgcataaa	tgtgcagaca	cacgtgtatg	60
aatgtgctat	gcaaataccc	ttccttttag	aagtatttgt	tattcatata	ggtgttttag	120
gaagtaaatt	gcttaaatct	ggtggtcttt	ttgatttaac	atccttttca	ccaatgataa	180
tttgcttttag	taataaaaagt	tagtctcttg	ttgttactgg	aatattgtta	attcatcaaa	240
aaaatcaaaa	gcctatcatg	acaggaatta	ttctaataac	tctctaaaag	gataatcata	300
ataataaatt	aactagcaaa	gtgacaatcc	ctttccttaa	ggtgtttatg	gcctggtagt	360
gaaaagagaa	acctgaagca	attaccccat	aattacgagg	aatacagaat	aatcactata	420
atggatgaat	ggatggatga	tgcagagaag	caatgcaatg	attaggctta	aggaaatcag	480
ggacaacttc	acaaaggaag	gactgtttta	ggagaggctt	aaagaatgga	ggccagggtgc	540
agtstctcac	gcctgtaatc	ctagcacttt	gggaggctga	ggcaggtgaa	tcacctgagg	600
ttaggagttc	aagaccagcc	tagccaacat	ggtgaaaccc	tgtctctatt	aaaaatacaa	660
aaattagccg	ggcatgggtg	caggcatctg	tagaatccca	gctacctggg	aggctgaggc	720
aggagaatcc	cttgaacccg	ggagacagaa	gttgacgcga	gccacgtttg	caccactgca	780
ctccagcctg	ggcaacagag	tgagactctg	tcttaaaaaa	aagaaaaaaa	aaaaaaaaaa	840
aaaactcgta						850

<210> 27

<211> 788

<212> DNA

<213> Homo sapiens

<400> 27

gtttttgttg	agtataggag	ttctttatat	actctggata	ttaacctctt	attagataca	60
tggtttgcaa	atattttctc	ccattctgta	ggttaccttt	tcactcttgt	ttcctttaat	120
gggcagaagt	taagtttgat	atggtctcat	ttgcctgctt	ttgctttcat	tgtctgtttt	180
tgggtgtcata	tccaagaaat	cattgccaaa	ttcagtgtcg	tgatgctttt	tcccgaagtt	240
ttcttctagg	agtttttcag	gtcttatatt	taggttttat	caactacatt	acgttttatg	300
ttgaagaaaa	aacackggaa	tagaattaat	gtttaaactg	ataataaatt	ttcttcccc	360
acaaaacaaa	ccaccctgaa	tataaatact	gtaaggccac	tctgtgtgct	tgggaaagtt	420
gactcagagg	tgtcagatcc	tagtgaaacg	attagatttt	aaagataaaa	gaagtcctct	480
cgggccagga	gtggtggctc	atgcctgtga	tcccagcact	ttgggagggt	gaggcaggca	540
gatcacttga	ggccaggagt	ttgagaccag	cctggccaac	atggcaaagc	cccatctcta	600
ctaaaaatac	aaaacttagc	tgggcttggt	ggtgcacact	tgtaatccca	gctacttggg	660
aggctgagtc	catgagaatt	gcttgaaccc	aagaggccag	ggttgcagtg	agccaagatc	720
gcaccactgc	actccagcct	gggcaacaga	gtcaagactg	tctcaaaaaa	aaaaaaaaaa	780
aactcgta						788

<210> 28

<211> 848

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (388)

<223> n equals a,t,g, or c

<400> 28

aattcggcag	aggaaacaca	atactgtttc	tgcgtcataa	caaagatcta	gttgcgcaaa	60
ctgcacagcc	agaccaaccc	aattatgggt	ttcctctgga	tctcttacgc	tgtgaaagcc	120
ttcttgggtt	ggaccctgca	acttgacgca	gagttctaaa	caaaaattac	acgctgcttg	180
tttccatggc	ttccctcacc	aatgaaatcc	ggcctgtcag	cagctgcacc	cctcagcata	240

11

ttggaccagc	tatcccagaa	gtcagctctg	tctgggttaa	actgtacatt	tatcatgtca	300
ctggacaagg	accaccatcc	cttttattgt	ccaaaggtag	aagacttcga	aaactgccag	360
atatatttca	gagttatgat	cgattgcnaa	taacatcttg	gggtcatgat	cctggagtag	420
ttcctacctc	aaatgtgctc	acgatgttga	atgatgcttt	aacacattct	gcagttttaa	480
ttcaggggca	tggctctgcat	gggataggag	aaactgtcca	tgtcccattt	ccatttgatg	540
aaacagaact	acaaggagag	ttcactcgtg	tcaatatggg	tgttcataaa	gcattgcaga	600
tactaaggaa	cagagtgrac	ttacagcatc	tctgtggata	tgtcaccatg	ttgaatgctt	660
ccagccaact	tgcagataga	aaactcagtg	atgcttctga	tgagagagga	gaacctgatt	720
tggcttctg	ctcagatgta	aatgggagta	cagagtcatt	tgaaatgggc	attgaggaag	780
caactataga	ttcagcaaca	aagcaaacct	ctggtgccac	aacagaagca	gattgggttc	840
ctctcgta						848

<210> 29

<211> 755

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (640)

<223> n equals a,t,g, or c

<400> 29

ggcagaggga	aatgcatagg	cttgtaatga	taattaagat	tcaatctcac	tctcaatgag	60
atcttgggat	tcttgcaagt	ttgaccttca	cttatgcaat	ctgtaaaatg	aaggcattgg	120
gcttagatga	cttagatggt	ttcttcagt	tcttacaggc	ttacatgtta	tatttttgaa	180
ttgctataaa	gcatgttttg	caaattctga	caccaaacaa	tgttttgcat	tcctatagca	240
cagataaacc	atgtttatag	tagccttact	cattctccat	tgggccttag	gtggtacagt	300
gatgtccaag	tgactcgtga	cctctcactt	cttccacttt	tccaggtaga	agatcagcct	360
tgctcagcct	cctgggatta	ggagatgttt	taagaaaagg	agaatttgca	tcaaagttct	420
gacattgttt	gaggaaaaga	ggtagatttc	ctaaaaattc	ccctgaagcc	cataggatat	480
attctcttca	aaataatgag	tgggccgggt	gcagtggctc	acacctgtta	tcccagcact	540
ttggaaggcc	atggtgggca	gatcacttga	ggtcaggagt	ttgagaccag	cctggccagc	600
atggtgaaac	cctgtctcta	ctaaaaatac	aaaaattagn	ccggatgtgg	tgggtgcatgc	660
ctgaggttgc	agacagccga	gatggtgcc	ctgcactcca	gcctgggcaa	cagagcgaga	720
ccctgtctca	gaaaaaaaaa	aaaaaaaaac	tcgaa			755

<210> 30

<211> 813

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (283)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (691)

<223> n equals a,t,g, or c

<400> 30

gcaggaat	ctacctatat	ttccttcctt	actgtgttgt	gtgtgttgt	atgtgttgt	60
gtttaatt	tagcatttgc	cagtttctgt	gggtgaaata	ctcccactac	agctgttttc	120
aagctaac	tgtgatacca	caaaaaatgg	aattgggaag	gcacaatcaa	gattaacaag	180
ccagtttag	ccaagacaat	ttttctgccc	tattagttgg	gcacaagtta	gaaaggctga	240

SUBSTITUTE SHEET (RULE 26)

12

tagtatctca	tgttggaaag	gtgagagaga	aggccctcat	gcnttattaa	tggcatatgc	300
attgaagtgc	cctgttttgag	ggcatgctgt	tagtaacttt	taaaatatga	gatgtcatac	360
tttttgactg	aaaatacaac	tcttgttaga	ttctatttta	tagaactact	taggtgcata	420
aatatacaaa	aataactgtc	attgcagcat	tatttgtaat	agtggaaaca	gaagactttt	480
cattaataag	agaatgggta	ggccagatcc	agtggctcac	acctgtaatc	ccaacatttt	540
gggaatccaa	ggcaggagga	tcgcttttagc	ctaggagttg	gagaccagca	tgggcaacat	600
aacaagacct	tgtctctact	aaaaaaaaat	aataataatt	agtctggcat	ggtggcacac	660
ctgtactccc	agctacttgg	gaggctgggg	ncaaggagga	ttgcttgagc	ccaggagatt	720
gaggctgcag	tgaactgtga	tcacaccact	gcacaccagc	ctgggtgaca	cagcaaaact	780
ctgtctcaaa	aaaaaaaaaa	aaaaaaactc	gta			813

<210> 31

<211> 513

<212> DNA

<213> Homo sapiens

<400> 31

ggcacgagat	tttttaaaaa	atcttaattt	ttttctctgt	tttagggatt	atcttaatta	60
aaacttagaa	aataatgact	tttggttag	gccagggcct	ttgttttctt	ttttgctacc	120
aggtacttgt	tgcctttaga	ctgaccaacc	agatccctgc	actgggggat	atatcccatc	180
tatcttccca	cataccatac	ttggctctct	ttggatagac	tctgatatta	agtacttggt	240
tctcttctac	ttgaaagtat	ctatatattca	tggaggatgg	tgcttcttaa	cgttctgggt	300
gcagggctct	aggcctgaag	ggcttttttg	gctagtgaag	atgggtttca	tcatgttttt	360
caagtcacac	tttcttcggt	ggtggtcttg	ttgccatacc	cagctgagct	tatatctaac	420
cagccctact	ttcagagagt	tggcattcag	gtgtcttcat	ataaagttca	gttatgctgg	480
agtaacagag	aacaaaaaaaa	aaaaaaaaaaa	aaa			513

<210> 32

<211> 576

<212> DNA

<213> Homo sapiens

<400> 32

ggcacgaggt	ctattaattt	gcttttcttt	agatgtattc	tagagggggg	aaaatcagta	60
gaagaacagt	tatgtaattc	ttacaagttc	tccatgtgtc	ttgccatctt	gctttttctc	120
atcctatcag	tactggatga	gaatgtttat	ttcactgaac	tttgccaaag	agtttcaaca	180
tttttttggt	taatcatagg	agaaaaaggt	ttatcttatt	tttaaaaatt	tttatttaat	240
tctttcatta	caaatgaagt	cccagaagtt	gtatttgttt	ctttaggctg	ttcttaattg	300
ttcatkggaa	caggcagggt	ttgaaggagt	ggggatactg	ggaaagccag	ggtgatgaga	360
aaataggaaa	ggggtcttgt	cattgggagg	ccactatacc	agtggccctt	gtaccaggac	420
taatatggta	ctttgaagct	ttaaattcat	ttctttattc	accagataat	tattgagtgc	480
ttactgggtc	tggacaagta	agcattcaat	aatttttaggc	atcccaggat	acatcagtga	540
acaaacaaac	ataaaaaaaaa	aaaaaaaaaaa	ctcgtga			576

<210> 33

<211> 1019

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (126)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (202)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (380)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (476)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (511)

<223> n equals a,t,g, or c

<400> 33

gtctcactgt	gccacgcagg	tgccctgcag	ccacggagac	gaatgtggac	ggccagaagg	60
tgtaccgaga	ctgtagctgt	atccctcaga	atctttcctc	tggttttggc	catgccactg	120
cagggnaaat	gcacttcaac	ttgtcagaga	aagcccctcc	ttctgggttt	catattcggt	180
gtgaattttc	tttacattcc	tncagcagca	ttcctgcact	aacggcaact	ctacgatgtg	240
tccgtgaccc	tcagagatcc	tttgccctgg	gaatccagtg	gattgtagtt	agaatactag	300
ggggcatccc	ggggcccatc	gccttcggct	gggtgatcga	caaggcctgt	ctgctgtggc	360
agraccagtg	tggccagcan	ggctcctgct	tggtgtacca	gawtcggcca	tgagccgcta	420
cataytcatc	atggggctcc	tgtacaagtg	ctgggcgtcc	tcttctttgc	catagnctgc	480
ttcttawama	agccccctgtc	ggagtcttca	natggcytgg	raamtgtgtt	gcccagccag	540
tcctcagccc	ctgacagtgc	ccacagatag	ccagctccag	agcagcgtct	gaccaccgcc	600
cgcgcccacc	cggccacggc	gggcactcag	catttcctga	tgacagaaca	gtgccgttgg	660
gtgatgcaat	cacacgggaa	cttctatttg	acctgcaacc	ttctacttaa	cctgtgtgtt	720
aaagtgcggc	gtgacctcct	gtccccagag	ctgtacggcc	ctgcagtggg	tgggaggaac	780
ttgcataaat	atatatttat	ggacacacag	tttgcacag	aacgtgttta	tagaatgtgt	840
tttatacccg	atcgtgtgtg	gtgtgcgtga	ggacaaactc	cgcaggggct	gtgaatccca	900
ctgggagggc	ggtggcctgc	agcccagagga	aggcttgtgt	gtcctcagtt	aaaactgtgc	960
atatcgaaat	atattttgtt	atttaagcct	gaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1019

<210> 34

<211> 433

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (309)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (408)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (418)

<223> n equals a,t,g, or c

<220>

<221> SITE
 <222> (419)
 <223> n equals a,t,g, or c

<400> 34
 ggcacagctc accttcctac cctccactgg aaaccactcc tctccatggt gacctcctgg 60
 attgcctcca tccccctccg ctgtgggggt ctgtgtatct gcttggtgtt tggattgggt 120
 cactgtctgg atctgtcaag gaagataacc attttttcag gagctgtgta catggtgaaa 180
 aatatacagt tctggttgta aggaactctc acttgggaat attattattt aaaaacttat 240
 acgttgagct cagtgtctgc acagaggtaa gaatactgtg gaaaggctat aaatattttt 300
 ccccaaagnc aggggttgga aacatttttc tttcctaggc tgttgagact cacagggaaa 360
 aaaaaaaaaa aaaatccggg ggggggcccc gtaccatttg gccctangg gggggttnna 420
 aaaagggcc gtt 433

<210> 35
 <211> 642
 <212> DNA
 <213> Homo sapiens

<400> 35
 aggaatgcc a ggtcgactc caccttgctg gccggcaagt cctcttaacc tgttggtctg 60
 ctttctttgt taaaaagttg gtctggctta tactgttgaa ggtcatggga tttttgctag 120
 catattattg aaatgagaca ttgtgtggc tggcggttgta ttgtttctgc taataggagc 180
 ccgcgtgtct ttcacatatg gttagtctga ttgctttttc tagcctggga ctttgccttg 240
 gagagagtcc tagcaaaata ccattcacag ccttcttcca cagggaagga tgactaagag 300
 tttagtgtctg gaagagcaga agaggaaagc tggaagatca gaaatgaaat tggagctggt 360
 gatgcgtgtg tctctatggt acagtgggca agccctagtc cttcttgggt tgatcactaa 420
 cttgtcatgc agtgtcttg gcaagtcctt tcacctctca ggacctctgt ctgtctccct 480
 atagaacggg gaaggtggcc gggcatggta cctcacacca ccagtgtttt gggaggatga 540
 ggcaagggga tcaactggag ctaggagttt gagaccagcc tcagcaacag agcaaattcg 600
 tctcaattta aaaaaattaa aaaaaaaaaa aaaaaactcg ta 642

<210> 36
 <211> 667
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (656)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (660)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (661)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (662)
 <223> n equals a,t,g, or c

<400> 36
 agagactttg gctgtgagcc ctcacctggg actgatactg gctctttgag ctttttagtc 60
 atgtgcttgt ctcttctctt acttagcttg tcatgccttg ctgtgccatg gtggcctcat 120
 tcagtgactg ctcttcaact ctcaccagaa agtgaccacc attcctgact tccaagatcc 180
 ttcttcaagg atatgatgga gagctcagag ctttccagct tcttagagta gctcagcatt 240
 tcctcaaat ggggtcttcc cttttcccggt agtgaaactc atcagccact gttctgcacc 300
 cttgcatggc ctctggagat cttttaacaa gtattgttga gcgtcacctt tctgccaagg 360
 atatggatgt aatggtatga gcaaaaacaa aaatactcgc cagtggaggg tatgatccag 420
 tgagggagaa agatgtcaat caaatgatta taccaataaa aagtagcaac catgactagt 480
 gctatgaaga ggagaaatac aatgcagtga atgagaacct agaatagggt gattctakcc 540
 agttagggaa agatggaaga tttttataag gaagtgactc ttgggctgag gtwcacggta 600
 aaaaaaaaaa aaaaaaactc gaggggggggc ccgtacccaa tcgaccctga tgatgnatgn 660
 nncatac 667

<210> 37
 <211> 654
 <212> DNA
 <213> Homo sapiens

<400> 37
 gccaacataa gcacacttaa cctagacttc aatatgcagt agacgcataa ataaacaaat 60
 caatgggtga atgcttatta cttttttcct taagcaactc tcctcatatt ttgtttgctt 120
 gttcttcatt ktctaggaga atgtggatta tattattcag gagctccgaa gacccaaata 180
 cactatatat ttcatattgta agtatgttag ttcaactttt caaacatgta acaacatccc 240
 agttagtgtg ttcatattgag cccttcatat catcaataac ttcatkgaat ctgtcactat 300
 aaaagtctag tttattttaat gtcccttccaa agtattaaaa atcttttgac ctgccgggcg 360
 cgggtggctca cactgtaat ccagcactt tggggggcca gggcgggagg atcatctgag 420
 gagtttgaga ccagcctgac caacatgggt aaaccccatc tctactaaaa atacaagatt 480
 agctgggcat ggtggcacat gcctgtaatc ccagctactt gggaggctga ggtcaggaga 540
 atcgcttgaa ccggagaggg ggagattgca gtgagccgag attgcgtcca ttgcaactca 600
 gcctgggcaa caaagcgaaa ctccatctca aaaaaaaaaa aaaaaaaact cgta 654

<210> 38
 <211> 731
 <212> DNA
 <213> Homo sapiens

<400> 38
 ggagagagag agaattgtga gaaataggaa tgcttttaca ccattggagg gagtgtaaat 60
 tagttcgacc attgtggaag acagtatggc aattcctcaa ggatctagaa ccagaaatac 120
 catttgacc agcaatccca ttactgggta tatacccaaa ggattgtaaa tcattctact 180
 acaaagacac atgcacacgt gtgtttattg cagcattatt cacaatagca aagacttggg 240
 aaccaacca aatgtccaac aatgatagac tggattaaga aaatgtggca catatacacc 300
 atggaatact atgcagccat aaaaaatgat gagttcacgt ctttggaggg acatggatga 360
 aactgcaaat catccttctc agtaaatat cgcaaggaca aaaaaccaa caccgcatat 420
 tctcactcat aggtgggaat tgaacaatga gaacacatgg acacaggaag gggaacatca 480
 cactctgggg actgttgtgg agtgagggga ggggggagtg atagcttttag gatataaac 540
 taatgctaaa tgacgagtta atgggtgcag cacaccagca tggcacatgt atacatatgt 600
 aactaacctg cacattgtgc acatgtacgc taawayttww wgtwtaataa taataaaaata 660
 aaataaaaata aaaaaagaaa agatgtggct ccaggtttct ttgcttctaa aaaaaaaaaa 720
 aaaaaactcg a 731

<210> 39
 <211> 378
 <212> DNA
 <213> Homo sapiens

```

<400> 39
tcgaccacag cgctccgtaag attaaatcag ataatgcaca cggaaatacg ttacaaatgg      60
aagtgttggt gttcttccaa gtttgcaagg agaggcagcg gcagtgttct tgcagtgtgt      120
ctgagttcca cgtgacttat attggattat tatataaatc ctgtaattga tctgtcatac      180
ttttatgtcc attctttatg tcatatttct ctctcacata tacatacaca gttgtataca      240
tacttaaatc tctatgtatt agcagtcctgc acaacatata ccttttaata tttatatattc      300
tgttcagttc tgttcatacc acagaatatg tggtataaac tcttttatta agcttaaaaa      360
aaaaaaaaaa gggcggcc                                     378

```

```

<210> 40
<211> 642
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> SITE
<222> (41)
<223> n equals a,t,g, or c

```

```

<220>
<221> SITE
<222> (49)
<223> n equals a,t,g, or c

```

```

<220>
<221> SITE
<222> (64)
<223> n equals a,t,g, or c

```

```

<220>
<221> SITE
<222> (607)
<223> n equals a,t,g, or c

```

```

<220>
<221> SITE
<222> (621)
<223> n equals a,t,g, or c

```

```

<400> 40
taaaggggaa acaaaaaggc tgggaaggct tccaaccgcg ntttgcggn cggcttctag      60
gaantagtg gaaatccccg gctggcagga attcggcagc agaaaatgac ttcagacaaa      120
tatgatcaat ctctacagtc ccctgatgaa ttacacaggt tcccaccacc atcagttcta      180
cctattcatc tcatccatgc tcattgttct gcctctttcc tgttccctatg gatgccctgg      240
catgtttgtt tctttctttc tggcctccta tttccctccc ctccagacatc acttcagcat      300
ctgtgccttc tcaactccct tatcctgggt gttaccattt cagcctatga gcatgccatt      360
aatttgccat cttttacaaa ttctctcttg acttcacatc cctctgtagc tgccctctcc      420
cttctctcct cttctttaca acaaaactcc ttaaaagaac tgttggtctg gcacagtggg      480
tcactcctat aatcccagca ctttcagaag ccaagggtggg aacatcactt gaggccaaaga      540
ggtcgagacc agcccaggca acacagttag acctcatcac tacaaaaaaa aaaaaaaaaa      600
actcganggg ggggcccggta nccaattggc cttaaagttag tc                                     642

```

```

<210> 41
<211> 442
<212> DNA
<213> Homo sapiens

```

```

<400> 41
ggcacgagat agaaccact gcctcctgat gaagtcoccta ctgttcaccc ttgcagtttt      60
tatgctcctg gcccaattgg tctcaggtaa ttggatatgtg aaaaagtgtc taaacgacgt      120
tggaatttgc aagaagaagt gcaaacctga agagatgcat gtaaagaatg gttgggcaat      180
gtgctggcaaa caaagggact gctgtgttcc agctgacaga cgtgctaatt atcctgtttt      240
ctgtgtccag acaaagacta caagaatttc aacagtaaca gcaacaacag caacaacaac      300
tttgatgatg actactgctt cgatgtcttc gatggctcct acccccgttt ctcccactgg      360
ttgaacattc cagcctctgt ctctgtctct aggatccccg actcattaaa gcaaagagggc      420
ttaaaaaaaaa aaaaaaaaaa aa                                         442

```

<210> 42

<211> 1734

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (1714)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1719)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1723)

<223> n equals a,t,g, or c

<400> 42

```

gcgggaggttc ctctttgctc tcgcccctac tctttctggg gttagatcga gcwaccctct      60
aaaagcagtt tagagtggta aaaaaaaaaa aaaacacacc aaacgctcgc agccacaaaa      120
gggatgaaat ttcttctgga catcctcctg cttctcccgt tactgatcgt ctgctcccta      180
gagtccttcg tgaagctttt tatcctaag aggagaaaat cagtcaccgg cgaaatcgtg      240
ctgattacag gagctgggca tggaattggg agactgactg cctatgaatt tgctaaactt      300
aaaagcaagc tggttctctg ggatataaat aagcatggac tggaggaaac agctgccaaa      360
tgcaagggac tgggtgccaa ggttcatacc tttgtggtag actgcagcaa ccgagaagat      420
atttacagct ctgcaaagaa ggtgaaggca gaaattggag atgttagtat tttagtaaat      480
aatgctgggt tagtctatac atcagatttg tttgctacac aagatcctca gattgaaaag      540
acttttgaag ttaatgtact tgcacatttc tggactacaa aggcatttct tcctgcaatg      600
acgaagaata accatggcca tattgtcact gtggcttcgg cagctggaca tgtctcggtc      660
cccttcttac tggcttactg ttcaagcaag tttgctgctg ttggatttca taaaactttg      720
acagatgaac tggctgcctt acaaataact ggagtcaaaa caacatgtct gtgtcctaatt      780
ttcgtaaaca ctggcttcat caaaaatcca agtacaagtt tgggaccac tctggaacct      840
gaggaagtgg taaacaggct gatgcatggg attctgactg agcagaagat gatttttatt      900
ccatcttcta tagctttttt aacaacattg gaaaggatcc ttctgagcg tttcctggca      960
gtttttaaac gaaaaatcag tggttaagttt gatgcagtta ttggatataa aatgaaagcg      1020
caataagcac ctagttttct gaaaactgat ttaccagggt taggttgatg tcatctaata      1080
gtgccagaat tttaatgttt gaacttctgt tttttctaata tatccccatt tcttcaatat      1140
catttttgag gctttggcag tcttcattta ctaccacttg tcttttagcc aaaagctgat      1200
tacatatgat ataaacagag aaataccttt agagggtgact ttaaggaaaa tgaagaaaaa      1260
gaaccaaaat gactttatta aaataatttc caagattatt tgtggctcac ctgaaggctt      1320
tgcaaaatth gtaccataac cgtttattta acatataatt ttatttttga ttgcacttaa      1380
atthttgtata atthttgttt ctttttctgt tctacataaa atcagaaact tcaagctctc      1440
taaataaaat gaaggactat atctagtggg atthtcacaat gaatatcatg aactotcaat      1500
gggtaggttt catcctaccc attgccactc tgtttcctga gagatacctc acattccaat      1560

```

18

gccaaacatt	tctgcacagg	gaagctagag	gtggatacac	gtgttgcaag	tataaaagca	1620
tacttgggat	ttaaggagaa	ttgagagaat	gtaccacaaa	atggcagcaa	taataaatgg	1680
atcacactta	aaaaaaaaaa	aagggggggc	cgcncctgng	ggnccaagct	ttcg	1734

<210> 43

<211> 517

<212> DNA

<213> Homo sapiens

<400> 43

gcacgagtag	aagcatgttc	ttcacttcaa	gaccaggac	cccatggaca	tctgcctac	60
agatcgcccc	actagccctg	cttcagtcac	tgggcatctg	gcagcactcg	ataggtgcca	120
tgtggtactg	cctgctctgt	gggtgcagct	gccatgccaa	ggcgtcccc	tctgtcctct	180
ccaggctctc	ctgtaacctc	ccagctctgc	tctcccatgc	cctccctcaa	ccagccctt	240
ccgtgggggc	tctcctggc	tctccccggc	ctgtccctcc	acacccctt	tcagaccctc	300
acagctgcct	ccccacacca	gccttcaggg	gactctgcag	cccacctctc	tgccactcc	360
ttctctctag	attctcactg	aagcttcccc	cgctctccct	agacccgcag	ctcatacccc	420
cggctactta	ttagaatgcc	tggcaagctt	ggataaaacc	ccatactcag	ccacaccag	480
gcccattaaa	ccagacacct	agagttggcc	tggaagc			517

<210> 44

<211> 486

<212> DNA

<213> Homo sapiens

<400> 44

gcacgagagg	aaatataaat	gtgcatgttc	tctacatgtg	gcttaagtaa	ttacttaata	60
attaccacat	tcttgctcct	cagtatctct	tcccttggtc	cccctacacc	tagcaaatta	120
tttgactcat	ccagtcattg	gaaatactga	gttcgaatca	aaatgctgga	gtgagaagga	180
atgttacacg	tagtgcagcc	tctccatgta	gacatgaaaa	aactgaggtc	cagaatttgt	240
gccttatcca	aagtcacagg	tttatgtggt	gatactcttc	ctctcctaga	gcctttaatt	300
ataattatta	ctattattat	catcaacagt	ttagcttttc	tctgccatct	gagaagatga	360
actaacgaat	ggctaaagtt	agaagtttag	aatggaaata	aggtctgact	cttgaaatcc	420
ttccagcatc	tttttcttta	gcaactctgt	tccacaggca	gtgggagaaa	aaaaaaaaaa	480
aaaaaa						486

<210> 45

<211> 826

<212> DNA

<213> Homo sapiens

<400> 45

ggcacagctg	gatttagtga	cttgctttta	gtgaatgtaa	tgtgtcagac	aagacggagt	60
attactttca	agaataagtt	acaaaaggag	tcacgcattt	atcctatgca	tctcctgttg	120
ctttcttgct	tgctggctgg	caaagcaagc	tgtcatgttg	tgagaagccc	tgtggataat	180
cccttggtgg	aaggaggtaa	tgcttatggc	caacagccag	taaggactgg	gccttgccaa	240
caaccacata	agtgcagctg	aaagtgaatt	gtccccattc	aagccttgag	atgactgcag	300
cccggggccag	caacttgatt	gcagcgtttt	gagagaccct	acaccagaca	cacctggcta	360
atttctactt	agacttttta	ctccacaaaa	actaagagat	aataaatctg	ttactttaaa	420
ctgctgagta	ttgtttactt	tgccttacgt	aagcagtata	gacagacttt	tacataaatc	480
ctgattccaa	tgcttatcca	ttgtgcatta	tgattaagtt	atagcacaat	ctcagtttcc	540
tcactcttat	aaaaagtga	aggaggcaga	ggccagcaga	tactttgagg	tcaggggtgc	600
aagaccagcc	tggccaacat	ggtgaaaccc	cgtctctact	aaaaatacaa	aaattagcca	660
ggcgtggtgg	ctcatgcccg	taatcccagc	tacttggggag	gctgaggcag	gggaattgct	720
tgaatccagg	aggcggaggt	tgcagtgcgc	tgagatcatk	ccactgtact	tcagcctggc	780
cgacagagtg	agactccatc	tcaaaaaaaaa	aaaaaaaaaaa	ctcgag		826

SUBSTITUTE SHEET (RULE 26)

<210> 46
 <211> 694
 <212> DNA
 <213> Homo sapiens

<400> 46
 gcttagatttt ttttaagtcct ctcaaatttg tacactcaga actaagtata ttcaaagtga 60
 gtctgatttg catagagaat gacattttct tcattcagac tttgttttta atgaaacctg 120
 ataccagtga ttttggcagc tgtaacaggc tgtatgtctc tttgaaatag acttttttaa 180
 aagcctagtt gtttctcact gtccctgtgcc attttgttgt tattgttgat ttttttgttc 240
 taagcttatg actttatatt tatccttatt aaatatgata cccttaaatt tagcctcctg 300
 ttccagccac ttagaattac ttaaaaagtt gattatgtca tacagggtat ttacttttcc 360
 catcccagat acctgtcatt tgcacatttg atcgctctcc tttccatatt ctcatccaag 420
 tcattttataa aaaaatgtta caaaggacag gttgctctgg gcccctgttg catactactg 480
 agccttcttc cagatttatc tgcactcttt aggtacagtt gtatagttgt ctgtgaagcc 540
 acttaacttt taagttaaaa aattcatatt ttttcacctt gcacagtgat atcaagagag 600
 actttatttt atgccttgct gaaatccaga tactatatat atgcctctag catttgctgg 660
 cctaaccata taaaaaaaaa aaaaaagggc ggcc 694

<210> 47
 <211> 856
 <212> DNA
 <213> Homo sapiens

<400> 47
 gaattattga aaataactga aagaaagcct agtggattgt tactaatgat ttaatgtatt 60
 ttcttttaac ctgtaggttc tctcttcac tcttgccctg ccctcttttt ctttggtttc 120
 ttccctccttg cagtttattt gttgaagaaa ccagttatct ctgttttggt tcccatggta 180
 tgaattttgc tgagtgcac tttacatgta gtttaatgtg ttgtttgggc cttcacattt 240
 cctgtaaatt gacagttgaa tctacaagct tgatcacatt cacatttttt ttaggggtgg 300
 ggggctggcg gtacacacag ttatttccat ttcattgatg tagcagtcgt tgataatcat 360
 gctgcgatct attcattata tgttacaaaa tggatgata attttatcat ttattaactg 420
 ttcttttaaa agtttatatc atatatctct gtgtgtatat ataaagatta atgtgcagga 480
 gttttgcttt cagtgaatgt ttgcattcca atcattgctt agaaagtttt tttgcccttg 540
 ccgggcgcgg tggtcacgc ctgtaatccc agcacttttg gagggccagg cgggcggatc 600
 acgaggtcag gagatcgaga ccaccccggc taaaacgggt aaaccccgtc tctactaaaa 660
 atacaaaaaa ttagccgggc gtagtggcgg gcgcctgtag tcccagctac ttgggaggct 720
 gaggcaggag aatggcgtga acccgggagg cggagcttgc agtgagccga ggtcccgcga 780
 ctgcactcca gcctgggcga cagagtcgag atccgtctca aaaaaaaaaa aaaaaaaaaa 840
 aaaaatgacc ctcgta 856

<210> 48
 <211> 1643
 <212> DNA
 <213> Homo sapiens

<400> 48
 gaattcggca cgaggaaact gttagccctt aatatgcac acatttgtgg ttccatagtg 60
 cttctccttt gcttgtttga tctctgcatg gcagcagtg ggcagctcca catttgagc 120
 ccatactcca aaatgcagag cactcttctc acagcacaca ttcccagccc caaacaaaac 180
 ctgaattttc aactctgccc attaaagtga atgtatccct gtaatttagt atgtacttat 240
 tatggaaaat gtaacaaaag cagagaagtg tgatttcatt ctgtatcaca aattgaagca 300
 aatcaacagc aaatacagca ggattcaggg aggttagtt tacaacgtac tttgtacctc 360
 ctgccattta aattattttg ccactctggg cttctgaaaa cacaaaggga gatacagccc 420
 tccaactatg agccttgcag agagagacaa aagggccaga ggtcctggga tggaatacta 480

20

gagccccac	cttctcatgc	tttgaaacc	tgccagagcr	cttaccctgc	tggaagatta	540
atgaagactc	cattctgtgt	ttcataacag	tagcgttggt	ttctccatca	aaaacagagg	600
gtcacagaaa	tgtgctgaaa	agatgtgggc	cagcaagggt	ctgtagtccc	acctcagtcg	660
ctgtgggctg	tgtttttcac	tgtaacaagc	acttttggtaa	actagaaaga	agaaaggatt	720
ctcaggatgt	gttcaaagct	aagagagttt	tcatttttaaa	aagaaacata	catactcact	780
ccatggcttt	cctcatcctc	ctctcttttt	tcttcttggg	gggaagctgg	atgcggggca	840
tgcacatttc	tgtatggaca	aatgtgttat	gtccacccat	actcttgtga	caactcccca	900
gcactgtcct	gcaataccat	gctggccttg	gtagtataaac	tccttgggtat	ctgtgagagt	960
cctctttttc	tatgccctag	actactttta	accacttttc	tctggaatga	ctcccacatt	1020
tgattgggta	ttgaaagggt	aacagcaaaa	tgatgattgt	ggagatggat	ctattagggtc	1080
tcattgttgt	cccttggttg	aaactatwtt	caaaaaagcc	ccaacaatgg	gcctgtcmcc	1140
ttgctagtca	tccattctta	atgcctattt	atcagccctc	tgaggtcata	taaaaggttgc	1200
caccttttga	accaagtatt	tgtattttact	atgggaaagg	tgtggactac	agattcgtat	1260
tatattattt	taatggattt	taagtaattt	ataagtatgc	tgagtgtaaa	ttttttttta	1320
aaactgtatt	ataaaaggac	atatcctgtg	aatataaca	ttttactgtt	taatagaata	1380
attctataag	agaatgatt	tatctcacc	acggaactga	ttacattccg	gatgcaatca	1440
ataggcactt	tgtaatttcc	tttttggttt	ttttcttttg	ctgggggggt	gaggggtaac	1500
aagataccat	ctgtataaag	tgcatgttgt	gtcactcaaa	atatgcactg	tatggctaca	1560
caaaagcagc	ttgatgaaca	aatcacccca	tggtcatta	aagaacaaag	cttcagagaa	1620
aaaaaaaaa	aaaaaaactc	gta				1643

<210> 49

<211> 709

<212> DNA

<213> Homo sapiens

<400> 49

gaagaaaagg	aagcagtaac	tacgaatagt	gcttatacat	gctgggggtct	gtttgcaggg	60
cccttcatgt	attaacctgt	ttactgctct	ccagtaaccc	tgtgggtgcag	gcaccatggt	120
ccctcaatga	ggaaagtaaa	tcacaagggg	tgacatgtgc	tgtgctcca	gctggggatt	180
tgaaccagg	tagtctagta	tcagcatgtg	tgcccttaac	cgtaacccta	taacggtttag	240
aagagcttca	gggaccttcg	tcaggacata	catcttgtaa	ataattgggt	tgggagtaaa	300
atgcatgctg	agtcaccagt	gaatcttctg	tgttctcatg	ttactttggg	catactctca	360
tcaaaacatt	gcagcagtct	cttacaagtt	ttgtttgttt	cctagtcatg	aggactggga	420
ttctgctttt	catgtttgat	tactcagagt	acatagtttg	gcatatttta	ggcacggtaa	480
atattgatcc	aatctgattc	ctagttcagt	ggttttatgc	tgtaacagct	ttttcctcct	540
cctttacgtt	gtcaagccac	tttctcatgg	tttcatcttt	tccttcttgc	tttggtttctg	600
gagcacacat	tttttacttt	tttttgattg	ccttctattt	ggttttcttt	aagggtggtgc	660
atttaaaaag	cagccccctc	ttcttcaaaa	aaaaaaaaaa	agggcgcc		709

<210> 50

<211> 541

<212> DNA

<213> Homo sapiens

<400> 50

tgcaggtaac	cggtccggaa	ttcccggtt	cgacccaagg	gggtccgtga	tgccctgtca	60
tggtcttctt	gcacagggcc	tcagcctggc	acctctgcca	ccgtgggctc	tctgttgtgt	120
gggggtgtcc	cgtgcattgc	aggacatcca	gcagcatccc	cggcctcctg	ctccgtgcca	180
gtagcgccgc	accccgccgt	cgtgacagcc	caggctctcc	ggtgtgcaga	atgcccgctg	240
gtcatgctga	gaggtacagg	ggtgctgccc	ccagggtttg	aacgctgtct	aactcccacc	300
tctgggtgtg	ctctcccctg	tgtgtagcgt	ggagtcactg	gatgagtgtg	gtgacctccc	360
tgtgtccagc	tgccctgggc	tgcaagcagg	tccctcctgc	agccctccag	gccaccctta	420
agcagagctg	gaccagcctg	gccaacatgg	tgaaacccca	tctctactaa	aaatacaaaa	480
attagccaag	cgtgggtgaa	ctctgtctca	aaaaaaaaaa	aaaaaaaaaa	aaagggcggc	540
c						541

<210> 51
 <211> 720
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (20)
 <223> n equals a,t,g, or c

<400> 51
 ccacgcgtcc gctccgcggn cgccctcgggc ggaacctgga gataatgggc agcacctggg 60
 ggagccctgg ctgggtgcgg ctgcgtcttt gcctgacggg cttagtgtctc tcgctctacg 120
 cgctgcacgt gaaggcgggc cgcgcccggg accgggatta ccgcgcgctc tgcgacgtgg 180
 gcaccgccat cagctgttcg cgcgctcttct cctccagggt gcctgsggac acgctggggc 240
 tctgtmctga tgctgctgag ctccctgggtg tctctcgctg gttctgtcta cctggsctgg 300
 atcctgttct tcgtgctcta tgawtttctg cattgtttgt aatcaccacc tatgctatca 360
 acgtgacctg atgtggctca gtttccggaa ggtccaagaa ccccagggca aggctaagag 420
 gcaactgagcc ctcaacccaa gccaggctga cctcatctgc tttgctttgg catgtgagcc 480
 ttgcctaagg gggcataatct ggggtccctag aaggccctag atgtggggct tctagattac 540
 cccctcctcc tgccataccc gcacatgaca atggaccaa tgtgccacac gctcgtctct 600
 ttttacaccc agtgccctct actctgtccc catgggctgg tctccaaagc tctttccatt 660
 gccaggggag ggaagggttct gagcaataaa gtttcttaga tcaaaaaaaaa aaaaaaaaaa 720

<210> 52
 <211> 979
 <212> DNA
 <213> Homo sapiens

<400> 52
 ggcacgagta caaagccaaa atgtgatgga acatcccatg atgcagacaa ttcattttac 60
 tccagctgta ctccactttc ttttcctgtg gtcttccacg tggagtgtct ctatctgagt 120
 cccctgtcca gcccttttta agggatctct gttgagcagg atttgaaatg tttcacattt 180
 tgcttaatcc tccacctcca ccctgatgtc ctgcagtaaa tattcacgca catttcagct 240
 tgacacactc taggcaagca gctcacccca gtgtgggcaa cagttctttt tttgcttcac 300
 tagctaacca gctggatgac tcatctctgc ctttagattt tccagggtgga tgttgacat 360
 ggcacattct gctcaccaaa ctcttgcgta agcatagcaa gaccagagt ttccttgaca 420
 cctctctca catgcacaag gggagaggca gctcctctct gctcctttct gagaggcatg 480
 aatcggtgaa aacaacagca tagcccatcc cagcaatgtc ctcaaaaaat tccaactgcc 540
 cattctttac ggtgagtttt ctaaacaggt ttctcccatg acaattttct ctacttgctg 600
 tcttaatagg agatttttgt tccccccac ctgtattttt aatggacaca tatacctttc 660
 tgataaaaat atgtaaaata ttctgttcgt ttttaaaatg tcatattcaa gtctgtggcc 720
 atcttttgtt cttaatatcc acgtctataa aatgggctag aaaacagcat cattgctcaa 780
 ggtgtaaagc tattggttta tctagctgaa aagggtgtgca aggactattg aaaaaagaaa 840
 tgttcattca gaaacatggg ctcttttatt ttgtacatat cttacagcat aggatttttt 900
 cccctggtgt atatgccaaa gatcagcctc agctgaaaaa aaaaaacaca tatgcccccta 960
 acttactgct tgcttccaa 979

<210> 53
 <211> 380
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (6)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (7)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (11)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (376)

<223> n equals a,t,g, or c

<400> 53

ggttcnnacc	ntagtggttc	caaagaattc	ggcacgaggt	gtatgtgcat	actccactca	60
cattgtcttt	tattttttaa	tttaaaccag	gtagtctgct	ttcatgggaa	tttttctctc	120
tcctgttttt	gccaaaccca	aataagttat	attaacatat	tttctgggaa	aaatgggtgt	180
gattcaaagt	tagaacattt	gttattttac	ttcagaaagt	ctttattgaa	catctttctt	240
gtgtaggacc	ctgtgtagaa	aatgcaaaga	gaaatcatac	ttgtcctaca	ggaaattata	300
atcttgtcgg	gaagataaga	tgcagactga	tataattcaa	ggtaaaaaaa	aaaaaaaaaa	360
actcgagagt	tcttcnagag					380

<210> 54

<211> 2023

<212> DNA

<213> Homo sapiens

<400> 54

cccacgcgtc	cgcccacgcg	tccgaaaaaa	aaaaaaaaaa	aaaaaaattg	gcagactcca	60
gagcccacac	atttgcactc	tagactctac	tgcccttcctc	atgaagaatt	ttaggacccc	120
cgtctggctg	tgttggtgct	tgggggttcaa	attctggttg	aaagatggcg	gctgcagtgg	180
gaccactatt	atctctgtcc	tcacagagtt	caagctgaag	aagatgtgga	aaagtcccaa	240
tggaaactatc	cggaacatcc	tggggggggac	tgtcttccgg	gagcccacatca	tctgcaaaaa	300
catcccacgc	ctagtccctg	gctggaccaa	gcccatcacc	attggcaggc	acgcccattg	360
csaccagtac	aaggccacag	actttgtggc	agaccgggcc	ggcactttca	aaatggtctt	420
caccccaaaa	gatggcagtg	gtgtcaagga	gtgggaagtg	tacaacttcc	ccgcagcggc	480
gtgggcatgg	gcatgtacaa	caccgacgag	tccatctcag	gttttgcgca	cagctgcttc	540
cagtatgcca	tccagaagaa	atggccgctg	tacatgagca	ccaagaacac	catactgaaa	600
gcctacgatg	ggcgtttcaa	ggacatcttc	caggagatct	ttgacaagca	ctataagacc	660
gacttcgaca	agaataagat	ctggtatgag	caccggctca	ttgatgacat	ggtggctcag	720
gtcctcaagt	cttcgggtgg	ctttgtgtgg	gcctgcaaga	actatgacgg	agatgtgcag	780
tcagacatcc	tggcccaggg	ctttggctcc	cttggcctga	tgacgtccgt	cctggtctgc	840
cctgatggga	agacgattga	ggctgaggcc	gctcatggga	ccgtcaccgc	ccactatcgg	900
gagcaccaga	agggccggcc	caccagcacc	aaccccatcg	ccagcatctt	tgctgggaca	960
cgtggcctgg	agcaccgggg	gaagctggat	gggaaccaag	acctcatcag	gtttgcccg	1020
atgctggaga	aggtgtgctg	ggagacgggtg	gagagtggag	ccatgaccaa	ggacctggcg	1080
ggctgcattc	acggcctcag	caatgtgaag	ctgaacgagc	acttcctgaa	caccacggac	1140
ttcctcgaca	ccatcaagag	caacctggac	agagccctgg	gcaggcagta	gggggaggcg	1200
ccacccatgg	ctgcagtggg	ggggccaggg	ctgagccggc	gggtcctcct	gagcgcggca	1260
gagggtgagc	ctcacagccc	ctctctggag	gcctttctag	gggatgtttt	tttataagcc	1320
agatgttttt	aaaagcatat	gtgtgttttc	cctcatgggtg	acgtgaggca	ggagcagtgc	1380
gttttacctc	agccagtcag	tatgttttgc	atactgtaat	ttatattgcc	cttggaaacac	1440
atgggtgccat	atttagctac	taaaaagctc	ttcacaaaat	tgtctgctgt	gtttgtccct	1500
gaggggagga	ggtagtggga	ccctgaggca	gaggccctgc	tagagctggc	aggttcccct	1560

23

ggggcagacc	agagcacctc	aggaaggggc	tgccacggca	gggaagggac	caggcagccc	1620
tgggagcccg	cattccacag	gggcccactg	cggagtcttc	ggacactcag	ggcacargcc	1680
tgtgggttcc	ctggaatfff	ctagcatgat	ccagtttctg	tgtccagttc	tccattctga	1740
gagtcaatca	gttcctgata	ggttgtcatt	gatttttttc	ttcgttgggt	ttaaccttct	1800
aaacatctcc	aggccacttt	cttagccttt	ttctaggtac	taaaaagagg	tcctaccac	1860
acctgcctca	cacttctcct	ttccaaggct	gcctgagttt	ggaggggctt	gggtgtgtgt	1920
gaacaagggc	cctgcattgt	ctaggcctgc	agttcccagg	cttgggttca	ctttcaccat	1980
gcattggcaa	aactagaaaa	gtaagcttgt	gacaaattgt	tct		2023

<210> 55

<211> 885

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (7)

<223> n equals a,t,g, or c

<400> 55

gggtcgnacc	cacgcgtccg	aattttacttt	gctactttta	tgattaattg	gcaatgatca	60
atgcacaacc	ttttactctc	atgtgttatt	ttcaattttc	cccttgtgtt	tattgtagca	120
agaactccct	accttccctc	cttattatct	atttgtaatt	tggaagcccc	agtatacctt	180
agaattgata	caggatggcc	tcatttatgt	atggcttgag	agtttttttt	aacagaaaaa	240
acattgattc	tctaaaaaat	aagagtttat	atcatagtgt	ctcaatatct	tcctatctac	300
aaggacaaaa	ttttttttca	gaagcaaaac	aactagcata	ctaactttct	gtttatgcag	360
tagtaaatat	tgggtgatta	ctgcacaatt	tccaggaawt	atgcagagat	aactacagag	420
atgagtagaa	taaaactcat	tttagagctt	caaactctag	tcagagatgt	agttacaaac	480
aaataatcca	gtgtagttag	ttaggtactc	tggcagaagt	gtaatgaaag	tagtatgaaa	540
aaacagagaa	agaaatcgaa	ggaacacatg	gacaaagtga	tattaaaaag	aatgaggccg	600
ggtgcagtg	ctcacgcctg	tgatcccagc	actttgggag	gacctgaggt	caggagtcca	660
agtccagctt	ggccaacatg	gtgaaagctc	atctttacta	aaaatacaaa	aattagccag	720
atgtgggtgg	aagtgcctgt	aaccccagct	actcctgagg	ctgaggggca	gcagaattgc	780
ttgaaccagg	gaggtggagg	ttgcagttag	ccgagattgc	gccactgcac	tccagcctgg	840
ctgacaagag	caaaacactg	tcaaaaaaaa	aaaaaaaggg	cggcc		885

<210> 56

<211> 1106

<212> DNA

<213> Homo sapiens

<400> 56

ggcacgagct	gagaggtgtg	ccctgacatg	ggtccagaaa	catgggtgac	ttgatattgc	60
ttctcttcca	cagtgcagtt	ggctgtaacc	tgaaaagttag	aggggccctt	cagacccttc	120
atgactctat	gactttgtcc	tctttctatt	cctcgaaaac	ttctctcatt	tgagccattc	180
ctgtcctggg	gagagatatg	caagtgtctg	cttctcctct	ttgtaccaag	tacggtggcc	240
ccatttgggt	taaagccatg	agcccctgcc	aagtctgacc	atccacgcct	acattttacc	300
caagctcctc	ctttgtggcc	aagaaccatc	actttcttgg	acccaccctt	ttctcttccc	360
ttccagctgc	attggtaggt	atcttttgga	gtctttgctt	tgggagtggc	tgcacttgcc	420
acagtgtgat	gtgggcacta	ggggccttgt	ggtcctgctg	ggcttctttt	ctcaccaagg	480
cttccctctt	gtcctccatc	taaggggggg	ttctgattca	cgctcctgcc	ttcaacaaaa	540
tgcaggagac	tcacagatct	ctcttgaaat	caaagccata	atgtccagac	tgccaccttt	600
gccagttttg	cttcagtgtg	atattaggga	aaagctagaa	cactggtttc	agagccacac	660
agaccaggtt	gtaatctctg	ctgtatttgt	tgtatgacct	ctgccaagtc	atttccctgc	720
ttgggttctt	catctgtgaa	acatgaaaaa	tattatttag	ctcataaatg	gttttgagtg	780
ctgggggttg	gtgtgaaatg	tttggcctcg	gccaggtgca	gtggcctgta	atcccagcac	840
tttgggaggg	cgaggcgggc	agatcacctg	aggttgggag	ttcgagacca	gcctgaccaa	900

SUBSTITUTE SHEET (RULE 26)

24

catggagaaa	cctgtctct	actaaaaatg	caaaattagt	cgggcgtggt	ggcacatgcc	960
cataatccca	ctactcggga	ggctggggca	ggacaatcgc	ttgaaccag	gaggtggagg	1020
ttgcagttag	ccaagatcac	gccattgcac	tccagcctgg	gcaacaagag	caaaactcta	1080
tcttaagaaa	aaaaaaaaaa	aaaaaa				1106

<210> 57

<211> 764

<212> DNA

<213> Homo sapiens

<400> 57

ggagctgcag	gatcttcaca	gttccccag	ccccttctctg	atgttcacac	atgtcacatg	60
ttctgcccac	ctcagatgga	tctggagcct	ttctggttct	gtttaatggc	agccctatctt	120
atctttttatt	gcctccttct	ctatttttttg	cacatattca	aagatggggg	gagtaggtta	180
ccctccactg	aatacaaaata	caaaagcttg	agtgtactgg	tgttctgcaa	gaagcatgac	240
tgttctttct	gaactgagct	tacttccctg	aacaccacgc	agggggcatc	tgcacctgaa	300
actgcagggc	attcttgga	tcccacgttt	ggattgacag	tgccaacctg	ggaggccagt	360
ccctttttcca	tcatcacctt	ttccttcttg	tcagatatgt	cataacccca	aacaggcccc	420
catgatttga	taaatgtcta	ataatgttca	tgccaggtat	ttggtgactt	aaaagtgttc	480
acgggctggg	cgcagtgtct	catgcctata	atcccagcac	tttgagaggc	tgagacgggt	540
ggatcatctg	aggccaggag	tatgagacca	gcctggccaa	caaggcaaaa	ccccatctct	600
actaaaaata	caaaaattag	ccgggcatgg	tggcgggcgc	ctgtaattca	gctactcggg	660
aggcagaggc	ggaggttgca	gtgagccgag	atagcgycgc	tgcactccag	cctgggcaac	720
agagagactc	tgcctaaaaa	aaaaaaaaaa	aaaaaagggc	ggcc		764

<210> 58

<211> 738

<212> DNA

<213> Homo sapiens

<400> 58

ggcacgaggt	aagaattaca	tcttgacgca	attagccttt	gccacaatgg	tgtattacaa	60
acaacttcaa	aattcagtg	ctgaaaaaaa	ttattttgtt	tctccagatg	tttgagtcag	120
ctgggcaggt	tttgcttcac	attgcaggtc	tgcaggctctg	ggtcttctctc	acatgtcttt	180
catccttttt	ggtcccattg	agttattcag	ggtacattcc	tctcatgggtg	atggcagagg	240
cacaccaaata	ggcaagccca	accacgcaag	cacttttcaa	actgcttttt	gcatcacatc	300
tgtaaacatt	ctattagcca	aagcaaaaaca	catagtccag	cccaaaatta	agaggctgag	360
aaggacattc	catcttttagt	tgcagaaaat	gcaaaactac	caggcataga	atgtagacac	420
aggaaataat	aaagagtcag	ataaaataat	tcaacctctc	agaccccata	aagatattga	480
ttgaaatgtg	tttgaaactg	agggaaggat	ttggggtttg	cagttattct	cagtggacca	540
gagaaagaag	agatttgaga	gttctctgag	cagcaggcta	tgagacagag	cacattaaac	600
agggagggct	cttgaaatca	atacctgtga	aaaggagtga	aagggaagcaa	aactgggcaa	660
agggaaaagt	tgagctttga	tgtggtctca	gcaaagggtt	caggcaactc	catgggaagt	720
gttggaactt	gtggccct					738

<210> 59

<211> 441

<212> DNA

<213> Homo sapiens

<400> 59

gggggcatgt	gatttttagt	atggacttaa	gagctccatg	gcttgggttc	aaattccact	60
tctgccgttc	actagctgtg	tgaccttggg	caagtacctt	aacctctctg	tgccacattt	120
ttctcatttg	cacaaggaga	ataatagttt	actacttcat	agggttgtga	tgagtctgac	180
aatgagtcac	tatgtgtaaa	atgtttttca	cagtgcctga	cacagaatgc	tatagtagat	240
caacatttgc	tgtaactatt	actatttgtt	attagtgcac	ttgctgtatt	ttgtttaatg	300

25

agaggaagtt	taataacact	aggattaaaa	cattccttct	ggcatgtct	tcctgacaag	360
taaaaaagtt	gctacttggt	ttccttgggt	aatcattgaa	aaaaaaaaa	caaaaaacaa	420
aaaaaaaaa	aaagggcggc	c				441

<210> 60
 <211> 784
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (56)
 <223> n equals a,t,g, or c

<400> 60	
gatttttagt	actgctatac
ttcttacaac	tctgttccca
ccccataact	taatatactt
ccccctttct	tagtaccctt
aaaaactttt	ggattggttg
cgacttctgg	gtgcaaatcc
aaactctgta	aaatgggcat
agccattcca	tattgagggc
acccattatt	attgtcattg
ttcttcttgt	gagagctata
tgatccaagc	caggtatggt
gtgggaagat	tgcttgagac
cattccagcc	tgatgacat
cgta	

<210> 61
 <211> 539
 <212> DNA
 <213> Homo sapiens

<400> 61	
gacctctac	atztatgagc
ctgcttagaa	cactcacagg
actcccctcc	tcttgcaagg
gaagggcggt	ttcatatgcc
tgaaaccggt	aggggaattc
tcttgccctg	atcctgaagc
ggaaattgaa	tatggactgg
ataatatttt	gtagttctgt
tttacgagtt	gctttgcttt

<210> 62
 <211> 604
 <212> DNA
 <213> Homo sapiens

<400> 62	
ggtttgggga	gtcgggtcga
gaggagagtt	aacttcatgt
caccccatgc	acttgccacc
aacaaatgaa	tgtttggttt

26

atagagtatc	atagcaagcc	tgcattcatc	tgtcacccag	ctccaaaaat	tataaaactca	300
tagctaattc	tgtttcactt	ttactcccac	ttctttccct	cccactcca	ctggatcatt	360
ttgaagcaaa	ttccaaatgt	cacgtcgttt	cattagcttc	tatttctaaa	taagggtgtc	420
cttaaacata	accagaatac	ccccttttga	aaaggaaggc	tgggtgaggt	gactcattcc	480
tctaattcca	gcacttttag	aagccaaggt	caggatgata	gcttgaggcc	aggagttcaa	540
ggccagactg	agcagcatag	tgagatccag	tcttaaaaaa	aaaaaaaaaa	aaaaaagggc	600
ggcc						604

<210> 63

<211> 752

<212> DNA

<213> Homo sapiens

<400> 63

attgaaggat	gatgttaatt	ttgtattata	gtgttatata	tgtaactacc	tgccctaaa	60
tataacactg	tatgtatcat	ttcaacatac	ttgccagctc	tactgattat	gaatattaat	120
cacagataag	gaaattgtaa	aatatccttt	tctcaaaagg	cagacacatt	tatagccctg	180
tgatcctgac	tgacacagta	tgaagagctt	tcctagtaca	tatttcaaaa	gttctagctt	240
ccagaatacc	aaataaccaga	ctgggtgttat	aagtgttctg	atttcttatg	aaatagagta	300
tgctgctttc	tatcatttgt	cttgtaagat	cactcttcca	tcactctgtg	gcagraattg	360
tttcattttc	gaayccttag	tggcctcaca	gtgcctggac	acataaagg	actcaatgtt	420
tgctgaagga	aaaataagtt	acagtattag	ccagggtgtg	tggctcacac	tgtaatccca	480
gcatttgagg	ggccraggcg	ggcggatcac	gagktcagga	gattgagacc	atcctggcta	540
atgcggtgaa	accccgcttc	tactgaagat	acaaaaaaat	tagcctggcg	tgggtggcgg	600
tgctgtagt	cccagctact	tgggaggctg	aagcgggaga	atggcatgaa	cccaggaggc	660
agagcttgca	gtgagtcgag	attacgccgc	tgcaatccag	cctgggcgac	agagtgaaga	720
ctctgtctca	aaaaaaaaaa	aaaaaaactc	ga			752

<210> 64

<211> 769

<212> DNA

<213> Homo sapiens

<400> 64

gcacgagaat	ttttgtactg	ctataactcag	ttgcctgtct	gtagtaccoc	tgtacgtatc	60
ttttcttaca	actctgttcc	cagtaccocct	atgttttagtc	ccttgttctc	atgttctcac	120
tacccaata	cttaaaaactt	gttctcagta	tccttgttgt	tagtaccctg	ttctcactcc	180
ccttttctta	gtacccttga	ggggggaaaa	aagggtataa	tggggtataa	gtccaaaaac	240
ttttggattg	tttgatttga	actgagtcaa	agtaaaccag	tggtctggag	ttcgacttcg	300
ggtgcaaadc	cctgttgcat	catttactgg	ccttggtggc	gaatagggtta	ttaaactctg	360
taaaatgggc	attaaaacgt	gtgtcattca	tagtggttgc	gtgaatatgt	gagccattcc	420
atattgaggg	ttcacacagt	gtccagcaac	tggctaaagt	ttgcaaacct	taccatttat	480
tattgtcatt	gttagtggtg	tactttgagg	ctgtcacaaa	taagcagata	tttcttcttg	540
tgagagctat	ataatccctt	agtgtagaga	aaaatttaat	tttgttacaa	gtgatccaag	600
ccaggatagg	tggcaagtgc	ctgtataccc	agctgtactt	gggagggtga	agtgggaaga	660
ttgcttgaga	ccagggtgtc	gaggctgccg	tgagccttgt	ttgcatcact	gcattccagc	720
ctggatgaca	tagcaagacc	ctgtctcctt	aaaaaaaaaa	aaaaaaaaaa		769

<210> 65

<211> 74

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (74)

SUBSTITUTE SHEET (RULE 26)

27

<223> Xaa equals stop translation

<400> 65

Met	Ser	Ser	Cys	Phe	Gln	Leu	Leu	Leu	Thr	Tyr	Arg	Ala	Trp	Phe	Ser
1				5					10					15	

Thr	Ser	Ser	Leu	Ala	Glu	Gln	Met	Cys	Arg	Thr	Gly	Leu	Lys	Ser	Arg
			20					25					30		

His	Ser	Pro	Thr	Ser	Glu	Gln	Thr	Glu	Arg	Cys	Ala	Arg	Ser	Trp	Cys
		35					40					45			

Leu	Val	His	His	Cys	Phe	Pro	Ser	Gln	Thr	Phe	Leu	Phe	His	Ala	Cys
	50						55				60				

Leu	Thr	Asp	Lys	Pro	Leu	Ala	Arg	Pro	Xaa
65					70				

<210> 66

<211> 60

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (15)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (60)

<223> Xaa equals stop translation

<400> 66

Met	Asn	Cys	Asp	Val	Leu	Trp	Cys	Val	Leu	Leu	Val	Cys	Xaa	Ser
1				5					10				15	

Leu	Phe	Ser	Ala	Val	Gly	His	Gly	Leu	Trp	Ile	Trp	Arg	Tyr	Gln	Glu
			20					25					30		

Lys	Lys	Ser	Leu	Phe	Tyr	Val	Pro	Lys	Ser	Asp	Gly	Ser	Ser	Leu	Ser
		35					40					45			

Pro	Val	Thr	Ala	Ala	Val	Asn	Ser	Phe	Leu	Thr	Xaa
	50					55					60

<210> 67

<211> 135

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (135)

<223> Xaa equals stop translation

<400> 67

28

Met	Ser	Tyr	Lys	Pro	Ala	Leu	Phe	Gly	Phe	Leu	Phe	Leu	Leu	Leu	Leu	
1				5					10					15		
Leu	Ser	Asn	Trp	Leu	Val	Lys	Tyr	Glu	His	Lys	Leu	Thr	Leu	Pro	Glu	
		20						25					30			
Pro	Gln	Gln	Glu	Glu	Glu	Lys	Pro	Lys	Thr	Ser	Glu	Asn	Asp	Ser	Lys	
		35					40					45				
Asn	Ser	Lys	Ala	Val	Asn	Thr	Lys	Glu	Val	Asn	Arg	Thr	His	Ala	Cys	
	50					55					60					
Phe	Ala	Leu	Gln	Asp	Glu	Ile	Leu	Gln	Arg	Leu	Leu	Phe	Ser	Glu	Met	
65					70					75					80	
Lys	Met	Lys	Val	Leu	Glu	Asn	Gln	Met	Phe	Ile	Ile	Trp	Asn	Lys	Met	
			85						90					95		
Asn	His	His	Gly	Arg	Ser	Ser	Arg	His	Arg	Asn	Phe	Pro	Met	Lys	Lys	
			100					105					110			
His	Arg	Met	Arg	Arg	His	Glu	Ser	Ile	Cys	Pro	Thr	Leu	Ser	Asp	Cys	
		115					120					125				
Thr	Ser	Ser	Ser	Pro	Ser	Xaa										
	130					135										

<210> 68

<211> 36

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (36)

<223> Xaa equals stop translation

<400> 68

Met	Gly	Gly	Gln	Met	Met	Asn	Gln	Leu	Ile	Thr	Val	Ala	Phe	Val	Arg	
1				5					10					15		
Trp	Arg	Phe	Leu	Ile	Cys	Phe	Leu	Ser	Leu	Met	Lys	Ala	Ile	Leu	Lys	
			20					25					30			
Lys	Pro	Thr	Xaa													
			35													

<210> 69

<211> 126

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (126)

<223> Xaa equals stop translation

29

<400> 69

Met Arg Trp Ile Leu Ile Leu Val Ile Ala Leu Trp Phe Ile Glu Leu
 1 5 10 15

Leu Asp Val Trp Ser Thr Cys Ser Gln Pro Ile Cys Ala Lys Trp Thr
 20 25 30

Arg Thr Glu Ala Glu Gly Ser Lys Lys Ser Leu Ser Ser Glu Gly His
 35 40 45

His Met Asp Leu Pro Asp Val Val Ile Thr Ser Leu Pro Gly Ser Gly
 50 55 60

Ala Glu Ile Leu Lys Gln Leu Phe Phe Asn Ser Ser Asp Phe Leu Tyr
 65 70 75 80

Ile Arg Val Pro Thr Ala Tyr Ile Asp Ile Pro Glu Thr Glu Leu Glu
 85 90 95

Ile Asp Ser Phe Val Asp Ala Cys Glu Trp Lys Cys Gln Ile Ser Ala
 100 105 110

Val Gly Ile Phe Val Tyr Ser Glu Ala Gly Cys Ser Leu Xaa
 115 120 125

<210> 70

<211> 52

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (52)

<223> Xaa equals stop translation

<400> 70

Met Leu Ser Thr Ile Leu Ser Phe Val Cys Asn Cys Ala Cys Arg Leu
 1 5 10 15

Asn Arg Ile Leu Ile Val Leu Ile Thr Cys Leu Ile Leu Val Ser Pro
 20 25 30

Val Arg Gln Ala Cys Phe Leu Glu Ala Gly Thr Glu Cys His Ser His
 35 40 45

Leu Cys Ser Xaa
 50

<210> 71

<211> 98

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (98)

<223> Xaa equals stop translation

SUBSTITUTE SHEET (RULE 26)

30

<400> 71

```

Met Ser Ile Met Leu Leu Thr Phe Thr Leu His Phe Pro Ser Thr Leu
 1             5             10             15

Leu Ser Tyr Leu Pro Glu Asn Tyr Val Ile Pro Ser Leu Phe Ser Asn
      20             25             30

Leu Gln His Trp Ile Cys Cys Val His Ser Gln Leu Val Thr Cys Phe
      35             40             45

Val Phe Gln Arg Asp Asn Val Ser Thr Glu Lys Arg Thr Leu Ala His
      50             55             60

Ser Asn Thr Ser Ser Ala Thr Ser His His Leu Ser Pro Cys Thr Thr
      65             70             75             80

Gly Asp Gly Leu Pro Ser Ser Trp Gly Gly Gln Thr His Pro Leu Leu
      85             90             95

```

His Xaa

<210> 72

<211> 45

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (45)

<223> Xaa equals stop translation

<400> 72

```

Met His Leu Leu Leu Ile Asn Phe Leu Pro Ala Val Cys Ile Ile Leu
 1             5             10             15

Leu Lys Asn Leu Gln Gln Ala Leu Cys Phe Ala Gln Leu Phe Ile Met
      20             25             30

Ser Ile Asn Gln Gly Leu Gly Pro Asn Glu Met Ser Xaa
      35             40             45

```

<210> 73

<211> 48

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (48)

<223> Xaa equals stop translation

<400> 73

```

Met Ala Phe Arg Val Leu Tyr Tyr Ser Val Trp Phe Ile Phe Leu His
 1             5             10             15

```

SUBSTITUTE SHEET (RULE 26)

31

Val	Ser	Phe	Ala	Thr	Pro	Lys	Val	Thr	Gly	Leu	Ile	Ala	Ser	Thr	Tyr
			20						25					30	

His	Phe	Leu	Tyr	Val	Phe	Met	Phe	Leu	Leu	Met	Ile	Leu	Ser	Ala	Xaa
		35						40					45		

<210> 74
 <211> 27
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (27)
 <223> Xaa equals stop translation

<400> 74

Met	Val	Phe	Ile	Leu	Glu	Gln	Ile	Lys	Asn	Gln	Val	Phe	Phe	Leu	Phe
1				5					10					15	

Leu	Leu	Leu	Lys	Leu	Thr	Cys	Val	Ser	His	Xaa
			20						25	

<210> 75
 <211> 42
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (40)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (42)
 <223> Xaa equals stop translation

<400> 75

Met	Gln	Leu	Ile	Gln	Leu	Ile	Thr	Leu	Thr	Ile	Thr	Gln	Val	Leu	Phe
1				5					10					15	

Leu	Asp	Thr	Ile	Met	Ser	Thr	Tyr	Val	Ala	Asp	Thr	Asp	Tyr	Val	Val
			20						25					30	

Leu	Pro	Val	Ser	Ser	His	Lys	Xaa	Phe	Xaa
		35					40		

<210> 76
 <211> 23
 <212> PRT
 <213> Homo sapiens

32

<220>

<221> SITE

<222> (23)

<223> Xaa equals stop translation

<400> 76

Met	Thr	Leu	Met	Thr	Ser	Ile	Tyr	Phe	Phe	Leu	Ala	Ile	Phe	Met	Ser
1				5					10					15	

Thr	Arg	Ser	Glu	Arg	Leu	Xaa
			20			

<210> 77

<211> 59

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (59)

<223> Xaa equals stop translation

<400> 77

Met	Ser	Leu	Leu	Phe	Ile	Val	Ser	Leu	Leu	Glu	Leu	Gly	Pro	Met	Ala
1				5					10					15	

Leu	Leu	Ala	Glu	Arg	Lys	Ala	Met	Lys	Pro	Ser	Leu	Gly	Leu	Arg	Leu
			20					25					30		

Glu	Glu	Glu	Glu	Glu	Glu	Thr	Pro	Phe	Glu	Glu	Gln	Arg	Ala	Val	Ser
		35					40					45			

Val	Ile	Pro	Gly	Val	Pro	Val	Thr	Tyr	Leu	Xaa
	50					55				

<210> 78

<211> 48

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (48)

<223> Xaa equals stop translation

<400> 78

Met	Asn	Phe	Val	Ala	Ala	Leu	Ile	Phe	Ser	Pro	Asp	Gln	Tyr	Asn	Phe
1				5					10					15	

Ile	Leu	Arg	Ile	Arg	Leu	Phe	Trp	Phe	Leu	Ile	Ile	Cys	Val	Leu	Ser
			20					25					30		

Gly	Ile	Leu	Leu	Leu	Phe	Pro	Ser	Arg	Thr	Phe	Ser	Leu	His	Pro	Xaa
		35					40					45			

<210> 79
 <211> 53
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (53)
 <223> Xaa equals stop translation

<400> 79
 Met Ser Phe Leu Val Phe Ser Phe Phe Cys Phe Gly Phe Ser Asn Ser
 1 5 10 15
 Arg Phe Ser Arg Asp Tyr Gln His Tyr Leu Ser Leu Leu Ser Ser Pro
 20 25 30
 His Ala Gln Lys Arg Asn Lys Ile Ile Arg Glu Ser Ser Ile Ser Ala
 35 40 45
 Leu Leu Thr Ser Xaa
 50

<210> 80
 <211> 45
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (45)
 <223> Xaa equals stop translation

<400> 80
 Met Gln Ile Pro Phe Leu Leu Glu Val Phe Val Ile His Thr Gly Val
 1 5 10 15
 Leu Gly Ser Lys Leu Leu Lys Ser Gly Gly Leu Phe Asp Leu Thr Ser
 20 25 30
 Phe Ser Pro Met Ile Ile Cys Phe Ser Asn Lys Ser Xaa
 35 40 45

<210> 81
 <211> 61
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (59)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE

34

<222> (61)

<223> Xaa equals stop translation

<400> 81

Met	Val	Ser	Phe	Ala	Cys	Phe	Cys	Phe	His	Cys	Leu	Phe	Leu	Val	Ser
1				5					10					15	

Tyr	Pro	Arg	Asn	His	Cys	Gln	Ile	Gln	Cys	Arg	Asp	Ala	Phe	Ser	Arg
			20					25					30		

Ser	Phe	Leu	Leu	Gly	Val	Phe	Gln	Val	Leu	Tyr	Leu	Gly	Phe	Ile	Asn
		35					40					45			

Tyr	Ile	Thr	Phe	Tyr	Val	Glu	Glu	Lys	Thr	Xaa	Glu	Xaa
	50					55					60	

<210> 82

<211> 25

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (25)

<223> Xaa equals stop translation

<400> 82

Met	Val	Phe	Leu	Trp	Ile	Ser	Tyr	Ala	Val	Lys	Ala	Phe	Leu	Val	Trp
1				5					10					15	

Thr	Leu	Gln	Leu	Ala	Ala	Glu	Phe	Xaa
		20				25		

<210> 83

<211> 21

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (21)

<223> Xaa equals stop translation

<400> 83

Met	Phe	Ile	Val	Ala	Leu	Leu	Ile	Leu	His	Trp	Ala	Leu	Gly	Gly	Thr
1				5					10					15	

Val	Met	Ser	Lys	Xaa
			20	

<210> 84

<211> 42

<212> PRT

<213> Homo sapiens

<220>

SUBSTITUTE SHEET (RULE 26)

35

<221> SITE

<222> (42)

<223> Xaa equals stop translation

<400> 84

Met	Cys	Val	Cys	Leu	Ile	Cys	Ser	Ile	Cys	Gln	Phe	Leu	Trp	Cys	Lys
1				5					10					15	

Tyr	Ser	His	Tyr	Ser	Cys	Phe	Gln	Ala	Asn	Ile	Val	Ile	Pro	Gln	Lys
			20					25					30		

Met	Glu	Leu	Gly	Arg	His	Asn	Gln	Asp	Xaa
		35					40		

<210> 85

<211> 48

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (48)

<223> Xaa equals stop translation

<400> 85

Met	Thr	Phe	Gly	Leu	Gly	Gln	Gly	Leu	Cys	Phe	Leu	Phe	Cys	Tyr	Gln
1				5					10					15	

Val	Leu	Val	Ala	Phe	Arg	Leu	Thr	Asn	Gln	Ile	Pro	Ala	Leu	Gly	Tyr
			20					25					30		

Ile	Ser	His	Leu	Ser	Ser	His	Ile	Pro	Tyr	Leu	Ala	Leu	Phe	Gly	Xaa
		35					40					45			

<210> 86

<211> 44

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (44)

<223> Xaa equals stop translation

<400> 86

Met	Cys	Leu	Ala	Ile	Leu	Leu	Phe	Leu	Ile	Leu	Ser	Val	Leu	Asp	Glu
1				5					10					15	

Asn	Val	Tyr	Phe	Thr	Glu	Leu	Cys	Gln	Arg	Val	Ser	Thr	Phe	Phe	Cys
			20					25					30		

Leu	Ile	Ile	Gly	Glu	Lys	Gly	Leu	Ser	Tyr	Phe	Xaa
			35				40				

SUBSTITUTE SHEET (RULE 26)

<210> 87
 <211> 60
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (54)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (60)
 <223> Xaa equals stop translation

<400> 87
 Met Trp Thr Ala Arg Arg Cys Thr Glu Thr Val Ala Val Ser Leu Arg
 1 5 10 15
 Ile Phe Pro Leu Val Leu Ala Met Pro Leu Gln Gly Lys Cys Thr Ser
 20 25 30
 Thr Cys Gln Arg Lys Pro Leu Leu Leu Val Phe Ile Phe Val Val Asn
 35 40 45
 Phe Leu Tyr Ile Pro Xaa Ala Ala Phe Leu His Xaa
 50 55 60

<210> 88
 <211> 52
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (52)
 <223> Xaa equals stop translation

<400> 88
 Met Leu Thr Ser Trp Ile Ala Ser Ile Pro Ser Arg Cys Gly Val Leu
 1 5 10 15
 Cys Ile Cys Leu Cys Phe Gly Leu Val His Cys Leu Asp Leu Ser Arg
 20 25 30
 Lys Ile Thr Ile Phe Ser Gly Ala Val Tyr Met Val Lys Asn Ile Gln
 35 40 45
 Phe Trp Leu Xaa
 50

<210> 89
 <211> 32
 <212> PRT
 <213> Homo sapiens

37

<220>

<221> SITE

<222> (32)

<223> Xaa equals stop translation

<400> 89

Met Val Ser Leu Ile Ala Phe Ser Ser Leu Gly Leu Cys Leu Gly Glu
 1 5 10 15

Ser Pro Ser Lys Ile Pro Phe Thr Ala Phe Phe His Arg Glu Gly Xaa
 20 25 30

<210> 90

<211> 36

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (36)

<223> Xaa equals stop translation

<400> 90

Met Cys Leu Ser Leu Leu Leu Leu Ser Leu Ser Cys Leu Ala Val Pro
 1 5 10 15

Trp Trp Pro His Ser Val Thr Ala Leu Gln Leu Ser Pro Glu Ser Asp
 20 25 30

His His Ser Xaa
 35

<210> 91

<211> 49

<212> PRT

<213> Homo sapiens

<400> 91

Met Ser Phe Gln Ser Ile Lys Asn Leu Leu Thr Cys Arg Ala Arg Trp
 1 5 10 15

Leu Thr Pro Val Ile Pro Ala Leu Trp Gly Ala Arg Ala Gly Gly Ser
 20 25 30

Ser Glu Glu Phe Glu Thr Ser Leu Thr Asn Met Val Lys Pro His Leu
 35 40 45

Tyr

<210> 92

<211> 25

<212> PRT

38

<213> Homo sapiens

<220>

<221> SITE

<222> (25)

<223> Xaa equals stop translation

<400> 92

Met	His	Thr	Cys	Val	Tyr	Cys	Ser	Ile	Ile	His	Asn	Ser	Lys	Asp	Leu
1				5					10					15	

Gly	Thr	Asn	Pro	Asn	Val	Gln	Gln	Xaa
		20					25	

<210> 93

<211> 47

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (47)

<223> Xaa equals stop translation

<400> 93

Met	Ser	Tyr	Phe	Ser	Leu	Thr	Tyr	Thr	Tyr	Thr	Val	Val	Tyr	Ile	Leu
1				5					10					15	

Lys	Ser	Leu	Cys	Ile	Ser	Ser	Leu	His	Asn	Ile	Tyr	Leu	Leu	Ile	Phe
			20					25					30		

Ile	Phe	Leu	Phe	Ser	Ser	Val	His	Thr	Thr	Glu	Tyr	Val	Leu	Xaa
		35					40					45		

<210> 94

<211> 87

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (87)

<223> Xaa equals stop translation

<400> 94

Met	Pro	Trp	His	Val	Cys	Phe	Phe	Leu	Ser	Gly	Leu	Leu	Phe	Pro	Ser
1				5					10					15	

Pro	Gln	Thr	Ser	Leu	Gln	His	Leu	Cys	Leu	Leu	Thr	Ser	Leu	Ile	Leu
			20					25					30		

Gly	Val	Thr	Ile	Ser	Ala	Tyr	Glu	His	Ala	Ile	Asn	Leu	Pro	Ser	Leu
		35						40				45			

Gln	Asn	Ser	Leu	Leu	Thr	Ser	His	Pro	Ser	Val	Ala	Ala	Leu	Ser	Leu
	50						55					60			

39

Leu Ser Ser Ser Leu Gln Gln Asn Ser Leu Lys Glu Leu Leu Ala Gly
 65 70 75 80

His Ser Gly Ser Leu Leu Xaa
 85

<210> 95

<211> 112

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (112)

<223> Xaa equals stop translation

<400> 95

Met Lys Ser Leu Leu Phe Thr Leu Ala Val Phe Met Leu Leu Ala Gln
 1 5 10 15

Leu Val Ser Gly Asn Trp Tyr Val Lys Lys Cys Leu Asn Asp Val Gly
 20 25 30

Ile Cys Lys Lys Lys Cys Lys Pro Glu Glu Met His Val Lys Asn Gly
 35 40 45

Trp Ala Met Cys Gly Lys Gln Arg Asp Cys Cys Val Pro Ala Asp Arg
 50 55 60

Arg Ala Asn Tyr Pro Val Phe Cys Val Gln Thr Lys Thr Thr Arg Ile
 65 70 75 80

Ser Thr Val Thr Ala Thr Thr Ala Thr Thr Thr Leu Met Met Thr Thr
 85 90 95

Ala Ser Met Ser Ser Met Ala Pro Thr Pro Val Ser Pro Thr Gly Xaa
 100 105 110

<210> 96

<211> 301

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (301)

<223> Xaa equals stop translation

<400> 96

Met Lys Phe Leu Leu Asp Ile Leu Leu Leu Leu Pro Leu Leu Ile Val
 1 5 10 15

Cys Ser Leu Glu Ser Phe Val Lys Leu Phe Ile Pro Lys Arg Arg Lys
 20 25 30

SUBSTITUTE SHEET (RULE 26)

Ser Val Thr Gly Glu Ile Val Leu Ile Thr Gly Ala Gly His Gly Ile
 35 40 45
 Gly Arg Leu Thr Ala Tyr Glu Phe Ala Lys Leu Lys Ser Lys Leu Val
 50 55 60
 Leu Trp Asp Ile Asn Lys His Gly Leu Glu Glu Thr Ala Ala Lys Cys
 65 70 75 80
 Lys Gly Leu Gly Ala Lys Val His Thr Phe Val Val Asp Cys Ser Asn
 85 90 95
 Arg Glu Asp Ile Tyr Ser Ser Ala Lys Lys Val Lys Ala Glu Ile Gly
 100 105 110
 Asp Val Ser Ile Leu Val Asn Asn Ala Gly Val Val Tyr Thr Ser Asp
 115 120 125
 Leu Phe Ala Thr Gln Asp Pro Gln Ile Glu Lys Thr Phe Glu Val Asn
 130 135 140
 Val Leu Ala His Phe Trp Thr Thr Lys Ala Phe Leu Pro Ala Met Thr
 145 150 155 160
 Lys Asn Asn His Gly His Ile Val Thr Val Ala Ser Ala Ala Gly His
 165 170 175
 Val Ser Val Pro Phe Leu Leu Ala Tyr Cys Ser Ser Lys Phe Ala Ala
 180 185 190
 Val Gly Phe His Lys Thr Leu Thr Asp Glu Leu Ala Ala Leu Gln Ile
 195 200 205
 Thr Gly Val Lys Thr Thr Cys Leu Cys Pro Asn Phe Val Asn Thr Gly
 210 215 220
 Phe Ile Lys Asn Pro Ser Thr Ser Leu Gly Pro Thr Leu Glu Pro Glu
 225 230 235 240
 Glu Val Val Asn Arg Leu Met His Gly Ile Leu Thr Glu Gln Lys Met
 245 250 255
 Ile Phe Ile Pro Ser Ser Ile Ala Phe Leu Thr Thr Leu Glu Arg Ile
 260 265 270
 Leu Pro Glu Arg Phe Leu Ala Val Leu Lys Arg Lys Ile Ser Val Lys
 275 280 285
 Phe Asp Ala Val Ile Gly Tyr Lys Met Lys Ala Gln Xaa
 290 295 300

<210> 97

<211> 105

<212> PRT

<213> Homo sapiens

<220>

41

<221> SITE

<222> (105)

<223> Xaa equals stop translation

<400> 97

Met	Trp	Tyr	Cys	Leu	Leu	Cys	Gly	Cys	Ser	Cys	His	Ala	Lys	Ala	Val
1				5					10					15	

Pro	Ser	Val	Leu	Ser	Arg	Leu	Ser	Cys	Asn	Leu	Pro	Ala	Leu	Leu	Ser
			20					25					30		

His	Ala	Leu	Pro	Gln	Pro	Ser	Pro	Ser	Val	Gly	Ala	Pro	Pro	Gly	Ser
	35						40					45			

Pro	Arg	Pro	Val	Pro	Pro	His	Pro	Leu	Ser	Asp	Pro	His	Ser	Cys	Leu
	50					55					60				

Pro	Thr	Pro	Ala	Phe	Arg	Gly	Leu	Cys	Ser	Pro	Pro	Leu	Cys	Pro	Leu
65					70					75					80

Leu	Pro	Pro	Arg	Phe	Ser	Leu	Lys	Leu	Pro	Pro	Leu	Ser	Leu	Asp	Pro
				85					90					95	

Gln	Leu	Ile	Pro	Pro	Ala	Thr	Tyr	Xaa
		100						105

<210> 98

<211> 44

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (44)

<223> Xaa equals stop translation

<400> 98

Met	Cys	Met	Phe	Ser	Thr	Cys	Gly	Leu	Ser	Asn	Tyr	Leu	Ile	Ile	Thr
1				5						10				15	

Thr	Phe	Leu	Leu	Leu	Ser	Ile	Ser	Ser	Leu	Val	Pro	Pro	Thr	Pro	Ser
			20					25					30		

Lys	Leu	Phe	Asp	Ser	Ser	Ser	His	Trp	Lys	Tyr	Xaa
		35					40				

<210> 99

<211> 50

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (50)

<223> Xaa equals stop translation

<400> 99

42

Met	His	Leu	Leu	Leu	Leu	Ser	Cys	Leu	Leu	Ala	Gly	Lys	Ala	Ser	Cys
1				5					10					15	
His	Val	Val	Arg	Ser	Pro	Val	Asp	Asn	Pro	Leu	Trp	Gln	Gly	Gly	Asn
			20					25					30		
Ala	Tyr	Gly	Gln	Gln	Pro	Val	Arg	Thr	Gly	Pro	Cys	Gln	Gln	Pro	His
		35					40					45			
Lys	Xaa														
	50														

<210> 100
 <211> 48
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (48)
 <223> Xaa equals stop translation

<400> 100

Met	Thr	Leu	Tyr	Leu	Ser	Leu	Leu	Asn	Met	Ile	Pro	Leu	Asn	Leu	Ala
1				5					10					15	
Ser	Cys	Ser	Ser	His	Leu	Glu	Leu	Leu	Lys	Lys	Leu	Ile	Met	Ser	Tyr
			20					25					30		
Arg	Val	Phe	Thr	Phe	Pro	Ile	Pro	Asp	Thr	Cys	His	Leu	His	Ile	Xaa
		35					40					45			

<210> 101
 <211> 100
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (100)
 <223> Xaa equals stop translation

<400> 101

Met	Tyr	Phe	Leu	Leu	Thr	Cys	Arg	Phe	Ser	Leu	His	Leu	Leu	Pro	Cys
1				5					10					15	
Pro	Leu	Phe	Leu	Cys	Phe	Leu	Pro	Pro	Cys	Ser	Leu	Phe	Val	Glu	Glu
			20					25					30		
Thr	Ser	Tyr	Leu	Cys	Phe	Val	Ser	His	Gly	Met	Asn	Phe	Ala	Glu	Cys
		35					40					45			
Ile	Phe	Thr	Cys	Ser	Leu	Met	Cys	Cys	Leu	Val	Leu	His	Ile	Ser	Cys
	50					55					60				

43

Lys Leu Thr Val Glu Ser Thr Ser Leu Ile Thr Phe Thr Phe Phe Leu
 65 70 75 80

Gly Trp Trp Gly Trp Arg Tyr Thr Gln Leu Phe Pro Phe His Asp Val
 85 90 95

Ser Ser Arg Xaa
 100

<210> 102
 <211> 59
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (59)
 <223> Xaa equals stop translation

<400> 102
 Met His His Ile Cys Gly Ser Ile Val Leu Leu Leu Cys Leu Phe Asp
 1 5 10 15

Leu Cys Met Ala Ala Val Gly Gln Leu His Ile Trp Ser Pro Tyr Ser
 20 25 30

Lys Met Gln Ser Thr Leu Leu Thr Ala His Ile Pro Ser Pro Lys Gln
 35 40 45

Asn Leu Asn Phe Gln Leu Cys Pro Leu Lys Xaa
 50 55

<210> 103
 <211> 65
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (65)
 <223> Xaa equals stop translation

<400> 103
 Met Leu Gly Ser Val Cys Arg Ala Leu His Val Leu Thr Cys Leu Leu
 1 5 10 15

Leu Ser Ser Asn Pro Val Val Gln Ala Pro Cys Ser Leu Asn Glu Glu
 20 25 30

Ser Lys Ser Gln Gly Val Thr Cys Ala Val Leu Pro Ala Gly Asp Leu
 35 40 45

Asn Pro Gly Ser Leu Val Ser Ala Cys Val Pro Leu Thr Val Thr Leu
 50 55 60

Xaa

SUBSTITUTE SHEET (RULE 26)

65

<210> 104

<211> 45

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (45)

<223> Xaa equals stop translation

<400> 104

Met	Pro	Cys	His	Gly	Leu	Leu	Ala	Gln	Gly	Leu	Ser	Leu	Ala	Pro	Leu
1				5					10					15	

Pro	Pro	Trp	Ala	Leu	Cys	Cys	Val	Gly	Val	Ser	Arg	Ala	Leu	Gln	Asp
			20					25					30		

Ile	Gln	Gln	His	Pro	Arg	Pro	Pro	Ala	Pro	Cys	Gln	Xaa
	35						40					45

<210> 105

<211> 93

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (61)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (68)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (93)

<223> Xaa equals stop translation

<400> 105

Met	Gly	Ser	Thr	Trp	Gly	Ser	Pro	Gly	Trp	Val	Arg	Leu	Ala	Leu	Cys
1				5					10					15	

Leu	Thr	Gly	Leu	Val	Leu	Ser	Leu	Tyr	Ala	Leu	His	Val	Lys	Ala	Ala
		20						25					30		

Arg	Ala	Arg	Asp	Arg	Asp	Tyr	Arg	Ala	Leu	Cys	Asp	Val	Gly	Thr	Ala
		35					40					45			

Ile	Ser	Cys	Ser	Arg	Val	Phe	Ser	Ser	Arg	Leu	Pro	Xaa	Asp	Thr	Leu
	50					55					60				

Gly	Leu	Cys	Xaa	Asp	Ala	Ala	Glu	Leu	Pro	Gly	Val	Ser	Arg	Trp	Phe
65					70					75				80	

45

Cys Leu Pro Gly Leu Asp Pro Val Leu Arg Ala Leu Xaa
 85 90

<210> 106
 <211> 26
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (26)
 <223> Xaa equals stop translation

<400> 106
 Met Gln Thr Ile His Phe Thr Pro Ala Val Leu His Phe Leu Phe Leu
 1 5 10 15

Trp Ser Ser Thr Trp Ser Val Ser Ile Xaa
 20 25

<210> 107
 <211> 68
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (68)
 <223> Xaa equals stop translation

<400> 107
 Met Cys Ile Leu His Ser His Cys Leu Leu Phe Leu Asn Leu Asn Gln
 1 5 10 15

Val Val Cys Phe His Gly Asn Phe Ser Leu Ser Cys Phe Cys Gln Thr
 20 25 30

Gln Ile Ser Tyr Ile Asn Ile Phe Ser Gly Lys Asn Gly Cys Asp Ser
 35 40 45

Lys Leu Glu His Leu Leu Phe Tyr Phe Arg Lys Ser Leu Leu Asn Ile
 50 55 60

Phe Leu Val Xaa
 65

<210> 108
 <211> 45
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (45)
 <223> Xaa equals stop translation

SUBSTITUTE SHEET (RULE 26)

<400> 108

Met Ser Thr Gly Ser Leu Met Thr Trp Trp Leu Arg Ser Ser Ser Leu
 1 5 10 15

Arg Val Ala Leu Cys Gly Pro Ala Arg Thr Met Thr Glu Met Cys Ser
 20 25 30

Gln Thr Ser Trp Pro Arg Ala Leu Ala Pro Leu Ala Xaa
 35 40 45

<210> 109

<211> 53

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (53)

<223> Xaa equals stop translation

<400> 109

Met His Asn Leu Leu Leu Ser Cys Val Ile Phe Asn Phe Pro Leu Val
 1 5 10 15

Phe Ile Val Ala Arg Thr Pro Tyr Leu Pro Ser Leu Leu Ser Ile Cys
 20 25 30

Asn Leu Glu Ala Pro Val Tyr Leu Arg Ile Asp Pro Gly Trp Pro His
 35 40 45

Leu Cys Met Ala Xaa
 50

<210> 110

<211> 44

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (44)

<223> Xaa equals stop translation

<400> 110

Met Val Asp Leu Ile Leu Leu Leu Phe His Ser Ala Val Gly Cys Asn
 1 5 10 15

Leu Lys Ser Arg Gly Ala Leu Gln Thr Leu His Asp Ser Met Thr Leu
 20 25 30

Ser Ser Phe Tyr Ser Ser Lys Thr Ser Leu Ile Xaa
 35 40

<210> 111

<211> 65

47

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (65)

<223> Xaa equals stop translation

<400> 111

Met	Phe	Cys	Pro	Ser	Gln	Met	Asp	Leu	Glu	Pro	Phe	Trp	Phe	Cys	Leu
1				5					10					15	

Met	Ala	Ala	Leu	Phe	Ile	Phe	Tyr	Cys	Leu	Leu	Leu	Tyr	Phe	Leu	His
			20					25					30		

Ile	Phe	Lys	Asp	Gly	Val	Ser	Arg	Leu	Pro	Ser	Thr	Glu	Tyr	Lys	Tyr
		35					40					45			

Lys	Ser	Leu	Ser	Val	Leu	Val	Phe	Cys	Lys	Lys	His	Asp	Cys	Ser	Phe
	50					55					60				

Xaa

65

<210> 112

<211> 70

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (70)

<223> Xaa equals stop translation

<400> 112

Met	Phe	Glu	Ser	Ala	Gly	Gln	Val	Leu	Leu	His	Ile	Ala	Gly	Leu	Gln
1				5					10					15	

Val	Trp	Val	Phe	Leu	Thr	Cys	Leu	Ser	Ser	Phe	Leu	Val	Pro	Leu	Ser
			20					25					30		

Tyr	Ser	Gly	Tyr	Ile	Pro	Leu	Met	Val	Met	Ala	Glu	Ala	His	Gln	Met
		35					40					45			

Ala	Ser	Pro	Thr	Thr	Gln	Ala	Leu	Phe	Lys	Leu	Leu	Phe	Ala	Ser	His
	50					55					60				

Leu	Leu	Thr	Phe	Tyr	Xaa
65					70

<210> 113

<211> 54

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

SUBSTITUTE SHEET (RULE 26)

48

<222> (54)

<223> Xaa equals stop translation

<400> 113

Met	Ala	Trp	Val	Gln	Ile	Pro	Leu	Leu	Pro	Phe	Thr	Ser	Cys	Val	Thr
1				5					10					15	

Leu	Gly	Lys	Tyr	Leu	Asn	Leu	Ser	Val	Pro	His	Phe	Ser	His	Leu	His
			20					25					30		

Lys	Glu	Asn	Asn	Ser	Leu	Leu	Leu	His	Arg	Val	Val	Met	Ser	Leu	Thr
		35						40					45		

Met	Ser	His	Tyr	Val	Xaa
					50

<210> 114

<211> 41

<212> PRT

<213> Homo sapiens

<400> 114

Met	Phe	Ser	Leu	Pro	Gln	Tyr	Leu	Ile	Tyr	Phe	Val	Leu	Ser	Ile	Leu
1				5					10					15	

Val	Val	Ser	Thr	Leu	Phe	Ser	Leu	Pro	Leu	Phe	Leu	Val	Pro	Leu	Arg
			20					25						30	

Gly	Glu	Lys	Lys	Asp	Asp	Asn	Gly	Val
		35					40	

<210> 115

<211> 18

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (18)

<223> Xaa equals stop translation

<400> 115

Met	Ser	Lys	Ala	Arg	Phe	Pro	Phe	Leu	Leu	Ser	Leu	Arg	Trp	Phe	Ser
1				5						10				15	

Ala Xaa

<210> 116

<211> 71

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (71)

49

<223> Xaa equals stop translation

<400> 116

Met	Trp	Arg	Val	Thr	Arg	Arg	Gly	Glu	Leu	Thr	Ser	Cys	Leu	Ser	Gly
1				5					10				15		

Ala	Thr	Tyr	Leu	Phe	Phe	Tyr	Gly	Val	Ser	Thr	Pro	His	Ala	Leu	Ala
			20					25					30		

Thr	Tyr	Leu	Arg	Lys	Leu	Leu	Asp	Leu	Lys	Ser	Glu	Ser	Phe	Lys	Gln
		35					40					45			

Met	Asn	Val	Cys	Phe	Val	Leu	His	Leu	Pro	Trp	Glu	Ile	Leu	Asn	Ile
	50						55					60			

Tyr	Arg	Asn	Arg	Val	Ser	Xaa
65						70

<210> 117

<211> 17

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (17)

<223> Xaa equals stop translation

<400> 117

Met	Leu	Leu	Ser	Ile	Ile	Cys	Leu	Val	Arg	Ser	Leu	Phe	His	His	Leu
1				5					10				15		

Xaa

<210> 118

<211> 27

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (27)

<223> Xaa equals stop translation

<400> 118

Met	Phe	Ser	Leu	Pro	Gln	Tyr	Leu	Lys	Leu	Val	Leu	Ser	Ile	Leu	Val
1				5					10				15		

Val	Ser	Thr	Leu	Phe	Ser	Leu	Pro	Phe	Ser	Xaa
			20					25		

<210> 119

<211> 153

<212> PRT

<213> Homo sapiens

SUBSTITUTE SHEET (RULE 26)

50

<400> 119

His Glu Leu Gly Gly Leu Leu Ala Asp Phe Leu Leu Ser Arg Lys Ile
 1 5 10 15
 Leu Arg Leu Ile Thr Ile Arg Lys Leu Phe Thr Ala Ile Gly Val Leu
 20 25 30
 Phe Pro Ser Val Ile Leu Val Ser Leu Pro Trp Val Arg Ser Ser His
 35 40 45
 Ser Met Thr Met Thr Phe Leu Val Leu Ser Ser Ala Ile Ser Ser Phe
 50 55 60
 Cys Glu Ser Gly Ala Leu Val Asn Phe Leu Asp Ile Ala Pro Arg Tyr
 65 70 75 80
 Thr Gly Phe Leu Lys Gly Leu Leu Gln Val Phe Ala His Ile Ala Gly
 85 90 95
 Ala Ile Ser Pro Thr Ala Ala Gly Phe Phe Ile Ser Gln Asp Ser Glu
 100 105 110
 Phe Gly Trp Arg Asn Val Phe Leu Leu Ser Ala Ala Val Asn Ile Ser
 115 120 125
 Gly Leu Val Phe Tyr Leu Ile Phe Gly Arg Ala Asp Val Gln Asp Trp
 130 135 140
 Ala Lys Glu Gln Thr Phe Thr His Leu
 145 150

<210> 120

<211> 108

<212> PRT

<213> Homo sapiens

<400> 120

Leu Met Lys Asn Pro Ala Ala Val Gly Glu Met Ala Pro Ala Met Cys
 1 5 10 15
 Ala Lys Thr Cys Asn Ser Pro Leu Arg Lys Pro Val Tyr Arg Gly Ala
 20 25 30
 Ile Ser Lys Lys Leu Thr Arg Ala Pro Asp Ser Gln Lys Leu Leu Met
 35 40 45
 Ala Glu Asp Ser Thr Lys Lys Val Met Val Met Leu Trp Leu Asp Leu
 50 55 60
 Thr Gln Gly Arg Asp Thr Arg Ile Thr Asp Gly Lys Arg Thr Pro Met
 65 70 75 80
 Ala Val Lys Ser Phe Leu Met Val Met Ser Leu Arg Ile Phe Leu Glu
 85 90 95
 Arg Arg Lys Ser Ala Ser Arg Pro Pro Ser Ser Cys
 100 105

SUBSTITUTE SHEET (RULE 26)

<210> 121
 <211> 106
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (72)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 121
 Glu Tyr Ser Thr Pro Asp Thr Val His Leu Arg Lys Thr Ile Leu Phe
 1 5 10 15
 Ser Val Lys Val Pro Val Leu Ser Glu Lys Met Tyr Cys Ile Cys Pro
 20 25 30
 Lys Ser Ser Val Met Phe Arg Ala Arg His Cys Ser Cys Glu Ser Val
 35 40 45
 Ser Ser Ser Tyr Asn Cys Met Ser Trp Leu Met Lys Tyr Thr Trp His
 50 55 60
 Ala Leu Thr Ile Ser Met Glu Xaa Tyr Lys Glu Met Gly Ser Lys Pro
 65 70 75 80
 Ala Glu Leu Tyr His Val Lys Asn Glu Leu Thr Ala Ala Val Thr Gly
 85 90 95
 Asp Lys Glu Leu Pro Ser Asp Leu Gly Thr
 100 105

<210> 122
 <211> 20
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (15)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 122
 Asn Gln Gly Ser Ala Glu Gln Gln Trp Ala Pro Leu Gln Ala Xaa Lys
 1 5 10 15
 Leu Glu Arg Gln
 20

<210> 123
 <211> 42
 <212> PRT
 <213> Homo sapiens

<220>

<221> SITE
 <222> (12)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (13)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (37)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <400> 123
 Ile Arg His Glu Thr Leu Arg Asn Thr Asp Ala Xaa Xaa Gly Ile Val
 1 5 10 15

 Ile Tyr Ala Gly His Glu Thr Lys Ala Leu Leu Asn Asn Ser Gly Pro
 20 25 30

 Arg Tyr Lys Arg Xaa Ser Trp Arg Gly Arg
 35 40

 <210> 124
 <211> 40
 <212> PRT
 <213> Homo sapiens

 <400> 124
 His Glu Leu Gly Pro Val Cys Leu His Ala Ile Met Leu Ala Glu Leu
 1 5 10 15

 Ile Phe Leu Phe Arg Ser Leu His Gly Ile Leu Ala Ser Ala Gly Thr
 20 25 30

 Ile Gly Ala Val Ala Ala Trp Leu
 35 40

 <210> 125
 <211> 195
 <212> PRT
 <213> Homo sapiens

 <220>
 <221> SITE
 <222> (5)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <400> 125
 Asp Phe Gly Thr Xaa Ser Asp Pro Lys Leu Phe Glu Met Ile Lys Tyr
 1 5 10 15

 Cys Leu Leu Lys Ile Leu Lys Gln Tyr Gln Thr Leu Arg Glu Ala Leu
 20 25 30

 Val Ala Ala Gly Lys Glu Val Ile Trp His Gly Arg Thr Asn Asp Glu

53

35	40	45
Pro Ala His Tyr Cys Ser Ile Cys Glu Val Glu Val Phe Asn Leu Leu		
50	55	60
Phe Val Thr Asn Glu Ser Asn Thr Gln Lys Thr Tyr Ile Val His Cys		
65	70	75
		80
His Asp Cys Ala Arg Lys Thr Ser Lys Ser Leu Glu Asn Phe Val Val		
85	90	95
Leu Glu Gln Tyr Lys Met Glu Asp Leu Ile Gln Val Tyr Asp Gln Phe		
100	105	110
Thr Leu Ala Ser Pro Trp Pro Pro Met Asp Gln Ser Ala Phe Thr Ser		
115	120	125
Ser Leu Leu Arg Pro Ile Lys Ala Leu Gly Ser Gly Arg Ala Glu Gln		
130	135	140
Thr Ser Gly Asp Gln Leu Gln Lys Gly Ala Thr His Ser Arg Ala Ser		
145	150	155
		160
Ser Leu Leu Arg Ala Ala Glu Met Thr Arg Arg Pro Ala Ser Arg Glu		
165	170	175
Glu Leu Pro Asp Pro Gly Leu Phe Cys His Ser Ile Lys Leu Leu Phe		
180	185	190
Val Leu Leu		
195		

<210> 126
 <211> 25
 <212> PRT
 <213> Homo sapiens

<400> 126
 Leu Pro Gly Asn Phe Arg Pro Pro Arg Val Ile Leu Thr Phe Gln Trp
 1 5 10 15

Arg Phe Tyr Leu Ser Phe Arg Lys Leu
 20 25

<210> 127
 <211> 95
 <212> PRT
 <213> Homo sapiens

<400> 127
 Tyr Leu Leu Leu Pro Cys Gly Leu Leu Ser Phe Trp Met Cys Gly Ala
 1 5 10 15

Leu Val Val Ser Pro Phe Val Gln Asn Gly Gln Gly Gln Arg Leu Arg
 20 25 30

Glu Ala Arg Ser Leu Cys Leu Leu Lys Gly Thr Thr Trp Ile Phe Leu

35 40 54 45
 Met Leu Ser Leu Pro His Phe Leu Val Gln Glu Leu Lys Phe Ser Asn
 50 55 60
 Asn Phe Phe Ser Thr Val Val Ile Phe Ser Thr Ser Gly Phe Leu Gln
 65 70 75 80
 Pro Thr Leu Ile Phe Leu Lys Leu Ser Trp Lys Ser Thr His Leu
 85 90 95

<210> 128
 <211> 64
 <212> PRT
 <213> Homo sapiens

<400> 128
 Tyr Met Met Val His Cys Lys Tyr Ser Val Tyr Asn Leu Leu Asn Lys
 1 5 10 15
 Trp Ile Gly Phe Ser Ile Phe Pro His Trp Thr Trp Ile Asp Leu Glu
 20 25 30
 Ile Gly Gly Leu Asn Leu Gln Val Glu Ile Lys Gly Pro Asn Asn Cys
 35 40 45
 Arg Val Ala Gly Glu Gly Arg Tyr Lys Cys Ser Lys Gly Gly Ser Arg
 50 55 60

<210> 129
 <211> 74
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (53)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (60)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (61)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (72)
 <223> Xaa equals any of the naturally occurring L-amino acids

55

<220>

<221> SITE

<222> (73)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 129

```

Met Ser Ala Ala Leu Trp Thr Tyr Met Arg Phe Leu Ala Cys Leu Asn
 1           5           10           15

His Ser Ser Gly Ser Met Tyr Leu Ser Val Asn Ser Thr Pro Val Leu
      20           25           30

Leu Leu Leu Leu Val Pro Asn Ser Ala Arg Ala Arg Ala Glu Phe Leu
 35           40           45

Gln Pro Gly Gly Xaa Thr Ser Ser Arg Ala Ala Xaa Xaa Ala Val Glu
 50           55           60

Leu Gln Leu Leu Phe Pro Leu Xaa Xaa Gly
 65           70

```

<210> 130

<211> 65

<212> PRT

<213> Homo sapiens

<400> 130

```

Phe Arg Gln Ala Arg Asn Leu Met Tyr Val His Asn Ala Ala Asp Ile
 1           5           10           15

His Ser Ser Leu Pro Gln His Ile Thr Val Ile Ser Pro Arg Glu Leu
      20           25           30

Cys His Thr Phe Ser Leu Leu Lys Pro Ala Thr Leu Asp Leu Leu Cys
 35           40           45

Ser Leu Ser Val Gly Asn Leu Phe Arg Ile Ser Glu Arg Gln Cys Lys
 50           55           60

His
 65

```

<210> 131

<211> 56

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (55)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 131

```

Arg Val Asn Val Ser Ser Ile Met Asp Ile His Glu Val Pro Gly Leu
 1           5           10           15

Ser Lys Ser Gln Leu Trp Phe Asn Val Pro Val Cys Gln Leu His Thr

```

<400> 134
Asp Gly Glu Leu Ser Lys Cys Cys Met Cys Ser Asp Tyr Thr Ile Asp
1 5 10 15

57

Cys Tyr Phe Pro Ile Ser Leu Pro Leu Leu Gly Arg Pro Tyr Tyr Leu
 20 25 30

Arg His Asn Ile Glu Ile Arg Pro Tyr Ile Asn His Thr Met Ala Ser
 35 40 45

Lys Gly Ser Ser Lys Arg Met Gly Cys Thr Ser Phe Thr Leu Thr Gln
 50 55 60

Lys Leu Glu Ile Ile Ile Leu Ser Glu Lys Gly Met Trp Lys Ala Glu
 65 70 75 80

Ile Gly Gln Lys Leu Gly Xaa Leu His His Ser
 85 90

<210> 135

<211> 14

<212> PRT

<213> Homo sapiens

<400> 135

Met Leu Cys Ile Asn Val Gln Thr His Val Tyr Glu Cys Ala
 1 5 10

<210> 136

<211> 99

<212> PRT

<213> Homo sapiens

<400> 136

Leu Cys Cys Pro Gly Trp Ser Ala Val Val Arg Ser Trp Leu Thr Ala
 1 5 10 15

Thr Leu Ala Ser Trp Val Gln Ala Ile Leu Met Asp Ser Ala Ser Gln
 20 25 30

Val Ala Gly Ile Thr Ser Val His His Gln Ala Gln Leu Ser Phe Val
 35 40 45

Phe Leu Val Glu Met Gly Leu Cys His Val Gly Gln Ala Gly Leu Lys
 50 55 60

Leu Leu Ala Ser Ser Asp Leu Pro Ala Ser Ala Ser Gln Ser Ala Gly
 65 70 75 80

Ile Thr Gly Met Ser His His Ser Trp Pro Glu Arg Thr Ser Phe Ile
 85 90 95

Phe Lys Ile

<210> 137

<211> 282

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (129)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (206)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 137

Phe	Gly	Arg	Gly	Asn	Thr	Ile	Leu	Phe	Leu	Arg	His	Asn	Lys	Asp	Leu
1				5					10					15	

Val	Ala	Gln	Thr	Ala	Gln	Pro	Asp	Gln	Pro	Asn	Tyr	Gly	Phe	Pro	Leu
		20						25					30		

Asp	Leu	Leu	Arg	Cys	Glu	Ser	Leu	Leu	Gly	Leu	Asp	Pro	Ala	Thr	Cys
	35						40					45			

Ser	Arg	Val	Leu	Asn	Lys	Asn	Tyr	Thr	Leu	Leu	Val	Ser	Met	Ala	Pro
	50					55					60				

Leu	Thr	Asn	Glu	Ile	Arg	Pro	Val	Ser	Ser	Cys	Thr	Pro	Gln	His	Ile
65					70					75					80

Gly	Pro	Ala	Ile	Pro	Glu	Val	Ser	Ser	Val	Trp	Phe	Lys	Leu	Tyr	Ile
				85					90					95	

Tyr	His	Val	Thr	Gly	Gln	Gly	Pro	Pro	Ser	Leu	Leu	Leu	Ser	Lys	Gly
			100					105					110		

Thr	Arg	Leu	Arg	Lys	Leu	Pro	Asp	Ile	Phe	Gln	Ser	Tyr	Asp	Arg	Leu
		115					120					125			

Xaa	Ile	Thr	Ser	Trp	Gly	His	Asp	Pro	Gly	Val	Val	Pro	Thr	Ser	Asn
	130					135					140				

Val	Leu	Thr	Met	Leu	Asn	Asp	Ala	Leu	Thr	His	Ser	Ala	Val	Leu	Ile
145					150					155				160	

Gln	Gly	His	Gly	Leu	His	Gly	Ile	Gly	Glu	Thr	Val	His	Val	Pro	Phe
			165					170						175	

Pro	Phe	Asp	Glu	Thr	Glu	Leu	Gln	Gly	Glu	Phe	Thr	Arg	Val	Asn	Met
		180						185					190		

Gly	Val	His	Lys	Ala	Leu	Gln	Ile	Leu	Arg	Asn	Arg	Val	Xaa	Leu	Gln
		195					200					205			

His	Leu	Cys	Gly	Tyr	Val	Thr	Met	Leu	Asn	Ala	Ser	Ser	Gln	Leu	Ala
	210					215					220				

Asp	Arg	Lys	Leu	Ser	Asp	Ala	Ser	Asp	Glu	Arg	Gly	Glu	Pro	Asp	Leu
225					230					235				240	

Ala	Ser	Gly	Ser	Asp	Val	Asn	Gly	Ser	Thr	Glu	Ser	Phe	Glu	Met	Val
				245					250					255	

Ile Glu Glu Ala Thr Ile Asp Ser Ala Thr Lys Gln Thr Ser Gly Ala
 260 265 270

Thr Thr Glu Ala Asp Trp Val Pro Leu Val
 275 280

<210> 138

<211> 31

<212> PRT

<213> Homo sapiens

<400> 138

Gly Thr Arg Ser Ile Asn Leu Leu Phe Phe Arg Cys Ile Leu Glu Gly
 1 5 10 15

Gly Lys Ser Val Glu Glu Gln Leu Cys Asn Ser Tyr Lys Phe Ser
 20 25 30

<210> 139

<211> 136

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (42)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (67)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (121)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (126)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (134)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 139

Leu Thr Val Pro Arg Arg Cys Pro Ala Ala Thr Glu Thr Asn Val Asp
 1 5 10 15

Gly Gln Lys Val Tyr Arg Asp Cys Ser Cys Ile Pro Gln Asn Leu Ser
 20 25 30

Ser Gly Phe Gly His Ala Thr Ala Gly Xaa Met His Phe Asn Leu Ser

60

35 40 45

Glu Lys Ala Pro Pro Ser Gly Phe His Ile Arg Cys Glu Phe Ser Leu
 50 55 60

His Ser Xaa Ser Ser Ile Pro Ala Leu Thr Ala Thr Leu Arg Cys Val
 65 70 75 80

Arg Asp Pro Gln Arg Ser Phe Ala Leu Gly Ile Gln Trp Ile Val Val
 85 90 95

Arg Ile Leu Gly Gly Ile Pro Gly Pro Ile Ala Phe Gly Trp Val Ile
 100 105 110

Asp Lys Ala Cys Leu Leu Trp Gln Xaa Gln Cys Gly Gln Xaa Gly Ser
 115 120 125

Cys Leu Val Tyr Gln Xaa Arg Pro
 130 135

<210> 140
 <211> 39
 <212> PRT
 <213> Homo sapiens

<400> 140
 Leu Val Met Gln Cys Leu Gly Gln Val Leu Ser Pro Leu Arg Thr Ser
 1 5 10 15

Val Cys Leu Pro Ile Glu Arg Gly Arg Trp Pro Gly Met Val Pro His
 20 25 30

Thr Thr Ser Ala Leu Gly Gly
 35

<210> 141
 <211> 76
 <212> PRT
 <213> Homo sapiens

<400> 141
 Gln Asn Thr Ile His Ser Leu Leu Pro Gln Gly Arg Met Thr Lys Ser
 1 5 10 15

Leu Val Leu Glu Glu Gln Lys Arg Lys Ala Gly Arg Ser Glu Met Lys
 20 25 30

Leu Glu Leu Leu Met Arg Val Ser Leu Trp Tyr Ser Gly Gln Ala Leu
 35 40 45

Val Leu Leu Gly Leu Ile Thr Asn Leu Ser Cys Ser Val Leu Gly Lys
 50 55 60

Ser Phe His Leu Ser Gly Pro Leu Ser Val Ser Leu
 65 70 75

61

<210> 142

<211> 75

<212> PRT

<213> Homo sapiens

<400> 142

Met Pro Arg Pro Ser Pro Leu Ser Ser Pro Gly Ser Pro Val Thr Ser
 1 5 10 15

Gln Leu Cys Ser Pro Met Pro Ser Leu Asn Pro Ala Leu Pro Trp Gly
 20 25 30

Leu Leu Leu Ala Leu Pro Gly Leu Ser Leu His Thr Pro Phe Gln Thr
 35 40 45

Leu Thr Ala Ala Ser Pro His Gln Pro Ser Gly Asp Ser Ala Ala His
 50 55 60

Leu Ser Ala His Ser Phe Leu Leu Asp Ser His
 65 70 75

<210> 143

<211> 55

<212> PRT

<213> Homo sapiens

<400> 143

Met Asp Thr Tyr Thr Phe Leu Ile Lys Ile Cys Lys Ile Phe Cys Ser
 1 5 10 15

Phe Leu Lys Cys His Ile Gln Val Cys Gly His Leu Leu Phe Leu Ile
 20 25 30

Phe Thr Ser Ile Lys Trp Ala Arg Lys Gln His His Cys Ser Arg Cys
 35 40 45

Lys Ala Ile Gly Leu Ser Ser
 50 55

<210> 144

<211> 67

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (17)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (18)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (57)

62

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (67)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 144

Met	Ile	Met	Gly	Tyr	Lys	Ser	Gln	Lys	Thr	Phe	Gly	Leu	Phe	Asp	Leu
1					5				10					15	

Xaa	Xaa	Val	Lys	Gly	Lys	Thr	Ser	Val	Leu	Glu	Phe	Asp	Phe	Trp	Val
			20					25					30		

Gln	Ile	Pro	Val	Ala	Ser	Leu	Leu	Ala	Leu	Trp	Leu	Asn	Arg	Leu	Leu
		35						40					45		

Asn	Ser	Val	Lys	Trp	Ala	Leu	Lys	Xaa	Cys	Val	Ile	His	Ser	Val	Ala
	50						55					60			

Val	Asn	Xaa
65		

<210> 145

<211> 68

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (59)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 145

Met	Lys	Ser	Phe	Pro	Ser	Thr	Tyr	Phe	Lys	Ser	Ser	Ser	Phe	Gln	Asn
1				5					10					15	

Thr	Lys	Tyr	Gln	Thr	Gly	Val	Ile	Ser	Val	Leu	Ile	Ser	Tyr	Glu	Ile
			20					25					30		

Glu	Tyr	Ala	Ala	Phe	Tyr	His	Leu	Ser	Cys	Lys	Ile	Thr	Leu	Pro	Ser
		35					40					45			

Ser	Val	Ser	Arg	Asn	Cys	Phe	Ile	Ser	Glu	Xaa	Leu	Val	Ala	Ser	Gln
	50					55					60				

Cys	Leu	Asp	Thr
65			

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/21142

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C07H 21/00; C12N 1/15, 1/21, 5/10, 15/10, 15/12, 15/63

US CL :536/23.1, 23.5; 435/252.3, 254.11, 325, 320.1, 455, 471

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.1, 23.5; 435/252.3, 254.11, 325, 320.1, 455, 471

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

GENBANK, EMBL

searched SEQ ID NO: 11-20 and 65-74

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. AA437293, HILLIER et al., 'WashU-Merck EST Project 1997', full record, 30 May 1997.	1, 7-10
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. AA447438, HILLIER et al., 'WashU-Merck EST Project 1997', full record, 04 June 1997.	1, 7-10
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. AA183135, MARRA et al., 'The WashU-HHMI Mouse EST Project', full record, 07 January 1997.	1, 7-10

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

21 DECEMBER 1998

Date of mailing of the international search report

03 FEB 1999
 Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

SCOTT D. PRIEBE

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/21142

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. R64076, HILLIER et al., 'The WashU-Merck EST Project', full record, 26 May 1995.	1, 7-10
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. AA374532, ADAMS et al., 'Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence', full record, 21 April 1997.	1, 7-10
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. AA485289, HILLIER et al., 'WashU-Merck EST Project 1997', full record, 11 August 1997.	1, 7-10
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. D80195, FUJIWARA et al., 'Fujiwara et al (1995)', full record, 09 February 1996.	1, 7-10
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. C16143, FUJIWARA et al., 'Fujiwara et al (1995)', full record, 30 September 1996.	1, 7-10
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. AA338221, ADAMS et al., 'Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence', full record, 21 April 1997.	1, 7-10
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. AA326904, ADAMS et al., 'Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence', full record, 21 April 1997.	1, 7-10
X	LAIDLER et al. A SecY homolog in Arabidopsis thaliana. Journal of Biological Chemistry. 28 July 1995, Vol. 270, No. 30, pages 17664-17667, especially page 17665.	1, 2, 7-10
X	WARREN et al. Cloning of the cDNAs coding for cat growth hormone and prolactin. Gene. 1996, Vol. 168, pages 247-249, especially page 248.	1, 2, 7-10
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. U12702, RUVOLO et al., 'Pan Paniscus Ppa4 mitochondrion cytochrome oxidase subunit II (COII) gene', full record, 24 January 1995.	1, 7-10

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/21142

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MAUCUER et al. Stathmin gene family: Phylogenetic conservation and developmental regulation in <i>Xenopus</i> . Journal of Biological Chemistry. 05 August 1993, Vol. 268, No. 22, pages 16420-16429, especially page 16423.	1, 7-10
X	BISCHOFF et al. Nucleotide sequences of <i>Bacillus subtilis</i> flagellar biosynthetic genes <i>fliP</i> and <i>fliQ</i> and identification of a novel flagellar gene, <i>fliZ</i> . Journal of Bacteriology. June 1992, Vol. 174, No. 12, pages 4017-4025, entire document.	1, 7-10
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. X70772, GALLI et al., 'Chironomus tentans Sp240/420 gene', full record, 21 July 1995.	1, 2, 7-10
X	CHANG et al. Identification, characterization, and sequence analysis of a cDNA encoding a phosphoprotein of human herpesvirus 6. Journal of Virology. June 1991, Vol. 65, No. 6, pages 2884-2894, especially page 2889.	1, 7-10
X	ROELOF et al. Characterization of the <i>Lactococcus lactis</i> nisin A operon genes <i>nisP</i> , encoding a subtilisin-like serine protease involved in precursor processing, and <i>nisR</i> , encoding a regulatory protein involved in nisin biosynthesis. Journal of Bacteriology. May 1993, Vol. 175, No. 9, pages 2578-2588, especially page 2583.	1, 7-10
X	SCHMUCK et al. Cloning and functional characterization of the human 5-HT _{2B} serotonin receptor. FEBS Letters. 1994, Vol. 342, pages 85-90, especially page 87.	1, 2, 7-10
X	TAKEUCHI et al. A mitotic role for a novel fission yeast protein kinase <i>dsk1</i> and cell cycle stage dependent phosphorylation and localization. Molecular Biology of the Cell. March 1993, Vol. 4, pages 247-260, especially page 250.	1, 7-10

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/21142

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 23
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Claim 23 is unsearchable as it is drawn to unknown and unspecified compounds.

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-10, 21

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/21142

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Groups I-XV, claim(s) 1-10 and 21, drawn to a polynucleotide, vector comprising same, first claimed method of use, i.e. using polynucleotide to make a cell, and the cell made by the process. Claims 1-10 and 21 recite 63 independent polynucleotides. Group I consists of the first ten polynucleotides (SEQ ID NOs 11-20 or encoding SEQ ID NOs 65-74). Each of groups II-XV consists of up to four of the remaining 53 polynucleotides, in order.

Groups XVI-LXXVIII, claim(s) 11, 12, 14-16 and 17 (first part), drawn to a polypeptide, a method of making the polypeptide and first claimed method of use, i.e. in treatment. These claims recite 63 independent polypeptides, each of groups XVI-LXXVIII consists of a single polypeptide as set forth in SEQ ID NOs 65-117, respectively.

Groups LXXIX-CXLI, claim(s) 13 and 19, drawn to an antibody to a polypeptide and the first claimed method of using same. These claims recite 63 independent antibodies to 63 independent polypeptides, each of groups LXXIX-CXLI consists an antibody against a single polypeptide as set forth in SEQ ID NOs 65-117, respectively.

Groups CXLII-CLVI, claim(s) 17(second part), drawn to an additional method of using a polynucleotide. Group CXLII consists of methods reciting the first ten polynucleotides (SEQ ID NOs 11-20 or encoding SEQ ID NOs 65-74). Each of groups CXLIII-CLVI pertains to up to four of the remaining 53 polynucleotides, in order.

Groups CLVII-CLXXI, claim(s) 18, drawn to a second additional method of using a polynucleotide. Group CLVII consists of methods reciting the first ten polynucleotides (SEQ ID NOs 11-20 or encoding SEQ ID NOs 65-74). Each of groups CLVIII-CLXXI pertains to up to four of the remaining 53 polynucleotides, in order.

Groups CLXXII-CCXXXIV, claim(s) 20, drawn to an additional method of using the polypeptide. These claims recite 63 independent methods of using 63 independent polypeptides, each of groups CLXXII-CCXXXIV consists an antibody against a single polypeptide as set forth in SEQ ID NOs 65-117, respectively.

Groups CCXXXV-CCIL, claim 22, drawn to a third additional method of using a polynucleotide. Group CCXXXV consists of methods reciting the first ten polynucleotides (SEQ ID NOs 11-20 or encoding SEQ ID NOs 65-74). Each of groups CCXXXVI-CCIL pertains to up to four of the remaining 53 polynucleotides, in order.

The inventions listed as Groups I-CCIL do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Each of the corresponding polynucleotides, polypeptides and antibodies are independent products, with different uses and being structurally, biochemically and biologically different products. In additional or alternate methods of use are claimed for individual polynucleotides and polypeptides. 37 CFR 1.475(b) does not provide for unity of invention of more than 1 product or more than one method of using a product as a combination of invention having unity of invention. However, with respect to groups drawn to independent polynucleotides or alternate methods of using same recited in the alternative, in accordance with 1192 O.G. 68 (19 November 1966) applicant is entitled to an initial search of inventions pertaining to the first ten independent polynucleotides recited, and may elect to pay an additional fee for each search of up to four additional independent polynucleotides. For additional method of using each of the independent polynucleotides, applicant may further elect to pay an additional fee for an additional search involving the first ten polynucleotides and each additional search involving up to four additional polynucleotides. With respect to groups pertaining to independent polypeptides or antibodies to the independent polypeptides, each product or method of use is an additional invention. An additional fee must be paid for search of each additional invention relating to polypeptides or antibodies against same. With respect to the relationship between the claimed polynucleotides and the claimed polypeptides, there is no one-to-one correspondence, i.e. no corresponding scope, between claims drawn to polynucleotides and their use and those drawn to polypeptides, antibodies and their use. Consequently, there is no special technical feature linking the polynucleotides and the polypeptides or antibodies claimed.